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Abstract 
 
Acute kidney injury (AKI) is a common clinical problem within the intensive care unit. 
Sepsis is implicated in half the cases of AKI; in those patients requiring acute renal 
replacement therapy there is an associated mortality of 50%. However, other than 
maintenance of an adequate circulation, no specific therapy exists for septic AKI. This is 
in large part related to a poor understanding of the underlying pathophysiology..  
 
I used a 72 hr clinically relevant, fluid-resuscitated rat model of sepsis and recovery to 
undertake a detailed temporal characterization of the pathophysiology of septic AKI and 
relevant biomarkers of kidney injury and dysfunction, and to assess the impact of 
targeted treatments. As with human studies, renal histology demonstrated minimal tissue 
injury or early inflammatory cell infiltration, however renal recovery was associated with a 
marked increase in renal macrophage infiltration. A panel of 8 renal biomarkers revealed 
that urine NGAL was the most sensitive marker, having risen by 3 hours’ post-insult and 
elevated for 24hrs.  
 
Renal blood flow was maintained over the first 24 hrs, however a fall in renal cortical 
oxygenation occurred despite similar renal oxygen delivery and utilization at 24 hrs. 
Though electron microscopy showed normal mitochondrial structure, I found an increased 
expression of mitochondrial uncoupling protein-2 (UCP-2); this may further uncouple 
mitochondrial respiration. Multiphoton imaging of live healthy kidney slices incubated in 
either sham or septic serum showed a rise in tubular reactive oxygen species (ROS) and 
falls in NADH and mitochondrial membrane potential in the septic serum group, findings 
that are consistent with uncoupling. Pre-incubation with the ROS scavenger, 4-OH-
TEMPO, prevented these effects.  
 
 4 
The NLRP3 inflammasome plays an important role in pro-inflammatory cytokine 
production. A NLRP3 inflammasome inhibitor, P2X7 antagonist, prevented LPS-induced 
IL-1β production by peripheral blood monocytes in vitro, however this was related in part 
to its diluent vehicle, dimethyl sulfoxide (DMSO). In the kidney, proximal tubular P2X7 and 
caspase-1 expression was seen both in vivo and ex vivo during sepsis. DMSO/P2X7 
antagonist treatment after the onset of sepsis was associated with reduced renal IL-1β 
expression and improvements in tachycardia, stroke volume, albumin and lactate 
however effects on renal function were inconclusive. Further studies targeting the NLRP3 
inflammasome in sepsis are warranted. 
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1 Sepsis 
1.1 Epidemiology and definitions 
 
Sepsis is a common and serious global health issue, accounting for 20% of all 
admissions to intensive care units (ICU), and is the leading cause of death in non-cardiac 
ICUs (Angus et al. 2001). Although there has been a modest decrease in the mortality of 
sepsis over time, a third of patients still do not survive (Levy et al. 2010). While the 
systemic inflammatory response syndrome (‘SIRS’) criteria are sensitive but non-specific 
criteria of generalized inflammation, they are an over-simplification of the physiological 
changes associated with sepsis. As such, criteria for the systemic manifestations of 
infection have been elaborated further (Table 1). An underlying localized or generalized 
infection triggering a systemic inflammatory response syndrome, is associated with tissue 
dysoxia, organ failure and death (Levy et al. 2003).   
Sepsis, as defined by the international Surviving Sepsis Campaign, is the presence of 
infection (either suspected or proven) along with features of systemic inflammation (Table 
1) (Dellinger et al. 2013). Sepsis-induced hypotension is defined as a systolic blood 
pressure (SBP) <90 mmHg or mean arterial pressure (MAP) <70 mmHg or a SBP 
decrease >40 mmHg, or more than two standard deviations below normal for age in the 
absence of other causes of hypotension. Septic shock is defined as sepsis-induced 
hypotension persisting despite adequate fluid resuscitation. When accompanied by signs 
of infection-induced hypotension, organ dysfunction or tissue hypoperfusion (e.g. 
hyperlactataemia or oliguria) severe sepsis is said to have occurred.  
In order to improve outcomes, a rapid diagnosis is pivotal to prompt instigation of 
cardiovascular resuscitation. Because of the multiphasic nature of sepsis, an 
understanding of the sequence of temporal changes is essential to initiate context- and 
time-specific interventions.  
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Organ failure is a hallmark of severe sepsis and septic shock. Yet little is understood 
about the evolutionary drive behind organ failure in critical illness. Clinical trials in sepsis 
have been highly disappointing with multiple drug and interventional strategies all failing 
to show outcome benefit in large randomized controlled trials. These repeated failures 
highlight the major complexities presented by sepsis where multiple pathways are 
simultaneously affected, and where marked fluctuations occur over time.  
It is becoming increasingly apparent that many of the biological and physiological 
alterations previously viewed as pathological may actually be adaptive and protective, 
and that our well-meaning but misguided attempts to normalize or over-correct perceived 
abnormality may actually be injurious. Likewise, the host response to Infection is highly 
variable both between individuals as well as over time. An appropriately dosed 
intervention at one time point may thus cause harm when given earlier or later in the 
disease process. Similarly, the assumption that sepsis simply represents a pro-
inflammatory state has also been laid bare. Many patients, even on admission to 
intensive care, are in a state of immunosuppression. Thus, the addition of an 
immunosuppressive therapy may further compromise the host response, increasing the 
risk of secondary infection and a poor outcome (Boomer et al. 2011, Conway Morris et al. 
2013). Some small studies have shown that immunostimulatory therapies may be 
beneficial in the right patient subset (Boomer et al. 2014). A personalized medicine 
approach where patients can be individually targeted by relevant biomarkers to receive 
appropriate therapies given at optimal dose and duration will lead to better patient 
selection and, hopefully, improved outcomes. 
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Table 1 Diagnostic criteria for sepsis (Dellinger et al. 2013)	   
Variable Infection (documented or suspected) and ‘some’ of the following: 
General  Fever (>38.3oC) or hypothermia (core temperature <36°C) 
Heart rate >90 beats/min  
Tachypnea 
Altered mental status 
Significant oedema or positive fluid balance (>20 ml/kg over 24 hrs) 
Hyperglycaemia (plasma glucose >7.7 mmol/L) in absence of diabetes 
Inflammatory  Leukocytosis (WBC count >12,000/µl) 
Leukopenia (WBC <4000/µl) 
Normal WBC count with greater than 10% immature forms 
Plasma C-reactive protein >2 SD above the normal value 
Plasma procalcitonin >2 SD above the normal value 
Haemodynamic Arterial hypotension (SBP <90 mmHg, MAP <70 mmHg, or SBP 
decrease >40 mmHg in adults, or >2 SD below normal for age 
Organ 
dysfunction 
Arterial hypoxaemia (PaO2/FIO2 ratio < 300) 
Acute oliguria (urine output < 0.5 ml/kg/hr for at least 2 hrs despite 
adequate fluid resuscitation) 
Creatinine rise >0.5 mg/dl or 44.2 µmol/L 
Coagulation abnormalities (INR >1.5 or aPTT >60s) 
Ileus (absent bowel sounds) 
Thrombocytopenia (platelet count <100,000/ µ L) 
Hyperbilirubinaemia (plasma total bilirubin >4 mg/dl or 70 µmol/L) 
Tissue 
hypoperfusion 
Hyperlactataemia >1 mmol/L 
Decreased capillary refill or mottling 
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1.2 Global haemodynamic indices 
The traditional cornerstone of resuscitation in severe sepsis is the optimization of 
haemodynamic variables to achieve an oxygen delivery adequate to meet metabolic 
needs. It is essential to recognize tissue hypoperfusion early in the disease process, as 
this allows timely intervention to limit organ dysfunction (Jones and Puskarich 2009). 
However, it is unclear what the ‘ideal’ cardiac output or oxygen delivery indices should be 
for a particular patient with sepsis, indeed, attempts to augment cardiac output and global 
oxygen delivery in sepsis to set endpoints have failed to show benefit (Gattinoni et al. 
1995, Hayes et al. 1994).  
Tissue hypoxia may develop due to impaired blood flow secondary to a low perfusion 
pressure. However, it is unclear to which level MAP should be increased during septic 
shock to improve outcomes. Targeting MAP values of 80-85 mm Hg, as compared with 
65-70 mm Hg was not associated with improved survival (Asfar et al. 2014). In a post hoc 
analysis of control group data from a multicentre trial including 290 septic shock patients, 
MAP levels ≥70 mmHg was associated with worse outcomes, especially with 
augmentation of the vasopressor dose (Dunser et al. 2009). It is therefore prudent to 
assess blood pressure targets in the context of both flow and tissue perfusion, as patients 
with high lactate levels and no hypotension (‘cryptic shock’) may have mortality levels as 
high, if not higher, as patients who present with hypotension yet a normal lactate (Howell 
et al. 2007). 
Central venous pressure (CVP) reflects the right arterial pressure and has been used for 
many years as an index of preload. However, the predictive value of CVP as a surrogate 
of preload is extensively debated, with no conclusive evidence demonstrating its 
reliability. A recent meta-analysis evaluating the absolute value of CVP and change (delta 
CVP) in predicting fluid responsiveness reported a poor predictive value for both 
parameters (Marik et al. 2008). Subsequent studies targeting CVP as a fluid resuscitation 
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target confirmed the poor correlation between CVP values and other resuscitation 
endpoints (Michard et al. 2000).  
It therefore remains unsurprising that recent clinical trials of protocolized care guided by 
the above parameters have failed to demonstrate benefit (Peake et al. 2014, Yealy et al. 
2014).  
 
1.3 Microcirculation  
Although the main therapies for treating sepsis are traditionally targeted at correcting 
macrovascular disturbances and tissue perfusion, the role of the microcirculation is 
becoming increasingly investigated. Patients may proceed to organ dysfunction despite 
correcting cardiovascular instability, possibly because microcirculatory dysfunction may 
lead to tissue hypoxia despite a normal or even elevated global oxygen delivery.  
Patients with sepsis demonstrate a reduction in microvascular blood flow as 
demonstrated by sublingual microvascular visualization techniques (sidestream dark field 
imaging, SDF) (Spanos et al. 2010). These microcirculatory changes are more 
pronounced in septic non-survivors (De Backer et al. 2002). An increase in 
microcirculatory flow index (MFI) on initial resuscitation was associated with reduced 
organ failure without substantial differences in global haemodynamics, implying that the 
microcirculation may be a potential therapeutic target (Trzeciak et al. 2008). Following the 
acute early phase of sepsis when fluid resuscitation is needed, further supplementary 
intravenous fluid therapy has little impact on haemodynamics. (Ospina-Tascon et al. 
2010). 
Tissue oxygenation or, more accurately, microvascular oxygenation, may be measured 
non-invasively using near-infrared spectroscopy (NIRS) whereby near-infrared light can 
measure oxy- and deoxy-hemoglobin within the microvasculature. Measurements are 
usually taken on the thenar muscle or may be transcranial (Lichtenstern et al. 2012). 
Patients with severe sepsis have longer tissue oxygen saturation recovery times and 
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lower NIRS-derived local oxygen consumption values compared to healthy volunteers 
(Creteur et al. 2007, Doerschug et al. 2007, Skarda et al. 2007). Vasopressor 
administration aimed at achieving a MAP >65 mmHg in patients with septic shock was 
associated with an improvement of NIRS variables measured at the level of the thenar 
eminence (Georger et al. 2010). Further studies are required to evaluate the utility of 
microvascular flow indices as targets in the management of severe sepsis and septic 
shock.  
 
1.4 Mitochondria 
Severe sepsis is characterized by profound disturbances in global haemodynamics and 
organ perfusion. The traditional dogma that MODS was primarily due to tissue 
hypoperfusion has been undermined by the finding in resuscitated septic patients that 
skeletal muscle oxygen tension is elevated, suggesting oxygen availability yet a decrease 
in oxygen consumption (Boekstegers et al. 1991, Sair et al. 2001). Histology also remains 
relatively normal despite significant organ dysfunction (Hotchkiss et al. 1999, Lerolle et al. 
2010).  
Decreased oxygen consumption (VO2) may represent, at least in part, an adaptive 
mechanism (Mongardon et al. 2009). Mitochondria, the primary consumer of O2 within the 
body, can regulate metabolism though determining availability of energy substrate (i.e. 
ATP). A prolonged inflammatory result can result in decreased mitochondrial activity 
through inhibition of mitochondrial respiration by increased production of nitric oxide and 
other mediators (Brealey 2002). Respiratory protein subunits and transcripts are also 
down-regulated (Brealey et al. 2002, Carre et al. 2010). This reduction in energy 
availability may divert the body from its normal activities and direct its efforts towards 
dealing with the acute stressor of infection. However, with overwhelming inflammation, 
this response may become exaggerated, resulting in decompensation with organ 
dysfunction and, ultimately, death in many cases. A clear association was reported 
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between the degree of mitochondrial dysfunction, organ failure and mortality (Brealey et 
al. 2002).  
Although the initial response to sepsis may be one of mitochondrial ‘hibernation’ with a 
reduction in O2 utilization, the recovery phase involves a rebound increase in oxygen 
consumption and resting energy expenditure (Kreymann et al. 1993). This is likely to 
reflect the creation of new, healthy and active mitochondria (biogenesis) to meet cellular 
metabolic energy demands and to fulfill other roles including calcium homeostasis, 
maintenance of cellular redox state, and cell signaling. The onset of mitochondrial 
biogenesis in sepsis corresponds with the restoration of normal mitochondrial oxidative 
respiration (Haden et al. 2007).  The course of sepsis and recovery is characterized by an 
increment in markers of mitochondrial biogenesis with increased mitochondrial number 
and density (Carchman et al. 2013).  
Understanding the time course of changes in mitochondrial function in sepsis, and how 
these changes relate to recovery is important when considering any potential therapeutic 
intervention. Alterations to respiratory protein subunits and transcripts occur within the 
first 24 hours of admission to ICU and correlate to eventual outcome (Brealey et al. 
2002). Skeletal muscle antioxidant reserves are reduced within 48 hours of admission to 
critical care, and are also associated with mortality risk (Carre et al. 2010).  
At present, monitoring of mitochondrial function is limited to experimental work. Promising 
real-time in vivo techniques include NADH fluorometry, magnetic resonance 
spectroscopy (MRS) and near infrared spectroscopy (Ekbal et al. 2013). Such techniques 
have shown promise in animal models of different shock states and warrant further 
investigations in sepsis.  
1.5 Immunology  
Sepsis is defined as a dysregulated host response to an infection. Excessive 
inflammation is integral. The innate immune system is the first line defence against 
pathogens, and is involved in initiating and propagating inflammation. It is activated by a 
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series of pattern recognition receptors (PRRs) that enables discrimination of ‘self’ from 
‘non-self’ antigens. PRRs recognize conserved pathogen-associated molecular patterns 
(PAMPs) on invading organisms, or respond to host-derived damage associated 
molecular patterns (DAMPs) released in response to stress, tissue injury or cell death. 
Several classes of PRRs have been identified, including transmembrane Toll-like 
receptors (TLR), C-type lectin receptors (CLRs), the retinoic acid inducible gene-I (RIG-I) 
receptors, intracellular Nod-like receptors (NLRs), and the recently identified HIN-200 
receptors (Ferrari et al. 1997, Kahlenberg et al. 2005, Wewers and Sarkar 2009). 
Extracellular PAMPs and DAMPs are recognised by TLRs and CLRs, whereas NLRs and 
RIGs recognize intracellular molecular patterns. 
PRRs are expressed primarily by innate immune cells, but also by endothelial and 
epithelial cells. The innate immune system is ‘primed’ by activation of PRRs by PAMPs 
and/or DAMPs, which leads to activation of numerous proinflammatory transcription 
factors, the best characterized being nuclear factor kappa-B (NF-κB), with subsequent 
transcription of multiple mediators (including cytokines and chemokines) and receptors.  
An excessively dysregulated host response results in detriment to the host (‘critical 
illness’). In many circumstances it remains unclear why some patients develop such a 
response to infection. Some bacterial toxins, including Staphylococcus aureus 
enterotoxin A, may result in a life-threatening ‘toxic shock syndrome’ secondary to non-
specific polyclonal T-cell activation (Tilahun et al. 2014). However, in the vast majority of 
septic patients, there is no single identifiable cause. High levels of circulating plasma 
cytokines result in a cascade of events including enhanced neutrophil chemotaxis and 
phagocytic activity, increased capillary leak, complement activation, cellular stress, and 
activated coagulation factors, and these are associated with organ dysfunction in sepsis 
(Cinel and Opal 2009).  
Genome-wide transcription profiling in human sepsis has demonstrated pro- and anti-
inflammatory mechanisms occur concurrently (Cinel and Opal 2009). There is no distinct 
pro- or anti-inflammatory phase nor any clear transition point during sepsis. Most of the 
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research on immunomodulation in sepsis has focused on attenuating the pro-
inflammatory phase. This includes the use of monoclonal antibodies against IL-1 (Opal et 
al. 1997) and tumor necrosis factor-α (TNF-α) (Abraham et al. 2001), TLR4 antagonists 
(Rice et al. 2010), inducible nitric  oxide synthase (iNOS) inhibitors (Bakker et al. 2004, 
Lopez et al. 2004), antioxidants (Staubach et al. 1998) and modulation of the coagulation 
system (Ranieri et al. 2012). Despite initial promise in pre-clinical studies and early 
clinical studies, no immunomodulatory therapy to date has yet conclusively demonstrated 
any benefit in sepsis.  
A significant subset of patients with critical illness do not die in the early pro-inflammatory 
phase of an acute infection. Ongoing immune dysfunction affecting T-cells, monocytes, 
and neutrophils predisposes the patient to the acquisition of nosocomial infections and 
subsequent renewed deterioration (Boomer et al. 2011, Conway Morris et al. 2013). 
There is a growing interest in immunostimulatory therapy in the latter stages of sepsis, 
including GM-CSF and interferon gamma, and more recently IL-7 and anti-PD1 therapy 
(Boomer et al. 2014). It remains likely that future immunotherapy will be individualized, 
guided by biomarkers of the immunological phenotype.  
1.6 Animal models of sepsis 
Improvements in survival over the past few decades have not been attributable to any 
single intervention or discovery, but have been achieved in a series of steps. Due 
diligence and attention to basic care is seen as a keystone in patient management.  
The focus of treatment has historically been placed on the supposed benefits they 
provide. More recently, greater insight has been gained into the harm associated with 
therapies prescribed in our well-intentioned attempts to treat and cure. Aggressive 
diseases often require aggressive treatment, with serious side-effects perhaps being an 
inevitable consequence. Primum non nocere. As such, we are now faced with the 
realization that more is not necessarily better, and attempts to restore ‘normal’ physiology 
in critical illness are not necessarily logical or beneficial.  
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Another increasingly recognized problem area is that of long-term morbidity in survivors 
of critical illness. Severe muscle weakness, neuropathy, cognitive dysfunction and 
secondary infections are some of the long-term conditions that can afflict these patients. 
We are becoming ever aware of the iatrogenic contributions to such problems. 
1.6.1 Adjuvant therapies 
An area of sepsis research that has been highly disappointing has been the failure to 
develop any effective therapeutic agent for sepsis. Multiple phase II and phase III clinical 
trials of adjuvant therapies have been performed, ranging from specific 
immunomodulatory agents (such as monoclonal antibodies directed against a pro-
inflammatory cytokine such as TNFalpha or IL-1), to semi-specific (e.g. activated protein 
C) or general anti-inflammatory therapies (e.g. corticosteroids), to extracorporeal 
techniques such as plasmapheresis (that non-specifically removes ‘evil humours’) or 
polymyxin B absorption columns (that binds and remove endotoxin and excess circulating 
inflammatory mediators). Unfortunately, none have shown consistent benefit. 
Understanding the natural history of sepsis is a fundamental part of designing trials to 
evaluate potential therapeutic agents. Evolution has ensured that we can adapt to 
adverse situations, such as mounting an appropriate immunological and physiological 
response to survive an infection. However, if the insult is prolonged and severe, the same 
host response – albeit exaggerated - may have a detrimental effect. There is likely to be a 
complex interplay between the multiple interventions required for immediate life saving 
treatment and intrinsic adaptive changes. As medical interventions have evolved far 
quicker than biology, critical illness is no longer an adaptive state determined by evolution 
alone. This makes it very challenging to extrapolate findings from a simplistic animal 
model of sepsis to the complex clinical setting.  
While many animal models of sepsis make some attempt to provide fluid resuscitation 
(discussed later), therapies that alter physiology and immunology including mechanical 
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ventilation, catecholamines, sedatives, steroids, and antibiotics are routinely used in 
clinical practice but rarely so in animal models of sepsis. To control for all these variables 
in a preclinical model would be impractical, given the number of permutations of different 
treatment conditions and the timing of their initiation.  
1.6.2 Species differences - immunology and metabolism 
Species differences clearly exist in both health and disease. The changes in gene 
expression profiling of leukocytes in response to three commonly studied inflammatory 
conditions (trauma, endotoxaemia, and burns) were compared in mice and humans 
(Seok et al. 2013). No correlation was seen between mouse and human genomic 
responses in any of the three conditions. Furthermore, although there was reasonable 
similarity between the genomic responses in the three inflammatory conditions among 
humans, this was not seen in mice. The authors concluded that their “study supports 
higher priority for translational medical research to focus on the more complex human 
conditions rather than relying on mouse models to study human inflammatory diseases”. 
While this study raises important questions, it is by no means conclusive (Perlman et al. 
2013).  
The circulating leukocyte pool in humans predominantly consists of neutrophils whereas 
that of mice predominantly consists of lymphocytes; direct comparisons may not be valid. 
Circulating immune cells may also be non-representative of the immune cell phenotype at 
the site of injury. Several genes and proteins in humans also do not have direct homologs 
in mice and vice versa (Mestas and Hughes 2004). Despite this, the genetic analysis was 
limited to human genes with identified murine orthologs. Some of the arguments cited 
against the validity of the Seok study in fact strengthen the argument that the 
immunophenotype of mice and humans are not directly comparable. Yet, this disparity 
has not hampered several important scientific discoveries. 
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The dose of endotoxin (lipopolysaccharide, LPS) required to induce the septic phenotype 
differs vastly between different species, with mice requiring several log orders more than 
humans (Suffredini et al. 1995) (Reynolds et al. 2002) (Nezic et al. 2009),(Taveira da 
Silva et al. 1993). Even non-human primates display significant differences in their 
immune response. Baboons and other monkey species display more resilience to LPS 
and live bacteria than humans (Hinshaw et al. 1981, Taylor et al. 1987). Blood cultures 
from septic baboons reveal bacterial counts in the range of 107 E.Coli per ml after 
infusion, far higher that that seen in critically ill septic patients. There are even variances 
in immune response across different species of mice. BALB/c mice injected with LPS 
were protected when pre-treated with anti-TNF sera, whereas CD-1 mice were not 
protected (Remick et al. 1995).  
In addition to differences in mouse and human septic immunophenotypes (Mestas and 
Hughes 2004) there are significant differences in their metabolic profiles (Zolfaghari et al. 
2013). In mice, sepsis resulted in severity-dependent reductions in core temperature and 
global metabolism with significant myocardial dysfunction. On the other hand, rats 
maintained body temperature and did not decrease their oxygen consumption.  
1.6.3 Method of sepsis induction  
In addition to the vastly different doses of LPS required to simulate sepsis in rodents, 
there are fundamental differences in the immmunophenotype of endotoxaemia compared 
to faecal peritonitis or pneumonia. Endotoxic animal models are characterized by 
hypotension, lactic acidosis, myocardial depression and elevated proinflammatory 
cytokines. While LPS has been used as a convenient mainstay of inducing an 
inflammatory phenotype, it primarily activates one arm of the immune system via TLR4. It 
is therefore not surprising that mice strains with different LPS sensitivity were equally 
susceptible to mortality from caecal ligation and puncture (CLP) (Echtenacher et al. 
2001). Furthermore, the magnitude and temporal change of cytokines varies between 
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mice subjected to CLP or LPS, with earlier and more severe cytokine responses seen 
after LPS (Remick et al. 2000).  
1.6.4 Fluid resuscitation 
Intravenous fluid therapy is the cornerstone of resuscitation in sepsis to correct the 
intravascular volume depletion resulting from vasodilation and increased capillary leak 
(Coletta et al. 2014, Dormehl et al. 1992). Although the best type of fluid, the ideal 
volume, and the best means of assessing fluid status remain hotly debated, to omit fluid 
resuscitation in the acute phase of sepsis would be deemed clinically negligent. Despite 
this, several preclinical models of sepsis do not even attempt fluid resuscitation. 
A systematic review of preclinical studies investigating renal blood flow (RBF) in sepsis 
revealed that 20 of 159 did not administer any fluid resuscitation and a further 34 did not 
mention whether they had done so (Langenberg et al. 2005). Sixteen of the 20 studies 
(80%) that did not administer fluid resuscitation demonstrated a reduction in RBF in 
contrast to 63 of the 106 studies (59%) where fluid was given. Nonetheless, studies 
specifically investigating responses with and without fluid resuscitation in the same model 
have shown important differences, with fluid resuscitation being associated with improved 
survival (Smith et al. 1993). The lack of fluid resuscitation in sepsis is associated with 
marked reductions in microvascular perfusion, and increased leukocyte-endothelium 
interactions and sequestration (Villela et al. 2014).  
1.6.5 Timing of therapeutic intervention 
It stands to reason that any therapeutic agent should be commenced soon after the 
induction of sepsis to maximize tis chances of success. However, septic patients 
presenting to the emergency department have invariably been unwell for some time 
beforehand. The exact time from onset of infection to clinical presentation is often 
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uncertain but may vary from hours to days. Many animal studies of putative therapeutic 
agents are often designed to administer the therapy before, at or soon after the time of 
infection/inoculation; any success is not likely to be representative of delayed therapy in a 
septic patient.  
1.6.6 Age and co-morbidity 
Sepsis primarily affects people above the age of 60 (Yealy et al. 2014), while those with 
pre-existing chronic co-morbidity have an age-independent increased risk of mortality 
(Huddle et al. 2013). Preclinical animal studies typically use mice aged 6-16 weeks, 
equivalent to a human age of 10-17 years (Turnbull et al. 2003). Not surprisingly, 
stepwise increases in mortality (20%, 70%, and 75%) were seen in more aged mice (4, 
12, and 24 months, respectively) after CLP. Others have demonstrated increased 
sensitivity of older mice to sepsis (Hyde et al. 1990). Older mice produce more TNF-
alpha, IL-6 and IL-10 (Saito et al. 2003, Turnbull et al. 2003), but benefit less from 
antibiotic treatment compared to young mice (Turnbull et al. 2003). Older mice also have 
different endothelial responses, with more extensive increase in expression of P- and E-
selectin and increased polymorphonuclear cell influx (Wulfert et al. 2012). This may 
contribute to increased organ failure (Maddens et al. 2012).  
1.6.7 Risk of death 
The efficacy of any therapeutic intervention may only be evident for a given severity of 
illness. A drug aimed at improving survival will not demonstrate any benefit if the baseline 
mortality in the control arm is 0% (or too low). In contrast, when severity is so great, 
inhibition of an excessive inflammatory response may provide some benefit independent 
of the drug’s mechanism of action. This was described by Eichacker et al in a meta-
regression analysis of preclinical studies (Eichacker et al. 2002). The treatment effects of 
anti-inflammatory agents were highly dependent on risk of death (p = 0.0001), with 
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animals being studied at significantly higher control mortality rates than humans (88% vs. 
39%, p = 0.0001) Anti-inflammatory agents studied in animal models with a similar risk of 
death to clinical studies demonstrated lack of benefit. Additionally, among the clinical 
trials included in the analysis, patients at greatest risk of death were most likely to benefit, 
whereas harm was seen following treatment in patients at low risk of death. Targeting 
treatment at a heterogeneous population may mask benefits seen within a specific 
subgroup of patients.  
To stand the best chance of successful translation of preclinical studies to clinical utility, 
preclinical studies need to be rigorously designed. However, it may not be pragmatic to 
overcome all of the limitations highlighted, and the results of preclinical studies need to 
be interpreted in context of the limitations of the experimental model used.  
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2 Sepsis induced acute kidney injury 
2.1 Epidemiology and definitions 
Acute kidney injury (AKI) is a common problem associated with a significant human and 
financial cost. The annual incidence varies from 17-620 per million in adults <60 and 80- 
89 years, respectively (Pisoni et al. 2008). Although AKI accounts for just 1% of hospital 
admissions in the USA, the incidence of in-patient AKI is estimated at 5-7% (Lameire et 
al. 2006). Within the intensive care unit (ICU) up to 5% of critically ill patients require 
renal replacement therapy (RRT) (Bagshaw et al. 2005, Uchino et al. 2005), and sepsis is 
implicated in half the cases of AKI (Uchino et al. 2005).  
Historically, AKI has been variously defined, resulting in marked variations in quoted rates 
of incidence and associated mortality from AKI (Ricci et al. 2006). To unify definitions, the 
Acute Dialysis Quality Initiative (ADQI) created the Risk-Injury-Failure-Loss-Endstage 
(RIFLE) criteria to diagnose and severity-stratify AKI (Appendix) (Bellomo et al. 2004). 
The RIFLE criteria uses urine output and either a rise in serum creatinine or fall in 
estimated glomerular filtration rate (eGFR) to define AKI. The Acute Kidney Injury 
Network (AKIN) modified the RIFLE criteria to further refine the AKI definition (Appendix) 
(Mehta et al. 2007). Most recently, the Kidney Disease: Improving Global Outcomes 
(KDIGO) group amalgamated the RIFLE and AKIN criteria, staging AKI severity on serum 
creatinine and urine output (KDIGO 2012). Though not intended to prognosticate for 
individuals, it does allow within-study comparisons. Importantly, these criteria are not 
designed to address aetiologies nor pathophysiological processes underlying AKI. 
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Table 2 KDIGO staging of AKI 
Stage Serum Creatinine Urine output 
1 1.5- 1.9 times baseline OR ≥0.3mg/dl (≥26.5 µmol/l) 
rise 
<0.5 ml/kg/h for 6-12 h 
2 2.0 – 2.9 times baseline <0.5 ml/kg/h for ≥12h 
3 3.0 times baseline OR  
Rise in serum creatinine >4 mg/dl (>353.6 µmol/l) 
OR Initiation of renal replacement therapy,  
OR In patients <18 years, decrease in eGFR to <35 
ml/min per 1.73m2 
<0.3 ml/kg/h for ≥24h, 
OR anuria for ≥12h 
 
The impact of AKI on immediate and long- term morbidity, mortality and financial 
resources is significant. Hospital mortality increases from RIFLE category R (17.9%) to F 
(33.2%) (Bagshaw et al. 2008), and the relative risk (RR) of mortality among patients with 
or without AKI increases progressively from Risk (RR=2.40), to Injury (RR=4.15), to 
Failure (RR=6.37) (Ricci et al. 2008). Five year survival in ICU patients who leave 
hospital following AKI was reported as 65-70% (Bagshaw 2006). Approximately 1 in 5 
patients who requires RRT has residual renal impairment at 1 year (Bagshaw et al. 
2005), while progression to CKD is related to AKI severity (Chawla et al. 2011). The 
estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing 
care is $128,200 (Hamel et al. 1997). Despite the relative frequency of the condition and 
its impact on morbidity and mortality, therapy is limited to supportive measures. This 
relates in part to the continued lack of understanding of the pathophysiology of sepsis-
induced AKI.  
2.2 Serum creatinine and urine output 
Glomerular filtration rate (GFR) is widely accepted as a marker of renal function but it is 
impractical to measure GFR routinely. Serum creatinine is used as a surrogate of GFR as 
creatinine is freely and non-selectively filtered by the kidneys. While serum creatinine 
may be a pragmatic tool to estimate GFR during stable renal function, there are 
significant limitations with its use in the diagnosis and monitoring of AKI: 
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1. A rise in serum creatinine is a relatively insensitive marker of early AKI as it may 
occur only after appreciable structural damage (Ronco and Rosner 2012). This 
may also explain why small rises in serum creatinine (26.5 µmol/l) are associated 
with increased mortality (Chertow et al. 2005).   
2. Assuming the rate of creatinine production remains constant, intravenous fluid 
therapy may have a dilutional effect so a fall in GFR measured by a rise in serum 
creatinine may not be evident for several hours (Waikar and Bonventre 2009).  
3. Creatinine production may fall in early sepsis, so concurrent reductions in GFR 
may not be evident (Doi et al. 2009). Creatinine is produced from creatine by 
non-enzymatic cyclization. This occurs throughout the body but especially in 
muscles where creatine concentrations are high. Creatine production itself occurs 
in the liver (Cocchetto et al. 1983). Creatinine production can therefore fall as 
lean muscle mass falls, or during liver disease; both of which are commonplace 
in the critically ill. 
4. Creatinine kinetics depend upon the baseline creatinine value. The percentage 
change in serum creatinine after severe AKI is highly dependent upon baseline 
kidney function (Waikar and Bonventre 2009).  
5. The modification of diet in renal disease (MDRD) formula used to calculate 
estimated GFR (eGFR) was designed for use in a population with stable GFR. 
GFR is not linearly associated with serum creatinine and estimation of GFR using 
this formula is less accurate at extreme values of serum creatinine (Levey et al. 
1999, Levey et al. 2006). The CKD-epi formula (Levey et al. 2009) also performs 
poorly when estimating GFR in patients with AKI, with high biases and errors 
(Kirwan et al. 2013).  
Creatinine clearance (CrCl) has been used as a measure of ‘nephron number’ with stable 
GFR. However, there are confounders to interpretation of CrCl in acute illness. 
1. CrCl systematically overestimates actual GFR due to tubular creatinine secretion.  
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2. The method itself is prone to large inherent variation between serial 
measurements (Bragadottir et al. 2013) and may be unreliable in the critically ill 
(Bouchard et al. 2010). 
3. CrCl as a measure of GFR assumes stable creatinine production and volume of 
distribution, both which may be altered in sepsis.  
4. Creatinine clearance may be stable despite tubular injury.  
The use of urine output to define AKI also has a number of limitations: 
1. Oliguria does not always result in renal injury as defined by a change in serum 
creatinine. Oliguria may occur more frequently compared to the number of 
patients developing AKI as defined by the change in serum creatinine (Prowle et 
al. 2011).  
2. A fall in urine output may occur only after significant renal injury 
3. Urine output may not fall despite clinically significant changes in serum creatinine 
4. Urine output may be modified by diuretic use 
5. Urine output prior to ICU admission is not always recorded 
Despite these limitations, the use of oliguria in addition to a rise in serum creatinine 
significantly improves the predictive value for mortality (Ricci et al. 2008).  
2.3 Histology 
As renal biopsies are rarely performed in critically ill septic patients with AKI, there is a 
relative paucity of histological data to aid understanding of the mechanisms underlying 
septic AKI at the tissue level. Only a few studies have been performed in humans 
(Rosenberg et al. 1971, Zappacosta and Ashby 1977), some being post-mortem (Diaz de 
Leon et al. 2006, Hotchkiss et al. 1999, Sato et al. 1978), or from biopsies performed a 
few days after the onset of AKI (Diaz de Leon et al. 2006). These findings were described 
in a systematic review of renal histopathology in septic AKI (Langenberg et al. 2008) in 
which marked heterogeneity was demonstrated. Acute tubular necrosis (ATN) was 
demonstrated in only 22% of renal histopathological specimens, with other findings 
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including acute tubulointerstitial nephropathy, acute glomerulonephritis, and completely 
normal histology in some cases These studies suggest that ATN is not the predominant 
histological feature in septic AKI, and that other mechanisms occur.  
A more recent study has shed additional light on renal histopathological changes seen 
during septic AKI (Lerolle et al. 2010). Percutaneous renal biopsies were performed in 19 
patients with septic AKI within 30 minutes of their death. As a control group, 9 patients 
without severe AKI who died from causes other than septic shock were biopsied. 
Compared to the control group, the patients who died from septic AKI had significantly 
greater renal monocyte/macrophage infiltration, polymorphonuclear leucocyte infiltration, 
and tubular apoptotic bodies, suggesting that immunological mechanisms may operate in 
addition to haemodynamic insults. As the degree of tubular cell injury is disproportionately 
low compared to functional impairment (Langenberg et al. 2008, Lerolle et al. 2010, 
Lipcsey and Bellomo 2011, Takasu et al. 2013), oliguria may reflect adaptive 
mechanisms during critical illness. 
2.4 Renal blood flow 
The haemodynamic instability associated with sepsis has led to the dogma that sepsis-
induced AKI is primarily a consequence of renal ischaemia and ensuing acute tubular 
necrosis (ATN) (Schrier and Wang 2004). Profound and rapid alterations in blood 
pressure and regional blood flow during septic shock may lead to loss of autoregulatory 
ability of the kidneys, renal hypoperfusion, and ischaemia. The lack of an accurate non-
invasive method to measure renal blood flow (RBF) on the ICU has limited our 
understanding. Early studies using indwelling renal vein catheters to measure renal blood 
flow in septic patients with AKI revealed preserved or even elevated RBF (Brenner et al. 
1990, Lucas et al. 1973, Rector et al. 1973). Recent experimental work has confirmed 
this. Renal blood flow may change over time, with an early rise in response to an infusion 
of E. Coli (Wan et al. 2009). A three-fold increase in both CO and RBF occurred during 
experimental sepsis in ewes (Langenberg et al. 2006), the decrease in renal vascular 
resistance being proportional to the increase in RBF. A recent systematic review of 159 
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animal studies suggested that interpretation of experimental data should be viewed in the 
light of potential confounding factors, including the method of sepsis induction, the 
animal’s size, consciousness level, time of measurement, use of fluid resuscitation, and 
systemic haemodynamics (Langenberg et al. 2005). 
Glomerular filtration rate (GFR) and creatinine clearance are dependent on filtration 
pressure, which is partly dependent on RBF. GFR is also indirectly dependent on tubular 
cell function via feedback mechanisms (tubular glomerular feedback; TGF). Despite an 
increase in global RBF, a reduction in glomerular filtration pressure may occur as a result 
of efferent renal artery vasodilatation or afferent artery vasoconstriction (renal 
microcirculation). The reduction in urine output and rise in serum creatinine commonly 
seen in critically ill septic patients may therefore occur despite normal or elevated global 
renal blood flow. In fact, oliguria may occur in the presence of adequate glomerular 
filtration and intact tubular function as tubular cells may effectively reabsorb filtered 
plasma. Experimental models of sepsis have confirmed that creatinine clearance and 
RBF may not correlate (Prowle et al. 2012, Wan et al. 2009). Oliguria may occur with a 
fall in creatinine clearance despite an increase in RBF during sepsis (Langenberg et al. 
2007). This suggests that changes in intra-renal circulation subsequent to modification in 
efferent arteriolar function and intra-renal shunting are much more likely to be responsible 
for septic AKI (Wan et al. 2009) than a global reduction in RBF.  
 
2.5 Renal Microcirculation 
Renal microvascular dysfunction has been characterized in preclinical models by a 
decrease in those vessels with continuous flow and an increase in vessels with 
intermittent or no flow (Holthoff et al. 2012, Seely et al. 2011, Tiwari et al. 2005). These 
changes are heterogeneous and may result in areas of hypoxia and normoxia, possibly 
explaining the patchy and sporadic histological changes. It is unclear if regions of hypoxia 
result in shutdown of cellular metabolism in an attempt to preserve cellular integrity 
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(‘oxygen conformance’), a phenomenon described in hepatocytes (Schumacker et al. 
1993, Subramanian et al. 2007). This may explain the loss of function with relatively well-
preserved histology.  
Inducible nitric oxide synthase (iNOS) has been implicated in sepsis-induced renal 
microcirculatory dysfunction. Activation of iNOS by LPS increases the influence of nitric 
oxide on afferent and efferent arteriolar tone and impairs endothelium-dependent nitric 
oxide effects (Ichihara et al. 2000). Increased renal nitric oxide (NO) in sepsis may 
contribute to the heterogeneous microcirculation by shunting. Inhibition of iNOS improved 
renal microcirculatory dysfunction in experimental sepsis (Wu et al. 2007, Wu and 
Mayeux 2007).  
Intra-renal shunting mediated by angiotensin may explain the findings of decreased renal 
vascular resistance and increased RBF yet oliguria and decreased creatinine clearance 
in fluid-resuscitated endotoxaemic sheep (Langenberg et al. 2007). Dilatation of the 
efferent artery relative to the afferent artery, thus decreasing filtration pressure and 
reducing GFR and urine output was considered a likely explanation. To test this 
hypothesis, they administered the potent vasoconstrictor, angiotensin II, to septic animals 
(Wan et al. 2009).. This drug has a preferential action on the efferent arteriole (Denton et 
al. 2000), whereas norepinephrine acts on both afferent and efferent arterioles (Myers et 
al. 1975). Angiotensin II also has constrictor effects on glomerular mesangial cells 
(Ausiello et al. 1980). Angiotensin II administration restored systemic arterial pressure but 
reduced global renal blood flow. Despite this, urine output and creatinine clearance 
increased significantly This observation is unlikely to be explained by the increase in 
MAP, as norepinephrine produced similar increments but had a less profound effect on 
creatinine clearance (Di Giantomasso et al. 2005, Di Giantomasso et al. 2003).  
Consistent with these experimental data, a post hoc analysis of the VASST study 
revealed that use of vasopressin (compared to norepinephrine alone) was associated 
with a trend to a lower rate of progression of AKI from RIFLE stage R to stage F or L, a 
lower rate of use of renal replacement therapy, and a trend towards lower mortality in 
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patients in the "Risk" category (Gordon et al. 2010). The mechanism underlying the 
relative reduction in glomerular filtration pressure is unlikely to be due to an absolute 
deficiency of circulating vasopressin, as vasopressin levels are often elevated, at least in 
the early stages, in patients with septic shock (Sharshar et al. 2003). Reduced sensitivity 
of vasopressin receptors due to circulating pro-inflammatory cytokines or impaired 
vasopressin release due to high circulating levels of noradrenaline may account for this 
(Bucher et al. 2002, Day et al. 1985). Local mechanisms may operate concurrently to 
regulate GFR (i.e.: tubular glomerular feedback).  
2.6 Tubular glomerular feedback 
Tubular glomerular feedback (TGF) enables the kidney to regulate GFR in accordance to 
the capacity of the renal proximal tubular epithelial cell (PTEC) at the level of the 
individual nephron. TGF allows compensatory reductions in GFR and thus tubular 
workload. TGF is a negative feedback mechanism that senses changes in luminal 
chloride (Cl-) delivery and reabsorption at the macula densa in the juxtaglomerular 
apparatus (JGA) and adjusts the vascular tone of the afferent arteriole accordingly 
(Schnermann et al. 1973).  
During states of hypovolaemia, RBF and perfusion fall. A decrease in renal perfusion 
pressure results in a decrease in GFR. Proximal tubular cells then reabsorb a greater 
proportion of filtered solute via the epithelial sodium channel, ENaC, resulting in 
decreased macula densa NaCl delivery (Salomonsson et al. 1993). The macula densa 
apical Na-K-2Cl (NKCC2) co-transporter senses this reduction in NaCl delivery (Vallon 
2003) with resulting renin release and activation of the renin-angiotensin system 
(Salomonsson et al. 1993). Increased angiotensin results in increased efferent arteriolar 
vasoconstriction relative to the afferent arteriole. The net effect is to maintain GFR to 
counter the decrease in renal perfusion pressure.  
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In addition to Cl- delivery to the macula densa, renal interstitial adenosine is a potent 
regulator of GFR. (Le Hir and Kaissling 1993). Extracellular adenosine activates A1 
receptors on vascular afferent arteriolar smooth muscle cells, resulting in vasoconstriction 
and a reduction in GFR (Schnermann et al. 1990). Renal adenosine concentrations are 
elevated in response to local ischaemia or endotoxic shock (Beach et al. 1991, Miller et 
al. 1978, Nishiyama et al. 1999). Antagonism of the A1 receptor attenuated reductions in 
MAP and RBF, suggesting that adenosine may mediate renal haemodynamic changes 
during endotoxin shock (Nishiyama et al. 1999).  
Adenosine may also modulate immune function via A2 receptors on antigen presenting 
cells (APCs) and lymphocytes. A2 receptor activation results in diminished phagocytosis, 
anti-inflammatory cytokine production, and lymphocyte apoptosis. In a CLP model of 
sepsis selective A2 receptor antagonism reduced lymphocyte apoptosis, lowered IL-6 
and IL-10 levels, and improved survival (Nemeth et al. 2006). Major actions of adenosine 
are summarized in (Figure 1). 
 
Figure 1 Major actions of adenosine are mediated via the A1 and A2 receptors. The main 
actions of adenosine are on immune function and vascular function. Adenosine results in 
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an anti-inflammatory phenotype, with decreased phagocytosis and anti-inflammatory 
cytokine production. In addition to systemic hypotension, adenosine results in a fall in 
GFR via afferent arteriolar constriction whilst maintaining deep cortical and medullary 
blood flow via A2 receptors.   
 
2.7 Bioenergetics and mitochondria 
The majority of renal ATP utilization is within the PTECs to enable reabsorption of filtered 
plasma solutes and water. The increased density of mitochondria within PTECs reflects 
the high metabolic demand of these cells (Hall et al. 2009). Given the paucity of 
histological damage and cell death in septic AKI, it is unlikely that any reduction in 
metabolism/function is a consequent to a significant and persisting fall in oxygenation. It 
is a reasonable assumption that PTEC workload and energy demand will be lowered by a 
reduction in GFR, and that local mediators may also play a role in the ‘metabolic 
shutdown’.  
Experimental studies investigating changes in renal oxidative phosphorylation during 
sepsis and endotoxaemia report variable results. Some demonstrated a reduction in renal 
oxidative phosphorylation (Tran et al. 2011), increased glycolysis (Smith et al. 2014) and 
decreased fatty acid oxidation (Kozlov et al. 2010). Even in the presence of hypotension 
and decreased RBF, total renal ATP and ATP/inorganic phosphate ratio remained 
unchanged during hyperdynamic sepsis implying a matched decrease in both oxygen 
supply and demand (May et al. 2007). Other investigators however found no difference in 
renal mitochondrial oxidative phosphorylation (Porta et al. 2006), renal gluconeogenesis 
(Caton et al. 2009), or state 3 or 4 respiratory control indices (Garrison et al. 1982). 
These differences may relate to the marked heterogeneity of the experimental and 
measurement techniques, the type and degree of the septic insult, the use of different 
species, duration, fluid resuscitation, etc  
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2.8 Immunology and Inflammation 
Damage associated molecular patterns (DAMPs) and pathogen associated molecular 
patterns (PAMPs) result in inflammasome activation, chemokine release and immune cell 
infiltration. Intrinsic renal cells, especially tubular epithelial cells, express components of 
the inflammasome pathway, including TLRs (El-Achkar et al. 2006, Wolfs et al. 2002) that 
are upregulated in sepsis. Renal tubular epithelial cells produce various proinflammatory 
cytokines and chemokines, e.g. IL-6, IL-18 and monocyte chemotactic protein (MCP-1) 
(de Haij et al. 2002).  
The kidney also contains resident antigen presenting cells (dendritic cells and 
macrophages) that modulate the local immune response to DAMPs and PAMPs filtered 
from the circulation (Rogers et al. 2014). The roles of resident immune cells include cell 
recruitment, regeneration and repair, and fibrosis. Resident renal macrophages assume a 
proinflammatory M1 phenotype (classically activated) or an anti-inflammatory M2 
phenotype (alternatively activated) (Rees 2010) depending on the local environment. In 
the early stages of sepsis, resident macrophages and dendritic cells may have important 
pro-inflammatory roles in antigen presentation and phagocytosis. During the resolution 
phase of sepsis, renal macrophages may play a different role. Endotoxin exposure 
confers renal protection from subsequent damage (preconditioning), mediated via the 
anti-inflammatory (M2) effect of renal macrophages (Hato et al. 2014). In renal tubules, 
preconditioning resulted in increased macrophage number and trafficking within the 
kidney, clustering of macrophages around S1 proximal tubules, and amelioration of 
peroxisomal damage, oxidative stress and injury to S2 and S3 tubules. 
TLR4 receptors may have an adaptive role in sepsis induced-AKI by internalizing filtered 
endotoxin through fluid-phase endocytosis (Kalakeche et al. 2011). MD2 and CD14, 
important co-effectors that participate in endotoxin-induced stimulation of TLR4, are 
detected in isolated murine tubular epithelial cells (Tsuboi et al. 2002). The levels of the 
soluble form of CD14 are increased in the urine of patients with sepsis and inflammation 
(Bussolati et al. 2002). S1 segments have evolved a protective mechanism of 
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upregulation of cytoprotective heme oxygenase-1 and sirtuin-1 (SIRT1) and showed no 
oxidative stress. In contrast, S2 segments did not upregulate SIRT1 and exhibited severe 
structural and functional peroxisomal damage (Kalakeche et al. 2011).  
Studies investigating the expression and activity of channels responsible for solute 
reabsorption are downregulated during inflammation. TNF-α downregulates the renal 
Na+-K+ pump and the Na+-K+2Cl- cotransporter in vivo (Kreydiyyeh and Markossian 
2006), while IL-1β inhibited, in a dose-dependent manner, Na+/K+-ATPase activity in both 
medullary and cortical renal cells (Kreydiyyeh and Al-Sadi 2002). LPS significantly 
downregulated ion transporters including the Na+/H+ exchanger 3 (NHE3), Na+/K+-
ATPase, renal outer medullary K+ channel (ROMK), epithelial Na+ channel (ENaC), Na+–
K+,2Cl−-cotransporter 2 (NKCC2), Na+–Cl−-cotransporter (NCC), and kidney-specific 
chloride channels -1 and -2 (CLCK-1 and -2) (Olesen et al. 2009, Schmidt et al. 2007). 
This effect was also seen in mice given lower doses of LPS where blood pressure was 
maintained. Similar effects were seen with injection of pro-inflammatory cytokines (IL-1β, 
TNF-α, INF-γ), and ischaemia-reperfusion injury but not with hypoperfusion (Schmidt et 
al. 2007). Alteration of renal sodium transporters during LPS-induced AKI thus appears 
mediated by cytokines rather than ischaemia. Of note, studies using knockout (KO) mice 
for TNF-α, IL-1β, and INF-γ show that even in the absence of these cytokines, renal 
tubular epithelial cells can still down-regulate ion transport channels in response to LPS. 
This suggests that multiple pathways are present (Schmidt et al. 2007).  
In sepsis and ischaemia, downregulation of sodium channel transporters such as ENaC 
decreases tubular reabsorption and therefore may reduce the metabolic demand of the 
kidney. Polyuria (due to decreased sodium and water reabsorption in the proximal 
collecting tubule) would be prevented by increased distal tubular Cl- delivery, which, has 
the direct effect of decreasing GFR (TGF) (Wilcox 1983).  
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2.9 Renal biomarkers 
A biomarker is a “characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” (Biomarkers Definitions Working 2001). Unlike 
traditional risk factors, biomarkers may provide a real-time picture of the underlying 
process- in addition to improving the diagnostic accuracy.  
As discussed, serum creatinine has several limitations as a biomarker for AKI. Serum 
creatinine rises late and it is relatively insensitive - even a relatively small rise is related to 
a worse prognosis (Tian et al. 2009). The ability to intervene early in the course of AKI 
may alter prognosis (Schrier 2004). Several biomarkers have been investigated as 
potential candidates for the diagnosis and monitoring of AKI.  
2.9.1 Neutrophil gelatinase-associated lipocalin 
Neutrophil gelatinase-associated lipocalin (NGAL) was first identified as a 25kDa protein 
found within granules of human neutrophils (Kjeldsen et al. 1993). It is released into the 
bloodstream in response to bacterial infections (Xu et al. 1994). Bacteria produce 
siderophores to acquire iron for growth. NGAL can bind to these siderophores, thereby 
preventing bacterial growth (Goetz et al. 2002). The presence of NGAL was subsequently 
described in epithelial cells of other tissues, including lung, colon, stomach, and kidneys 
(Cowland and Borregaard 1997). NGAL was first described as a biomarker for ischaemic 
AKI (Mishra et al. 2003). NGAL may facilitate repair and regeneration processes in 
injured tubular cells by inducing differentiation of renal progenitor cells (Mori et al. 2005).  
Its monomeric (25kD) form is the predominant form secreted by tubular epithelial cells, 
while the dimeric (45kD) form is predominantly secreted by neutrophils. NGAL is 
covalently conjugated with gelatinase (matrix metalloproteinase 9) as a 135-kD 
heterodimeric form (Cai et al. 2010). NGAL is dependent on renal clearance and 
undergoes glomerular filtration due to its low molecular weight and positive charge. 
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Filtered NGAL is captured and degraded to a 14-kDa fragment in PTEC lysosomes 
(Hvidberg et al. 2005). 
A recent systematic review of NGAL as a biomarker of AKI (Hjortrup et al. 2013).included 
11 studies with a total of 2,875 participants. The heterogeneity in study design and results 
made it difficult to evaluate the value of NGAL to predict AKI in critically ill patients (area 
under the receiver operated characteristic curve (AuROC) ranged from 0.54 to 0.98). 
Reasons cited included variations in study design, period from NGAL sampling to AKI 
follow-up (12 hours to 7 days), definition of baseline creatinine value, and urinary NGAL 
quantification method (normalizing to urinary creatinine or absolute concentration). 
2.9.2 Interleukin-18 
Mononuclear cells, macrophages and non-immune cells including proximal tubule cells, 
produce interleukin-18 (IL-18). IL-18 is a member of the IL-1 cytokine superfamily with a 
molecular weight of 18kDa. IL-18 has a major role in the Th1 response by stimulating the 
production of interferon-γ from T-cells and natural killer cells. Fas ligand-mediated cell 
death is also IL-18-dependent (Dao et al. 1996, Zhang et al. 2011). Mesangial cells 
express IL-18, and this increased significantly after LPS (Hardy et al. 2010). IL-18 is also 
expressed de novo within the distal convoluted and the connecting tubule and parts of the 
collecting duct (Gauer et al. 2007).  
In a meta-analysis of 18 studies the odds ratio for urinary IL-18 to predict AKI was 4.22, 
with sensitivity and specificity of 0.58 and 0.75, respectively, and an AUROC of 0.70. IL-
18 had better diagnostic accuracy in children and adolescents and also had better 
predictive value in cardiac surgical compared to general ICU patients. There was no 
significant difference in predictive performance of urinary IL-18 at various sampling times 
(Liu et al. 2013). 
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2.9.3 Kidney injury molecule -1 
Kidney injury molecule -1 (KIM-1) is a 90kDa type I membrane glycoprotein (Ichimura et 
al. 1998) expressed on non-differentiated renal PTEC undergoing regeneration after toxic 
or ischaemic injury (Bailly et al. 2002). Its structural homology to several known adhesion 
proteins points to a possible role in cell adhesion during regeneration.  
A recent meta-analysis of KIM-1 in a heterogeneous cohort of intensive care patients 
incorporated 2979 patients from 11 studies (Shao et al. 2014). This revealed that the 
sensitivity of urinary KIM-1 for the diagnosis of AKI was 0.74. (95% CI, 0.61-0.84), and 
specificity was 0.86 (95% CI, 0.74 -0.93%). Subgroup analysis suggested that population 
settings and detection time were the key factors affecting the efficiency of KIM-1 for AKI 
diagnosis  
2.9.4 Cystatin C  
Cystatin C is a 13kDa proteinase inhibitor produced by most nucleated cells. In humans, 
cystatins are the most important endogenous inhibitor of cysteine proteinases (Brzin et al. 
1984). Due to its small size, it is freely filtered in the urine. Once filtered, it is reabsorbed 
and degraded in the renal proximal tubule by the endocytic receptor, megalin (Kaseda et 
al. 2007). Urine cystatin C levels increase when the reabsorptive capacity of the proximal 
tubule is exceeded. Urine cystatin C is therefore undetectable unless proximal tubular 
dysfunction is present. Microalbuminuria may increase levels of urine cystatin C as 
cystatin C absorption is reduced by competitive inhibition (Nejat et al. 2012). Serum 
cystatin C is dependent on GFR and may be a useful marker in critical illness as it is 
independent of muscle mass.  
In a meta-analysis of studies involving intensive care patients (Zhang et al. 2011)., the 
estimated sensitivity and specificity of serum cystatin C for the diagnosis of AKI was 0.86 
and 0.82 respectively, with an AuROC of 0.87. Urinary cystatin C excretion had sensitivity 
and specificity values of 0.61 and 0.67, respectively with an AuROC of 0.67 (95% CI 
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0.63-0.71) in predicting AKI.  Some studies suggested that urine cystatin C may be an 
earlier and more sensitive marker of AKI compared to serum cystatin C (Sasaki et al. 
2011, Togashi et al. 2012). This may relate to the timing of measurement as it was of less 
value after 24 hours of ICU admission (Zhang et al. 2011).  
2.9.5 Clusterin 
Clusterin is a secreted glycoprotein with cytoprotective functions. PTEC clusterin 
expression in renal ischaemia reperfusion injury (IRI) is associated with upregulation of 
genes that may induce cell cycle progression and DNA damage repair, promoting cell 
proliferation (Nguan et al. 2014). Absence of clusterin renders mice susceptible to IRI 
(Zhou et al. 2010). Urine clusterin was elevated in experimental drug-induced AKI (Zhou 
et al. 2014) The utility of urine clusterin has not been investigated in sepsis-induced AKI. 
2.9.6 Osteopontin 
Osteopontin (OPN) is an extracellular structural protein present predominantly in bone 
and epithelial tissues. Within the normal kidney, OPN is mainly present in the loop of 
Henle and distal nephrons (Xie et al. 2001). Its intimate role in the regulation of 
calcification is crucial for the prevention of calcium stone formation within the kidney 
(Wesson et al. 2003). However, OPN may be upregulated in response to a number of 
insults including renal ischaemia, lupus nephritis, and ureteric obstruction (Xie et al. 
2001). OPN has been found in tissues with high cell turnover suggesting a possible role 
in tissue remodeling and repair (Persy et al. 1999). 
OPN is present to lesser degrees in macrophages, activated T cells, and smooth muscle 
cells (Mazzali et al. 2002). It is integral for macrophage migration into sites of 
inflammation, and T cell chemotaxis and co-stimulation (Giachelli et al. 1998, O'Regan et 
al. 1999). OPN expression correlates with the degree of macrophage infiltration in various 
models of acute and chronic kidney injury (Panzer et al. 2001, Pichler et al. 1995). 
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Causality has been shown by administering anti-OPN neutralizing antibodies that 
reduced macrophage recruitment (Panzer et al. 2001, Yu et al. 1998). OPN also has a 
direct effect on renal tubular cells by inhibition of iNOS and promotion of survival in renal 
tubular epithelial cells (Hwang et al. 1994, Ophascharoensuk et al. 1999). In a model of 
gentamicin-induced AKI, OPN was related to the proliferation and regeneration of tubular 
epithelial cells after tubular damage (Xie et al. 2001). In a model of IRI, differences were 
seen in the distribution of OPN in PTECs and distal tubular epithelial cells (DTECs). 
DTECs showed an early and persistent increase in OPN staining in the absence of major 
morphological injury, whereas staining in PTECs was delayed and mostly associated with 
morphological regeneration (Persy et al. 1999). Osteopontin promoted early interstitial 
macrophage influx, proximal tubular cell survival, and interstitial fibrosis in a mouse model 
of unilateral ureteral obstruction (Ophascharoensuk et al. 1999).  
The functional significance of these changes in sepsis is unclear, although it seems 
reasonable that OPN may promote recovery mediated via modulation of infiltrating cells 
and local responses by the proximal tubular epithelial cell. The utility of urine OPN as a 
biomarker in sepsis-induced AKI has not been previously investigated. 
2.9.7 Calbindin 
Calbindin-D28k is a cytoplasmic calcium-binding protein with high affinity for calcium. 
Renal calbindin-D28k is localized in the distal tubule and the proximal part of the 
collecting ducts. Functionally, it is thought to be involved in the regulation of reabsorption 
of calcium and possibly magnesium in the distal nephron. Urine calbindin was elevated in 
subacute drug-induced nephrotoxicity (Hoffmann et al. 2010). Its utility as a biomarker in 
sepsis-induced AKI has not been previously investigated. 
2.9.8 Monocyte chemoattractant protein -1  
Monocyte chemotactic protein-1 (MCP-1), also known as C-C motif ligand 2 (CCL2) is a 
13kDa chemokine that recruits monocytes, dendritic cells and T cells into sites of 
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inflammation (Carr et al. 1994, Xu et al. 1996). MCP-1 is detectable in the urine in various 
aetiologies of AKI including maleate-induced AKI (Munshi et al. 2011), and vasculitis 
(Ohlsson et al. 2009, Tam et al. 2004). Urine MCP-1 was elevated in a small subset of 5 
patients with septic AKI (Munshi et al. 2011). Patients with urosepsis had elevated levels 
of MCP-1 on diagnosis, and levels fell with initiation of treatment and clinical recovery 
(Olszyna et al. 1999). To date, there has not been any study of urine MCP-1 as a 
biomarker of sepsis-induced AKI. 
2.9.9 Limitation of biomarkers 
Multiple studies emphasize the potential benefit of one biomarker over another. Most 
have focused on demonstrating that kidney biomarkers appear at earlier time points than 
serum creatinine. The current non-utilization of current biomarkers may be due to:  
(Murray et al. 2014): 
1. poor integration with creatinine and urine output to enhance AKI management  
2. many emerging biomarkers with different test characteristics (in serum and 
urine). Standardization of the multiple methods and platforms for measuring 
assay ranges, levels and thresholds exist is required 
3. predictive models relating biomarker values to clinical outcomes on a continuous 
scale may enhance the practicality of biomarker measurements  
 
Specific clinical recommendations for applying these emerging biomarkers to optimize 
patient management are required. A kidney biomarker panel may prove to be more useful 
(Martensson et al. 2012), while specific treatment algorithms in response to elevated 
biomarkers need to be validated. Depending on the time of measurement, different AKI 
biomarkers had different predictive values for RRT requirement and mortality (Endre et al. 
2011). There is still no clear understanding of the time course of AKI biomarkers.  
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3 The Inflammasome 
3.1 The Inflammasome 
 
The innate immune system plays a crucial role in mediating the initial host response to 
infection by recognizing ‘danger signals’, including ‘pathogen- associated molecular 
patterns (PAMPS) and ‘damage- associated molecular patterns (DAMPS) (Thijs and 
Hack 1995). PAMPs and DAMPs bind to host cell pattern recognition receptors (PRRs) 
which exist in the extracellular and intracellular compartments. Activation of PRRs result 
in initiation of the inflammatory cascade, including cytokine production.  
A key mechanism responsible for the post-transcriptional processing and release of 
mature cytokines is formation of the inflammasome complex. The inflammasome is a 
multiprotein cytosolic complex that oligomerizes to provide a platform for processing and 
release of cytokines such as IL-β and IL-18 via direct activation of caspase-1 (Strowig et 
al. 2012). The human genome encodes 23 NLR proteins broadly divided into NLRP (with 
a pyrin domain) and NLRC (with a caspase recruitment domain), a subset of which is 
capable of forming an inflammasome complex. Seven cytoplasmic receptors form an 
inflammasome complex: NLRP1 (NLR family, pyrin domain containing 1, NALP1), NLRP3 
(also called NALP3 or cryopyrin), NLRP6, NLRP12, NLRC4 (NLR family, caspase 
recruitment domain (CARD) containing 4, also called IPAF), AIM2 (absent in melanoma-
2) and RIG-1 (retinoic acid inducible gene 1). Of these receptors, the NLRP3 
inflammasome is the best characterized.  
3.2 NLRP3 inflammasome 
This large mulltiprotein complex (>700KDa) forms in response to diverse PAMPs 
including lipopolysaccharide (LPS), peptidoglycan, bacterial DNA, viral RNA and fungi, 
and DAMPs such as monosodium urate crystals (MSU), calcium pyrophosphate 
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dehydrate, cholesterol crystals, amyloid β, hyaluronan and, possibly, glucose (Ferrari et 
al. 1997) (Table 3)  
 
Table 3 Activators of the inflammasome 
Sterile activators Pathogen activators (PAMPS) 
DAMPs Environment 
derived 
Bacteria 
derived 
Virus-
derived 
Fungus -
derived 
Protozoa-
derived 
ATP 
Cholesterol 
crystals 
MSU/CPPD 
crystals 
Amyloid β 
Hyaluronian 
Alum 
Asbestos 
Silica 
Alloy particles 
UV radiation 
Skin irritants 
Pore-forming 
toxins 
Lethal toxin 
Flagellin/rod 
proteins 
MDP 
RNA 
DNA 
RNA 
M2 protein 
β-glucans 
Hyphae 
Mannan 
Zymosan 
Hemozoin 
 
Abbreviations: CPPD, calcium pyrophosphate dehydrate; DAMP, danger-associated molecular 
pattern; MDP, muramyl dipeptide; MSU, monosodium urate; PAMP, pathogen associated molecular 
pattern  
 
Activators of the inflammasome are divided into two categories: sterile activators include 
host-derived DAMPs and environment-derived molecules, and pathogen activators 
including PAMPs derived from bacteria, virus, fungi and protozoa.   
Priming of the cell (signal 1) by activation of PRRs results in NFκB-dependent 
transcription of pro-IL-1β and upregulation of NLRP3. Assembly of the NLRP3 
inflammasome relies on the adaptor molecule ASC (Apoptosis-associated Speck-like 
protein containing a C-terminal caspase recruitment domain (CARD)). The ASC protein is 
composed of PYD (N-terminal pyrin domain) and CARD domains. The N-terminus of 
NLRP3 also contains a PYD that mediates homotypic binding with ASC via a PYD-PYD 
interaction. Through its CARD, ASC interacts with procaspase-1 leading to autocatalytic 
activation of caspase-1. This results in processing of pro-IL-1β and pro-IL-18 to their 
active forms (IL-1 β and IL-18) and their release (Figure 2). 
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Figure 2: Model of NLRP3 inflammasome activation  
NLRP3 is activated by a vast array of stimuli including extracellular pathogen PAMPs such as bacterial LPS via 
pattern recognition receptors (PRR) such as Toll-like receptors (TLR) and DAMPs.  This comprises signal 1 and 
leads to synthesis of the cytokine precursor pro-IL-1β via NF-κB and other components of the inflammasome 
such as NLRP3 itself. Many of the known activators of the inflammasome generate ROS which can bind to 
NLRP3 and this appears necessary for its activation.  Extracellular ATP binding to the P2X7 comprises signal 2.  
This promotes the recruitment and opening of the pannexin-1 pore channel which causes rapid K+ efflux, 
another event which appears necessary for NLRP3 activation.  NLRP3 assembly occurs when, through its pyrin 
domain, NLRP3 binds to the pyrin domain on an ASC molecule which then binds to pro-caspase-1 via its CARD 
domain.  This leads to cleavage of pro-caspase-1 and subsequent cleavage of pro-IL-1β and pro-IL-18 to their 
active forms.  
Abbreviations: DAMP, damage-associated molecular pattern; LPS, lipopolysaccharide; ROS, reactive oxygen 
species; PAMP, pathogen-associated molecular pattern; PRR, pattern recognition receptor; TLR, toll-like 
receptor; PYD, pyrin domain. 
 
NLRP3 is activated by many stimuli including PAMPs (e.g. LPS) and DAMPs. This 
comprises signal 1 and leads to synthesis of the cytokine precursor pro-IL-1β via NF-κB 
and other components of the inflammasome such as NLRP3 itself. Many known 
activators of the inflammasome generate ROS that bind to NLRP3; this appears 
necessary for its activation. Extracellular ATP binding to the P2X7 comprises signal 2. 
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This promotes recruitment and opening of the pannexin-1 pore channel which causes 
rapid K+ efflux, another event which appears necessary for NLRP3 activation. NLRP3 
assembly occurs when NLRP3 binds to the pyrin domain on an ASC molecule which then 
binds to pro-caspase-1 via its CARD domain. This leads to cleavage of pro-caspase-1 
and then cleavage of pro-IL-1β and pro-IL-18 to their active forms. 
The cell surface P2X7 receptor (P2X7) facilitates assembly of the NLRP3 inflammasome 
(Bauernfeind et al. 2011, Bergsbaken et al. 2011, Miao et al. 2011). ATP released into 
the extracellular milieu during inflammation is a potent stimulus for P2X7 activation 
(Bauernfeind et al. 2009, Fink and Cookson 2006, Shiohara et al. 2002). This results in 
formation of an ion pore and K+ efflux, with reduction in intracellular K+, a key step in 
inflammasome activation (Bryan et al. 2009). Activation of the P2X7 by LPS and ATP 
results in MyD88-dependent NfκB activation (signal 2), and transcription of pro-IL-1β (Liu 
et al. 2011). Following LPS priming of monocytes, P2X7 activation stimulates NADPH 
oxidase to generate superoxide anions, thereby facilitating NLRP3 activation (Bruey et al. 
2007). 
3.2.1 Processing of IL-1α, IL-1β, IL-18, and caspase-1 
IL-1 is a central player in the inflammatory cascade. It is produced by many cells, 
including activated monocytes and macrophages. It has a variety of effects on its target 
cells by activation of signal transduction pathways, such as MAPK and NF-κB, resulting 
in upregulation of several gene products in the inflammatory cascade, such as cyclo-
oxygenase (COX)-2, IL-6, chemokines, and cellular adhesion molecules. IL-1 has two 
isoforms, IL-1α and IL-1β, which bind to the same receptors and are both biologically 
active (Bevilacqua et al. 1989, Dinarello 2002).  
Inflammatory stimuli, especially LPS, engage with the TLR4 receptor of T cells, resulting 
in synthesis of pro-IL-1β. Pro-IL-1α is constitutively expressed and does not require TLR 
stimulation (Dinarello 2009). Both isoforms are produced as 31 kDa precursors stored 
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within the cell cytosol. The pro- IL-1β precursor remains within the cytosol and is cleaved 
to its mature form through the action of caspase-1 (or interleukin 1β Converting enzyme; 
ICE). Pro-IL-1β is also cleaved into its active form by other enzymes such as serine 
proteases (e.g., proteinase 3) and metalloproteinases (MMP-2 and MMP-9). Caspase-1 
is crucial for the processing of intracellular pro-IL-1β; although extracellular pro-IL-1β can 
be processed by a number of different proteases during inflammation (Ferrari et al. 2006, 
Thornberry et al. 1992).  
Caspase-1 is itself produced from the constitutively expressed cytosolic 45 kDa pro-
enzyme, pro-caspase; it requires post-translational processing to form 20 and 10k Da 
forms of active caspase-1 (Thornberry et al. 1992). Activation of caspase-1 occurs 
following assembly of the ‘inflammasome’. The NALP3 inflammasome is a multiprotein 
complex containing NALP3, apoptosis-associated speck-like protein (ASC), and caspase-
1, which oligomerise on cell activation (Ogura et al. 2006). Proteolytic activation of IL-1β 
occurs within the inflammasome complex. The exact mechanism of inflammasome 
formation and activation is not fully understood, and can be triggered by different 
mechanisms in different cell types.  
In addition to IL-1, IL-18 is a key mediator in the host response to infection and the 
inflammatory response (Dinarello 2002, Dinarello 2007). IL-18 is also constitutively 
produced as a precursor, pro-IL-18 (Dinarello 2007). Pro-IL-18 is cleaved by either 
caspase-1 or proteinase-3 (cf. pro-IL-1β above) into its active form, which is released into 
the extracellular space along with mature IL-1β. Extracellular release of active IL-1β and 
IL-18 is dependent on ATP-sensitive P2X7 activation. Contact with LPS alone is 
insufficient for extracellular release of IL-1β and IL-18; any one of a number of different 
stimuli, including extracellular ATP, nigericin, bacterial toxins, hypotonic stress, and T 
cells are usually required. The best-established stimulus to IL-1β and IL-18 post-
translational processing and release is ATP acting via the P2X7 (Dinarello 2007, Ferrari et 
al. 2006). 
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Experimental evidence supporting an attenuated inflammatory response with the use of 
P2X7 antagonists, or in P2X7 KO mice, may be directly related to inhibition of IL-1β 
release. However, the attenuated response may also be related to lack of induction of 
other inflammatory mediators. IL-1β may induce or release nitric oxide, COX-2, 
superoxide products, and other pro-inflammatory mediators (Dinarello 2009, 
Parvathenani et al. 2003). 
3.2.2 Effects of IL-1α, IL-1β, IL-18 
Il-1β has diverse functions relating to its unique ability to regulate inflammation at both the 
nuclear and membrane receptor levels. These include (i) induction of gene expression 
and synthesis of cyclooxygenase-1 (COX-2), prostaglandin-E2, platelet activating factor, 
NO, and IL-6 (Dinarello 2009, Parvathenani et al. 2003), (ii) expression of adhesion 
molecules on mesenchymal and endothelial cells (Myers et al. 1992, Ren et al. 2010, 
Wang et al. 1995, Yang et al. 2010) and (iii) angiogenesis via upregulation of VEGF 
(Sola-Villa et al. 2006) which may be an important protective mechanism in ischaemic 
injury. However, excessive IL-1 may be detrimental.  
IL-1 knockout (KO) mice and antagonist-treated rats subjected to ischaemia-reperfusion 
injury developed significantly less infiltration of polymorphonuclear leukocytes and had 
less severe renal histological and biochemical derangement (Furuichi et al. 2006, Haq et 
al. 1998, Rusai et al. 2008). Deficiency or neutralization of IL-1 conferred a similar 
protective effect in experimental glomerulonephritis (GN) (Chen et al. 1997, Lichtnekert et 
al. 2011, Timoshanko et al. 2004).  
Excessive tissue destruction may be mediated in part by IL-1α; the inflammation resulting 
from cell necrosis may be mediated by surface IL-1α (Chen et al. 2007).  IL-1α is also 
expressed on the membrane of monocytes and B-lymphocytes (Kaplanski et al. 1994, 
Kurt-Jones et al. 1985). In addition, the induction of many genes by INF-γ, including HLA-
DR, ICAM-1 and IL-18BP depends on basal IL-1α, but not IL-1β (Hurgin et al. 2007).  
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IL-18 is also a member of the IL-1 cytokine family. It is primarily expressed by 
macrophages and dendritic cells, but also by epithelial cells throughout the body 
(Perregaux et al. 2000, Takeuchi et al. 1999). One of its key features is its ability to 
induce INF-γ production (Takeuchi et al. 1999) and subsequent T cell polarisation 
(Takeda et al. 1998, Tomura et al. 1998). IL-18 plays an important role in the TH1 
response, primarily by its ability to induce IFN-γ production in T cells and natural killer 
cells (Dinarello 1999). Fas ligand-mediated cell death is also IL-18-dependent (Dao et al. 
1996, Zhang et al. 2011). IL-18 deficiency or neutralisation is associated with a reduction 
in renal tubular apoptosis in unilateral ureteric obstruction (UUO), I-R injury and 
glomerulonephritis (Bani-Hani et al. 2009, Sugiyama et al. 2008, Wang et al. 2012, Wu et 
al. 2008).  
3.2.3 Cell death and pyroptosis 
Caspase-1 activation with subsequent production of IL-1β and IL-18 has a biphasic 
effect; low levels cause cytokine production but, above a certain threshold, triggers 
pyroptosis (Bergsbaken and Cookson 2007).  
This catastrophic form of cell death, commonly found in monocytes, macrophages and 
dendritic cells, has morphological characteristics of apoptosis and necrosis. Cell lysis 
occurs due to caspase-1-dependent pore formation in the cell membrane, disruption of 
the cellular ionic gradient, osmotic driven water influx, and cell swelling. (Fink and 
Cookson 2006, Miao et al. 2011). This leads to further inflammasome activation, release 
of proinflammatory cytokines, damaged DNA and, ultimately, cellular disruption releasing 
other DAMPs. Release of mitochondria into the extracellular space results in discharge of 
ATP and also acts as a DAMP. 
An alternative mechanism of cell death relates to activation of the P2X7. Here, irreversible 
pore formation allows non-selective passage of ions and hydrophilic solutes of up to 900 
Da, resulting in colloido-osmotic cell lysis (Ferrari et al. 2006). P2X7-induced shrinkage 
depends on K+ efflux via KCa3.1, a voltage-independent potassium channel activated by 
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intracellular calcium, and a pathway of Cl- efflux distinct from that implicated previously in 
apoptosis (Taylor et al. 2008).  
3.2.4 Regulation of the inflammasome 
Activation of the inflammasome results in a rapid and substantial inflammatory response. 
As such, the inflammasome is tightly regulated at both transcriptional and post-
transcriptional levels. Basal expression of inflammasome components, in particular 
NLRP3, is relatively low (Bauernfeind et al. 2009); pro-apoptotic pathways, such as FAS 
ligand-receptor interactions, are required to induce ASC expression (Shiohara et al. 
2002).. ASC is localized to the nucleus in quiescent cells, but recruited to the cytoplasm 
on activation (Bryan et al. 2009). 
Alternatively, spliced inflammasome components generate protein variants with different 
activities. ASC has at least three different isoforms, one of which has an inhibitory effect 
on inflammasome activity (Bryan et al. 2010). Several proteins regulate inflammasome 
activity by sequestration of inflammasome components. Anti-apoptotic Bcl-2 proteins (e.g. 
Bcl-2, Bcl-xL) interact with NLRP1 to prevent ATP binding and inflammasome activation 
(Bruey et al. 2007). 
3.2.5 The NLRP3 inflammasome and host immunity in sepsis 
The NLRP3 inflammasome pathway has profound and diverse effects. Tight regulation of 
its activity is therefore crucial in maintaining health. Genetic deficiencies in the 
inflammasome pathway highlight its importance in host immunity. Both MyD88 (myeloid 
differentiation factor 88) and IRAK-4 (IL-1 receptor-associated kinase 4) are key elements 
of the TLR-IL-1 pathway (Burns et al. 2003). Loss of function mutations in MyD88 and 
IRAK-4 are associated with increased susceptibility to life-threatening severe 
staphylococcal and invasive pneumococcal infections (Picard et al. 2010, Takeuchi et al. 
2000, von Bernuth et al. 2008).  
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In addition to cytokine release, the NLRP3 inflammasome mediates host immunity by 
caspase-1 dependent pyroptotic cell death. This mechanism may be mediated by the 
P2X7 receptor (Taylor et al. 2008) which is crucial for destruction of intracellular 
pathogens including tuberculosis (Placido et al. 2006). Although pyroptosis and apoptosis 
are both programmed forms of cell death, unlike apoptosis, pyroptosis requires the 
activity of caspase-1 (Chen et al. 1996). 
3.2.6 The Inflammasome and Renal Disease  
Several primary renal diseases are associated with NLRP3 inflammasome activation, as 
are many systemic diseases affecting the kidneys (Table 4). These include I-R injury 
(Furuichi et al. 2006, Haq et al. 1998, Iyer et al. 2009, Rusai et al. 2008, Wang et al. 
2012, Wu et al. 2008), glomerulonephritis (Chen et al. 1997, Kinoshita et al. 2004, 
Lichtnekert et al. 2011, Schorlemmer et al. 1993, Sugiyama et al. 2008, Taylor et al. 
2008, Timoshanko et al. 2004, Turner et al. 2004), sepsis (Granfeldt et al. 2008, Hertting 
et al. 2003, Wang et al. 2005), CKD (Vilaysane et al. 2010, von Bernuth et al. 2008), and 
hypoxia (Edelstein et al. 2007). P2X7, IL-1β, IL-18, caspase-1, ASC, and NLRP3 are all 
associated with renal inflammation and injury. Virtually every model using genetic 
deletions and/or receptor antagonists/antiserum against the NLRP3 inflammasome 
pathway has shown lower disease severity, though publication bias cannot be excluded. 
Intrinsic renal cells express components of the inflammasome pathway. This is most 
prominent in tubular epithelial cells and, to a lesser degree, glomeruli. The precise 
mechanisms involving the NLRP3 inflammasome in disease relate to both systemic and 
local (renal) activation. Limited studies using global knockouts and bone marrow 
chimeras suggest that systemic production of cytokines may have a greater effect on 
renal injury (Wu et al. 2008). Genetic deletion or inhibition of the NLRP3 inflammasome 
pathway results in decreased local cytokines and chemokines, inflammatory cell infiltrate, 
and apoptosis. Locally released DAMPs result in inflammasome activation, resulting in 
chemokine release and immune cell infiltration. (Deplano et al. 2012).  
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The role of NLRP3 inflammasome activation in human renal disease remains uncertain. 
P2X7 and NLRP3 are upregulated in lupus nephritis and non-diabetic CKD, respectively 
(Turner et al. 2004, Vilaysane et al. 2010). Elevated serum IL-18 correlates with the 
development of diabetic nephropathy (Fujita et al. 2012), while urine IL-18 is raised in AKI 
associated with critical illness (Siew et al. 2010), cardiac surgery (Parikh et al. 2006), and 
radiocontrast (Turkmen et al. 2012). These support the notion that the inflammasome is 
intimately involved in wider inflammatory renal disease.  
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Table 4 The inflammasome and inflammatory renal disease 
P2X7 Disease Species Antagonist/ 
genetic deletion 
Effect Renal localisation of 
inflammasome component 
(Harada et 
al. 2000) 
TNF-α stimulation Rat - NA Mesangial cells 
(Goncalves 
et al. 2006) 
Unilateral ureteric 
obstruction 
Mouse P2X7 -/- Beneficial PTEC 
(Vonend et 
al. 2004) 
Hypertension 
Diabetes mellitus 
Rat - NA Glomerular podocytes 
(Turner et 
al. 2007) 
Experimental 
glomerulonephritis 
Mouse 
Rat 
- NA Glomeruli and infiltrating 
macrophages 
Glomeruli 
(Turner et 
al. 2007) 
Lupus Nephritis Humans - NA Glomeruli  
PTEC 
(Taylor et 
al. 2008) 
Experimental 
Glomerulonephritis  
Rat 
Mouse 
Antagonist  
P2X7 -/- 
Beneficial - 
NLRP3 Disease Species Antagonist/ 
genetic deletion 
Effect Renal localisation of 
inflammasome component 
(Deplano et 
al. 2012) 
Glomerulonephritis Rat Genetically 
susceptible 
strain 
NA Glomeruli and bone marrow 
derived macrophages 
(Vilaysane 
et al. 2010) 
Non-diabetic acute 
and chronic kidney 
diseases 
Human NA NA PTEC 
(Vilaysane 
et al. 2010) 
Unilateral ureteric 
obstruction 
Mice NLRP3−/−  Beneficial PTEC 
(Iyer et al. 
2009) 
Ischaemia- 
reperfusion injury 
Mice NLRP3−/− Beneficial - 
(Jalilian et 
al. 2012) 
None Dog NA NA Epithelial cells 
IL-1 
 
Disease Species Antagonist/ 
genetic deletion 
Effect Renal localisation of 
inflammasome component 
(Yamagishi 
et al. 2001) 
Unilateral ureteric 
obstruction 
Mouse IL-1 RA Beneficial PTEC 
(Haq et al. Ischaemia- Mouse IL-1 RA Beneficial - 
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1998) 
 
reperfusion injury IL-1R -/- 
(Chen et al. 
1997) 
IgA nephropathy Mice IL-1 RA Beneficial - 
(Matsumot
o et al. 
1988) 
Glomerulonephritis Human NA NA  
(Tam et al. 
1994) 
Glomerulonephritis Rat NA N/A  
(Lan et al. 
1995) 
Glomerulonephritis Rat IL-1RA Beneficial  
(Karkar et 
al. 1992) 
Glomerulonephritis Rat Antibody Beneficial  
(Karkar et 
al. 1995) 
(Tam et al. 
1996) 
Glomerulonephritis Rat IL-1RA and 
soluble IL-1R 
Beneficial  
(Timoshan
ko et al. 
2004) 
Crescentic 
glomerulonephritis 
Mice IL-1β -/- 
IL-1R -/- 
Beneficial - 
(Lichtneker
t et al. 
2011) 
Anti-GBM disease Mice NLRP3 -/- 
Caspase1 -/- 
ASC -/- 
IL-1R1 -/- 
Il-18 -/- 
No effect 
No effect 
No effect 
Benefit 
Mild  
Renal dendritic cells 
(Schorlem
mer et al. 
1993) 
SLE-like disease Mice IL-1 RA Beneficial - 
(Furuichi et 
al. 2006) 
Ischaemia- 
reperfusion injury 
Mice IL-1α/β -/-  
IL-1RA -/- 
Beneficial Glomeruli and cortical arterioles 
(Rusai et 
al. 2008) 
Ischaemia- 
reperfusion injury 
Rats IL-1 RA Beneficial - 
(Granfeldt 
et al. 2008) 
Endotoxaemia Pigs NA NA Endothelial cells of the cortical 
arterioles positive for IL-1β;  
IL-1ra detected in glomerulus and 
tubular cells 
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(Hertting et 
al. 2003)  
E.Coli pyelonephritis Mice IL-1 β -/-  Harmful - 
Caspase-1 Disease Species Antagonist/ 
genetic deletion 
Effect Renal localisation of 
inflammasome component 
(Homsi et 
al. 2006) 
Glycerol- induced AKI Rats Caspase-1 
inhibitor 
Beneficial Constitutive tubular expression of 
IL-18 
Induction of tubular IL-1β  
(Wang et 
al. 2005) 
Endotoxaemia Mice Caspase 1 -/- 
IL-1 Ra 
IL-18 antiserum 
Beneficial 
No effect 
No effect 
- 
(Gauer et 
al. 2007) 
None Humans NA NA Collecting duct alpha- and beta-
intercalated cells express P2X7, 
IL-18 
(Edelstein 
et al. 2007) 
Hypoxia Mice Caspase 1 -/-  
IL-18 BP 
Beneficial 
No effect 
IL-18 in PTEC 
IL-18 Disease Species Antagonist/ 
genetic deletion 
Effect Renal localisation of 
inflammasome component 
(Bani-Hani 
et al. 2009) 
 
Unilateral ureteric 
obstruction 
Mice Transgenic mice 
overexpressing 
human IL-18-BP 
Beneficial TECs 
(Wu et al. 
2008) 
Ischaemia- 
reperfusion injury 
Mice IL-18 -/- 
IL-18-/- BM 
chimera 
IL-18-BP 
Beneficial 
Beneficial 
Beneficial 
TECs 
(Sugiyama 
et al. 2008) 
Bovine albumin-
induced GN 
Mice IL-18R -/- Beneficial - 
(Kinoshita 
et al. 2004) 
Autoimmune disease Mice IL-18R -/- Beneficial - 
(Wang et 
al. 2012) 
Ischaemia- 
reperfusion injury 
Rat IL-18-binding 
protein 
Beneficial - 
(Zhang et 
al. 2011) 
Unilateral ureteric 
obstruction 
Mice Overexpresses 
human IL-18-BP  
Beneficial - 
(VanderBri
nk et al. 
2011) 
Unilateral ureteric 
obstruction 
Mice IL-18 -/- NA TECs 
ASC Disease Species Antagonist/ Effect Renal localisation of 
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genetic deletion inflammasome component 
(Iyer et al. 
2009) 
Ischaemia- 
reperfusion injury 
Mice ASC -/- Beneficial - 
Abbreviations: PTEC, proximal tubular epithelial cells, NLRP3, Nod-like receptor protein 3; IL-1RA, 
interleukin 1 receptor antagonist, ARF, acute renal failure; TEC, tubular epithelial cell; BM, bone 
marrow 
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3.2.7 Drugs modulating the NLRP3 inflammasome pathway 
Growing evidence suggests that the inflammasome and the IL-1β/IL-18 axis play an 
integral part in the pathogenesis of many acute and chronic conditions, including gout, 
rheumatoid arthritis, atherosclerosis, Alzheimer’s disease, diabetes mellitus and oxalate 
crystal nephropathy. Several components of the NLRP3 inflammasome are implicated in 
renal disease. Therapeutic interventions that modulate this pathway are being developed, 
e.g. inhibiting IL-1, P2X7 or caspase-1, and the functional significance of the 
inflammasome and the IL-1β/IL-18 axis in renal disease is of growing interest. To date, 
only IL-1 inhibitors have been successful in clinical studies of rheumatoid arthritis (RA) 
and cryopyrin-associated periodic syndrome (CAPS). 
3.2.7.1 IL-1 inhibitors 
The clinical application of IL-1 inhibitors has been slow as the first generation of 
inhibitors, the recombinant IL-1 receptor antagonists, have a short circulatory half-life and 
limited affinity for the receptor. A large molar excess of recombinant IL-1ra is needed to 
antagonize endogenous IL-1 effectively. Drugs inhibiting the action of IL-1 include 
recombinant human IL-1ra (Anakinra), a humanised monoclonal IL-1β antibody 
(Canakinumab), and a neutralising antibody against IL-1α and IL-1β (Rilonacept). IL_1 
antagonists may be beneficial in paediatric CPAS, systemic juvenile idiopathic arthritis, 
and type 2 diabetes mellitus (Hensen et al. 2013, Ruperto et al. 2012, Russo et al. 2014).  
3.2.7.2 P2X7 antagonists 
Drugs inhibiting the P2X7 are currently in Phase 1 and 2 clinical trials (Arulkumaran et al. 
2011). At present there are no data to demonstrate a beneficial effect of P2X7 
antagonism, although trials are still at an early stage. Preclinical data suggest P2X7 
antagonists have a potential role in the treatment of inflammatory rheumatological 
(Dell'Antonio et al. 2002, Dell'Antonio et al. 2002), renal (Taylor et al. 2009, Turner et al. 
2007), and pulmonary diseases (Fernando et al. 2007, Kolliputi et al. 2010, Wareham et 
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al. 2009). Although Phase 1 and 2 studies have demonstrated safety, preliminary studies 
have so far not shown clinical efficacy in the management of rheumatoid arthritis 
(Keystone et al. 2012). 
3.2.7.3 Caspase-1 inhibitors 
Small molecule inhibitors of caspase-1 have been used in experimental models. Only 
pralnacasan (VX-740) and VX-765 have been used so far in patients; however, concerns 
about liver toxicity with prolonged use of pralnacasan have resulted in discontinuation of 
clinical trials in RA, psoriasis, and osteoarthritis (Cornelis et al. 2007). A Phase 2 clinical 
trial of VX-765 has been completed, although results have yet to be published (Cornelis 
et al. 2007). 
3.3 Other Inflammasomes 
NLRP1 was the first inflammasome to be described (Levinsohn et al. 2012). It has its own 
CARD, so can bypass the requirement of the adapter molecule ASC for inflammasome 
activation (Figure 3). Cleavage by anthrax toxin directly activates CARD, leading to 
activation of caspase-1 (Levinsohn et al. 2012). An alternative mechanism of NLRP1 
activation is by the toxin inhibiting p38 mitogen-activated protein kinase and Akt kinase, 
leading to opening of the connexion channel for ATP release, resulting in P2X7 signalling 
(Ali et al. 2011). There are similarities with the mechanism of activation of the NLRP3 
inflammasome. 
A second class of inflammasomes contains members of the PYHIN family, rather than 
NLRs. Examples include AIM2 and Interferon-γ inducible protein 16 (IFI16) 
inflammasomes. These lack a CARD domain and require ASC for recruitment of pro-
caspase-1 to form a stable inflammasome complex. Following detection of bacterial or 
viral dsDNA, AIM2 and IFI16 inflammasomes assemble with subsequent secretion of IL-
1β and IL-18 (Roberts et al. 2009). AIM2 can recognise self-DNA, but this is limited under 
steady-state conditions because of its cytosolic location. In conditions where self-DNA is 
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not cleared from the extracellular compartment, it is likely that DNA can activate AIM2 
and drive inflammation.  
The NLRC4 inflammasome interacts directly with pro-caspase-1 via homotypic CARD 
interactions, leading to processing of caspase-1. This inflammasome complex plays an 
essential role in the innate immune response to the bacterial proteins flagellin and PrgJ 
(Zhao et al. 2011).  
The NLRP6 inflammasome associates with ASC, inducing caspase-dependent 
processing and release of IL-1β. At the mRNA level NLRP6 is highly expressed in mouse 
liver, kidney and small intestine, and plays a central role in modulating inflammatory 
responses in the gut to allow recovery from intestinal epithelial damage, tumorigenesis, 
and in controlling the composition of the gut microflora to prevent colonization by harmful 
bacteria (Lech 2010(Chen et al. 2011, Lech et al. 2010). Data on NLRP6 and renal 
disease are limited and warrant further study.  
The NLRP12 inflammasome is expressed in human myeloid cells. It acts as a negative 
regulator of inflammation by reducing Nf-κB activation and inhibiting chemokine 
expression through ATP hydrolysis (Ye et al. 2008). NLRP12 also reduces NFκB 
activation by TLR-signaling molecules (Williams et al. 2005).  
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Figure 3 Models for inflammasome activation and assembly.   
The NLR family members and the HIN-200 proteins, AIM2 and IFI16, assemble inflammasome complexes.   
NLRs are characterised by a NACHT domain with or without an N-terminal PYD domain and a variable number 
of LRRs.  AIM2 and IFI16 contain an N-terminal PYD domain followed by a DNA binding HIN-200 domain.  The 
PYD domain of NLRP3, 6 and 12, AIM2 and IFI16 recruit the adaptor protein ASC via homotypic binding to its 
PYD domain allowing indirect recruitment of caspase-1 through interaction with the CARD domain.  NLRP1 and 
NLRC4 directly recruit caspase-1 through a CARD domain.  NLRC4 is activated by NAIP proteins bound to 
specific ligands, NAIP 2 binds to the bacterial rod protein PrgJ whereas NAIP 5 and 6 bind to bacterial flagellin.  
Activation of the inflammasome leads to maturation and secretion of IL-1β and IL-18 aswell as inflammatory cell 
death by pyroptosis. 
Abbreviations: AIM2, absent in melanoma 2; CARD, caspase recruitment domain; DAMP, danger-associated 
molecular pattern; FIND, domain with function to find; IFI16, Interferon-γ inducible protein 16; LRR, leucine rich 
repeat; NACHT, nucleotide-binding and oligomerization domain; NAIP, NLR family apoptosis inhibitor; NLR, 
Nod-like receptor, PAMP, pathogen associated molecular pattern; PYD, pyrin domain. 
 
3.4 P2X7 receptor 
3.4.1 Purinergic receptors 
in 1970 Burnstock proposed that adenosine triphosphate (ATP) may have an extracellular 
role as a signalling molecule and a neurotransmitter in so-called non-cholinergic, non-
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adrenergic (NANC) neurotransmission. This role of ATP as an extracellular messenger 
(purinergic cell signaling) is now known to be not confined to the nervous system. Indeed, 
many roles for purinergic receptors in health and disease have now been identified. 
In 1978, Burnstock sub-classified the purinergic receptors into P1 and P2 receptors: 
adenosine acts on P1 receptors, whereas ATP and its breakdown products, ADP and 
AMP, act on P2 receptors. Burnstock and Kennedy later proposed a further sub-
classification of the P2 receptors, dividing them into P2X and P2Y receptors: P2X 
receptors are inotropic ligand-gated non-selective cation channel receptors and P2Y 
receptors are G protein coupled; there are currently seven P2X subtypes and eight P2Y 
subtypes (Burnstock 2006). 
3.4.2 P2X7 receptor 
The P2X7 receptor (P2X7) is a distinct member of the P2X subclass, as its downstream 
signaling is coupled to pro-inflammatory cascades. It is a 595-amino acid polypeptide with 
two membrane-spanning domains and a long intracellular C-terminus compared with 
other P2X receptors (North 2002). It is expressed on many cell types, the most studied 
being macrophages and monocytes, and has a key role in regulating cell survival and 
release of mature IL-1β and IL-18 (Ferrari et al. 2006). 
The P2X7 receptor is a ligand-gated cation channel best characterized in immune cells 
(Di Virgilio et al. 2001). Expression and activity of the P2X7 is significantly upregulated in 
response to inflammatory stimuli, including TNFα and LPS (Ferrari et al. 2006, 
Humphreys and Dubyak 1998, Mehta et al. 2001) P2X7 channel activation results in 
release of mature IL-1β and IL-18 (Rassendren et al. 1997, Sluyter et al. 2004); 
prolonged activation results in irreversible pore formation and cell death (Sluyter et al. 
2004, Taylor et al. 2008, Wilson et al. 2004). 
During active inflammation, local concentrations of extracellular ATP are raised, which is 
thought to be mainly a consequence of cell damage and lysis. To activate the P2X7 in 
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vitro, extracellular concentrations of ATP in the range of 1 mM are required, in contrast to 
concentrations of ≤100 µM needed to activate other P2 receptors. The ATP molecule 
binds to and activates P2X7, resulting in pore formation. This leads to K+ efflux from the 
cell, which is a crucial step in inflammasome assembly. In addition there is an influx of 
Ca2+, which is also required for the release of active IL-1β (Ferrari et al. 2006, MacKenzie 
et al. 2001). Prolonged activation of the P2X7 results in irreversible pore formation and 
allows non-selective passage of ions and hydrophilic solutes of up to 900Da; this can 
result in colloido-osmotic lysis and cell death by apoptosis or necrosis (Ferrari et al. 
2006). Pore formation is thought to allow entry of bacterial products (PAMPs) and 
extracellular ATP into the cell, which drives inflammasome formation (Pelegrin and 
Surprenant 2009). 
Oxidised ATP (oATP) is a potent, but non-selective, P2X7 antagonist that can attenuate 
inflammatory responses independent of P2 receptor blockade (Beigi et al. 2003). This 
must considered when interpreting much of the experimental data referred to in this 
review as oATP has been one of the most widely used P2X7 antagonists. In addition to 
blocking P2X7, oATP is known to antagonise P2X1 and P2X2 receptors, and inhibit NFkB.  
More selective P2X7 antagonists exist and have been used successfully in in vitro 
experiments, and in Phase 1 and Phase 2 clinical trials (Arulkumaran et al. 2011). 
3.4.3 The P2X7 and cell survival 
The P2X7 has a role in cell survival and growth. Its growth-promoting function seems 
contradictory to its established role in apoptosis; however, this receptor is expressed at a 
high level in some malignancies, which may be consistent with its growth-promoting role 
(Adinolfi et al. 2002). The anti-apoptotic property of P2X7 is based on studies using oATP 
(Adinolfi et al. 2009, Adinolfi et al. 2002) and KN-93 (Nagaoka et al. 2006). Basal 
activation of P2X7 (via autocrine/paracrine release of extracellular ATP) promotes cell 
growth (Adinolfi et al. 2005). 
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3.4.4 LL-37 
Although ATP is a P2X7 agonist, causing IL-1β processing and release from LPS-primed 
macrophages and monocytes, the concentration of ATP (0.5-5mM) required to induce IL-
1β release in vitro is believed to be far higher than is normally present in the extracellular 
space of tissues, at least under physiological conditions (North and Surprenant 2000).  
Several studies suggest that human cathelicidin-derived peptide, LL-37, may be a P2X7 
agonist. Cathelicidins are an integral part of the innate immune system, with human 
cationic antimicrobial protein-18 (hCAP18) being the only known cathelicidin in humans 
(Gudmundsson et al. 1996). LL-37 has a well-established antimicrobial function, exerting 
direct antimicrobial activity against both Gram-positive and Gram-negative organisms, 
and neutralising LPS (Durr et al. 2006). In the presence of LL-37, the concentration of 
ATP required to activate P2X7 was approximately 4000-fold lower than that usually 
needed to release the same amount of IL-1β (Elssner et al. 2004). LL-37 treatment of 
LPS-primed monocytes leads to caspase-1 activation and an increase in IL-1β release 
via P2X7R in a dose-dependent manner (Elssner et al. 2004). LL-37 treatment of LPS-
primed monocytes also results in transient release of ATP, peaking after 5-10 minutes at 
a concentration of ~150nM (Elssner et al. 2004)..  
3.4.5 P2X7 and antibody production 
The role of P2X7 in IL-1β and IL-18 release and in cell death is well established. The 
nephrotoxic nephritis model provides evidence that P2X7 may affect antibody production. 
P2X7 is primarily found on antigen-presenting cells, including dendritic cells and 
macrophages (Di Virgilio et al. 2001). In a nephrotoxic nephritis model there was a small 
decrease in the mouse anti-sheep IgG deposition in the glomeruli of P2X7 KO mice 
(Taylor et al. 2009). This raises the possibility that P2X7 may be involved in antibody 
production.  
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3.4.6 Current use of P2X7 antagonists in clinical trials 
Phase 1 and phase 2 clinical trials investigating the safety and efficacy of P2X7 
antagonists are currently underway (Arulkumaran et al. 2011). No serious safety 
concerns have been raised. Phase 2 clinical trials have investigated the use of P2X7 
antagonists in inflammatory bowel disease, rheumatoid arthritis, and chronic obstructive 
airway disease. Main side effects include gastrointestinal upset (diarrhoea and nausea), 
dizziness, and headaches.  
Factors underlying the limited efficacy to date include pharmacokinetics and 
pharmacodynamics. P2X7 polymorphisms may be another factor to consider. In future 
drug development, the affinity of P2X7 antagonists for different polymorphic forms of P2X7 
may need investigation and correlation with efficacy. With better understanding the 
underlying disease processes and more drug development, the prospects for P2X7 
targeted therapy is encouraging.  
3.4.7 P2X7 receptor in sepsis 
The importance of capase-1 and secretion of mature IL-1β in sepsis have been studied in 
rodent models (Mehta et al. 2001, Novogrodsky et al. 1994). Studies also suggest a key 
role for the regulation/inhibition of IL-1 β release as a therapeutic strategy (Li et al. 1995). 
However, a large Phase 3 randomised clinical trial failed to support the benefit of a 
recombinant human IL-1 receptor antagonist in patients with severe sepsis (Opal et al. 
1997). However, this finding does not preclude the use of a P2X7 antagonist in sepsis, as 
these have actions over and above IL-1β release that could be beneficial. An 
immunomodulatory agent that can interfere with more than one arm of the sepsis 
response, such as a P2X7 receptor antagonist, may have promise if given to the right 
patient and at the right time.  
Some experimental data suggests that P2X7 receptor antagonism may be beneficial in 
sepsis. LL37 is a potent mediator of the P2X7 pathway which reduces the ATP 
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concentration required to activate the P2X7 by 4000-fold (Elssner et al. 2004). In an in 
vivo model of sepsis, LPS-induced P2X7 activation, and subsequent IL-1β release, IL-1 β 
resulted in iNOS expression, increased levels of NO, and vascular smooth muscle 
hyporeactivity (Chiao et al. 2008). There is an association between sepsis severity, 
mitochondrial dysfunction, and outcome (Brealey et al. 2002). BzATP stimulation of P2X7-
transfected cell lines resulted in loss of the mitochondrial membrane potential with 
subsequent fragmentation of mitochondria and cell death (Adinolfi et al. 2005). 
Mitochondrial fragmentation was absent in cells lacking P2X7. Thus, it is plausible that a 
P2X7 antagonist could have a role in the preservation of mitochondrial function in sepsis. 
Apoptosis of lymphocytes is also associated with a worse outcome in sepsis (Hotchkiss 
et al. 1999, Hotchkiss et al. 2001) and blocking apoptosis has been improved survival in 
experimental models of sepsis (Chung et al. 2003, Hotchkiss et al. 2001). T lymphocytes 
express functional P2X7 (Aswad and Dennert 2006); blocking these receptors with P2X7 
antagonists to prevent apoptosis may also confer a survival advantage in sepsis. 
3.4.8 P2X7 receptor and renal disease 
Within the rat kidney, P2X7 is expressed at very low levels under normal conditions 
(Turner et al. 2003). Several studies reported upregulation of renal P2X7 expression 
under various pathological conditions in vivo and in vitro (Table 5). This was first 
described in a rat model of hypertension and diabetes mellitus (Vonend et al. 2004). 
Similarly, rats with streptozotocin-induced diabetes had significant P2X7 detectable in 
their glomeruli at 6 and 9 weeks. At the mRNA level this corresponded to a ten-fold 
increase in expression of P2X7. Immunohistochemistry and immuno-electron microscopy 
studies of diabetic rats showed that P2X7 were expressed mainly in glomerular podocytes 
(also with some expression in endothelial cells and mesangial cells). 
Turner et al demonstrated perhaps the most striking evidence for a pathogenic role of 
P2X7 using a rodent model of experimental glomerulonephritis (GN) (Turner et al. 2007). 
Here, an increased glomerular expression of P2X7 was demonstrated, co-existent with an 
 80 
increase in glomerular apoptotic cells. These findings are consistent with clinical findings 
of increased glomerular, and some tubular, expression of P2X7 in patients with lupus 
nephritis (Turner et al. 2007). P2X7 KO mice exposed to nephrotoxic serum were 
significantly protected from antibody-mediated GN (Taylor et al. 2009), with reduced 
glomerular macrophage infiltration, fibrin deposition, glomerular thrombosis and reduction 
in proteinuria, and protection of overall renal function compared to wildtype controls. 
Renal IL-1β levels were too low for quantification, though CCL2 (MCP-1) levels were 
reduced in P2X7 KO mice. In a rat model of antibody-mediated GN, the onset of 
glomerular P2X7 expression coincided with the onset of proteinuria (Turner et al. 2007); 
treatment with a selective P2X7 antagonist (A438079) reduced glomerular expression of 
CCL2, glomerular macrophage infiltration, severity of glomerular injury, and proteinuria. 
The P2X7 gene polymorphisms may contribute to susceptibility to lupus nephritis in 
selected patient populations, and blockade of the P2X7 has also been shown to be 
protective in murine lupus nephritis (Chen et al. 2013, Zhao et al. 2013).   
P2X7 is implicated in the pathogenesis of renal inflammation and fibrosis.  In a mouse 
model of unilateral ureteral obstruction (UUO), immunohistochemistry demonstrated P2X7 
expression in the epithelial cells of the renal cortex in KO mice on day 7 only (Goncalves 
et al. 2006). Myofibroblast number and collagen deposition were significantly reduced in 
P2X7 KO mice as were transforming growth factor-β (TGF-β) protein levels. By day 14, 
kidneys from the P2X7 KO mice showed reduced numbers of infiltrating macrophages 
and less tubular cell apoptosis. The tubulo-interstitial damage and subsequent fibrosis 
associated with UUO were attenuated in P2X7 KO mice, suggesting a role for tubular 
P2X7 in renal inflammation and fibrosis. 
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Table 5: P2X7 and inflammatory renal diseases 
  
Reference Disease Species Antagonist/ 
genetic deletion 
Effect Renal 
localisation of 
inflammasome 
component 
(Harada et 
al. 2000) 
TNF-α stimulation Rat - NA Mesangial cells 
(Goncalves 
et al. 2006) 
Unilateral ureteric 
obstruction 
Mouse P2X7 -/- Beneficial PTEC 
(Vonend et 
al. 2004) 
Hypertension 
Diabetes mellitus 
Rat - NA Glomerular 
podocytes 
(Turner et 
al. 2007) 
Experimental 
glomerulonephritis 
Mouse 
Rat 
- NA Glomeruli and 
infiltrating 
macrophages 
Glomeruli 
 Lupus Nephritis Humans - NA Glomeruli  
PTEC 
(Taylor et 
al. 2008) 
Experimental 
Glomerulonephritis 
Rat 
Mouse 
Antagonist 
P2X7 -/- 
Beneficial - 
(Zhao et al. 
2013) 
Murine lupus 
nephritis 
Mouse P2X7 -targeted 
small interfering 
RNA (siRNA) 
BBG 
Beneficial - 
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4 Animal models of sepsis and recovery 
4.1 Background 
Despite the clinical significance of septic AKI, therapy is limited to supportive care. The 
complex interplay between global and renal haemodynamics, microcirculation, 
bioenergetic dysfunction, and the immune system underlie the pathophysiology of septic 
AKI and recovery (Chapter 2). The relative contribution of different mechanisms to the 
pathophysiology of septic AKI and recovery needs to be ascertained for the development 
of novel diagnostics, monitoring and therapeutics.  
Animal models offer the advantage of knowing precisely when the septic insult 
commenced and allow control of volume status and other conditions in a relatively 
homogenous population. However, to be representative of the human condition, they 
have to simulate many of the physiological and pathological aspects of sepsis including a 
proper infectious insult, an adequate duration of study, and fluid resuscitation to avoid the 
consequences of untreated hypovolaemia leading to organ hypoperfusion (Chapter 1.6). 
Over many years the Singer lab at University College London (UCL) has developed an 
increasingly sophisticated long-term (3 day) rat model of faecal peritonitis where the 
animals are conscious and instrumented with tunnelled arterial and venous lines (to 
enable continuous blood pressure monitoring, continuous fluid administration and 
intermittent blood sampling). Additional studies can be performed as needed, including 
intermittent echocardiography, and tissue oxygen measurements. In two studies from the 
lab, 6h echocardiographic measurements of stroke volume and heart rate could 
reproducibly differentiate between eventual survivors and non-survivors (Dyson et al. 
2011, Rudiger et al. 2013). 
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The objective of this experiment was to characterize parallel changes in 
haemodynamic, biochemical, histological, and immunological parameters in a 
clinically relevant model of sepsis and recovery. 
4.1.1 Characterization  
Information from the characterization of the preclinical model was required prior to 
planning of further studies. The parameters that I characterized included: 
1. Global haemodynamics 
2. Biochemistry (renal and liver function tests, electrolytes) 
3. Systemic cytokines including pro-inflammatory cytokines (IL-1β, IL-6, IL-18, INF-
γ), anti-inflammatory cytokines (IL-10), and chemokines (MCP-1) 
4. Renal cytokine release including pro-inflammatory cytokines (IL-1β, INF-γ), anti-
inflammatory cytokines (IL-10, IL-4) and chemokines (MCP-1) 
5. Renal histology (including tubular injury, cell death, and macrophage infiltration) 
Additional studies were based on the results of this characterization study, including: 
1. Temporal changes in a panel of renal biomarkers in septic AKI and recovery 
(described in this chapter) 
2. Changes in renal haemodynamics and bioenergetics in sepsis (Chapter 5) 
3. The role and potential therapeutic intervention of the inflammasome in sepsis and 
sepsis-induced AKI (Chapter 6) 
4.1.2 Renal biomarkers in septic AKI 
The current lack of a sensitive marker of early parenchymal kidney injury in sepsis 
reduces the window of opportunity for early effective intervention to prevent renal 
dysfunction and failure. Numerous novel blood and urine markers of renal 
injury/dysfunction are currently being promoted but, at present, remain poorly 
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characterized. Measuring a panel of renal injury/dysfunction markers will likely enhance 
interpretation of this dynamic process. However, studies in septic patients are 
confounded by an inability to precisely time the onset of sepsis. Thus, the temporal 
relationship of these biomarkers to the onset and progression of renal dysfunction and 
injury is unknown. Some clinical trials have investigated the utility of biomarkers in 
predicting recovery from AKI. Serial measurements of a panel of renal biomarkers in a 
well-characterized, clinically relevant and closely monitored animal model with a defined 
onset of polymicrobial sepsis may provide invaluable information that could be 
translatable to the patient.  
We used a similar design to that described by Ozer et al who measured a panel of urinary 
biomarkers to monitor the reversibility of renal injury at different timepoints over 15 days 
following administration of nephrotoxic drugs such as gentamicin (Ozer et al. 2010). They 
compared changes in biomarkers against the degree of histological injury and standard 
measures of renal function, namely urea and creatinine. Using the fluid-resuscitated 3-
day rat model of faecal peritonitis, we investigated a panel of biomarker changes across 
the septic process of inflammation and recovery and correlated these against changes in 
renal histology and standard measures of renal biochemical function. Characteristics of 
the biomarker panel are detailed in Chapter 2.9.  
4.2 In vivo Methods 
4.2.1 Instrumentation of animals 
Male Wistar rats (Charles River, Margate, UK) weighing 300-375g were used throughout. 
All experiments were performed under a Home Office Project License (PPL 70/7029) and 
local UCL Ethics Committee approval. Before experimentation, the rats were housed in 
cages of six on a 12-12 h light–dark cycle. Six timepoints (3, 6, 12, 24, 48 and 72h) were 
selected to represent early, established and recovery phases of sepsis. Systemic 
haemodynamics were measured at these timepoints (Figure 4).  
 85 
 
 
Figure 4 Diagrammatic representation of the time course of experiments. Animals are 
cannulated and allowed 24 h to recover. Intravenous fluid is commenced 2 h following 
induction of sepsis and a bolus is given at 6 h, and 24 h. Transthoracic echocardiography 
is performed at baseline, 6 h, and prior to the terminal experiment.  
 
All invasive and imaging techniques were performed under general anaesthesia. 
Induction of anaesthesia was performed by placing an animal in a transparent plastic 
container filled with 5% isoflurane (Baxter Healthcare, Thetford, UK) in room air. A 
vaporiser (VetTech solutions, Congleton, UK) and a commercially available pump 
(Tetratec APS 400, Tetra GmbH, Melle, Germany) at a flow rate of 400 ml/min were used 
to administer the anaesthetic. Animals remained spontaneously breathing throughout.  
Following loss of the righting reflex, animals were placed in the supine position on a 
heated mat. Core (rectal) temperature was monitored continuously using a TES 1319 
thermometer (TES Electrical Electronic Corp, Taipei, Taiwan) and a heated lamp used to 
maintain core temperature between 36-37.5oC. Anaesthesia was maintained at a level 
(typically 2% isoflurane) that was adequate to abrogate the withdrawal reflex to pain.  
Under strict aseptic technique, the neck, chest and left flank were shaved and sprayed 
with 70% ethanol. A 2cm vertical incision was made on the ventral aspect of the neck, 
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and the salivary glands separated by blunt dissection. The right internal jugular vein was 
isolated and cannulated using PVC tubing (outer diameter 0.96 mm) (Biocorp Ltd, 
Huntingdale, Australia). The central venous cannula (CVC) was secured with 2.0 silk 
sutures and flushed with 0.1 ml saline and a small quantity of blood drawn back to ensure 
correct placement and patency of the line. The line was tunneled subcutaneously to exit 
the skin at the nape of the neck. A swivel/tether system (InsTech, Plymouth Meeting, PA, 
USA) was secured to the neck by four 2-0 silk sutures (Ethicon Inc, Somerville, NJ, USA). 
Surgical incision sites were sutured using 3.0 silk sutures. N-saline was infused at 0.1 
ml/hr to maintain patency. Prior to recovery from anaesthesia, 0.05mg/kg buprenorphine 
(Vetergesic, Reckitt Benckiser, York) was administered subcutaneously for ongoing pain 
relief.  
Rats were then placed in individual cages mounted on the tether/swivel system to secure 
the intravenous catheter and allow unimpeded movement around the cage on awakening 
from anaesthesia. The animals had free access to food and water.and were scored at 
least four times daily. The clinical score has been previously validated in our lab (Table 6) 
(Brealey et al. 2004). A cumulative score was calculated and animals with a score of ≥4 
or were culled to avoid excessive suffering. Animals culled prematurely, but which 
survived >90% of the predetermined time point, were included in the analysis. Peri-
mortem animals were excluded from analysis (typically animals with a core body 
temperature <35oC). 
Characteristic Score* 
Hunched 0- 1 
Bloated 0- 1 
Conjunctival injection 0- 1 
Piloerection 0- 1 
Lack of movement 0- 2 
Lack of alertness 0- 2 
* Score range from 0 (absent), 1 (present), and 2 (marked presence) 
Table 6: Clinical scoring characteristics 
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4.2.2 Induction of sepsis 
At 24 h post-CVC insertion, sepsis was induced by intraperitoneal injection of faecal 
slurry. Animals were re-anaesthetized briefly to received 3-5 µl/kg of fecal slurry (diluted 
1-in-8 in 0.9% saline), injected using a 19-gauge needle into the right lower quadrant of 
the abdomen after raising a skin fold to avoid bowel perforation. A similar procedure was 
not carried out in sham animals to avoid inadvertent perforation of the bowel. Clinical 
scoring was performed at 2 h, and every 4 h thereafter. 
4.2.3 Fluid therapy 
Fluid resuscitation at 10 ml/kg/h was initiated from 2 hours’ post-induction of sepsis. 
Sham animals received a similar fluid regimen. Starch-based solutions were avoided in 
view of potential nephrotoxicity. Similarly, chloride-rich solutions (0.9% saline) were 
avoided to avoid any adverse renal effects including reduced glomerular filtration rate 
(Wilcox 1983). Previous experience within the lab has shown that septic animals 
significantly reduce their oral food consumption and succumb to hypoglycaemia. A 1:1 
mix of 5% glucose and a Hartmann’s solution were used ( 
Table 7). 
The optimal volume and rate of fluid administration to maintain intravascular volume 
based on echo parameters has been previously determined by the lab (Rudiger et al. 
2013). To recreate a clinical scenario, intravenous fluid administration was started 2 
hours following sepsis at 10 ml/kg/h. This was halved to 5 ml/kg/h at 24 h and to 2.5 
ml/kg/h at 48 h. A 20 ml/kg fluid bolus was administered at 6 h, and 10 ml/kg fluid bolus at 
24 h at a rate of 1 ml/min. Prior to each fluid bolus (and at the terminal timepoint), 
transthoracic echocardiography was performed. 
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 Serum 0.9% 
Saline 
Hartmann’s 
Solution 
5% dextrose 
Sodium (mmol/L) 135 - 147 154 131 0 
Chloride (mmol/L) 98 - 106 154 111 0 
Lactate (mmol/L) < 2.0 0 29 0 
Potassium (mmol/L) 3.5 – 5.5 0 5 0 
Calcium (mmol/L) 2.1 – 2.8 0 2 0 
Bicarbonate (mmol/L) 22 - 28 0 0 0 
Glucose (mmol/L) 4 - 7 0 0 278 
Osmolarity (mOsm/L) 280 - 195 300 279 272 
pH (at room temperature) 7.35 – 7.45 5.5 6.5 4.3 
 
Table 7 Composition and pH of different solutions compared to serum 
Several rodent models of sepsis examining renal function have not given fluid, or 
included only a single bolus of subcutaneous fluid (Langenberg et al. 2007). This raises 
the possibility of hypovolaemia being a significant confounding factor in the pathogenesis 
of AKI. A separate experiment was therefore performed to ascertain the impact of this 
fluid resuscitation (a clinically relevant intervention) on the natural history of sepsis-
induced AKI in my rat model. Septic animals without fluid resuscitation were culled at 6 
hours (n=6 per group). 
4.2.4 Slurry dose finding study 
The dose of slurry producing a near-100% survival rate at 24h was determined to avoid a 
selection bias where only animals with a less profound septic response would be included 
in the analysis of renal haemodynamics. Doses ranged from 3-5 µl/Kg, based on previous 
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studies from the lab. I aimed to confirm a previous lab finding that a stroke volume <0.17 
ml measured at 6 h could differentiate between eventual survivors and non-survivors with 
positive and negative predictive values of 93% and 80%, respectively (Rudiger et al. 
2013). Cox-proportional regression analysis was performed to assess whether SV 
estimation at 6h could predict mortality at 24h.  
4.2.5 Intermittent estimation of cardiac output and ventricular 
function 
Prior to venous cannulation and at a subsequent timepoint (6 or 24 h post-induction of 
sepsis), transthoracic echocardiography was performed under a brief period of 1.2% 
isoflurane anaesthesia to determine global haemodynamics and left ventricular function. 
Scans were performed using a Vivid 7 Dimension™ device (GE Healthcare, Bedford, 
UK) with a 10 MHz probe recording at a depth of 2 cm. The parasternal long axis view 
(Figure 5) was used to obtain dimensions of the left ventricle at end-systole and end-
diastole. Measurements were obtained from aortic annulus to apex. M-mode 
echocardiography (Figure 6) was used to obtain a parasternal short-axis view of the left 
ventricle (LV) in systole and diastole. Measurements were obtained from the internal 
dimension of the cavity. All images were recorded at 235.8 frames per second. 
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Figure 5 Parasternal long axis view for measuring ventricular length in systole and 
diastole. Measurements are taken from the aortic root to the apex of the heart at end 
systole and end diastole. 
 
 
Figure 6 Parasternal short axis view for measuring ventricular width in systole and 
diastole. Measurements are taken at the origin of the papillary muscles at end systole 
and end diastole. 
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The volume of the left ventricle (v) in systole and diastole was calculated using the 
following formula for prolate spheroids: 
V = 4/3 π * (w/2) * l/2 
where w is ventricular width (parasternal short axis) and l is ventricular length 
(parasternal long axis). 
 
Left ventricular ejection fraction (LVEF) was calculated according to the following formula: 
LVEF = 100 * (EDV – ESV)/ EDV 
where EDV is end-diastolic volume and ESV is end-systolic volume  
 
Pulse wave Doppler (Figure 7) was used to measure stroke volume. Aortic blood flow 
was measured at the point the right carotid artery bifurcates from the aortic arch. The 
direction of blood flow was confirmed by colour Doppler.   
 
 
Figure 7: Blood flow measurements in the aortic arch. Colour Doppler was used to 
ensure correct probe placement. The waveform displays velocity (y-axis) over time (x-
axis). The area under each waveform (velocity-time integral; VTI) is proportional to stroke 
volume. 
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Pulse wave Doppler was used to derive the velocity-time integral (VTI) of blood flowing 
through the aorta.  
Stroke volume (SV) was derived from the following formula: 
SV = VTI x {π x (0.5 x d )2} 
where d is the aortic diameter, derived from measurements in a population of rats of 
similar size. The mean diameter of 0.26 cm has been previously calculated and a cross-
sectional area of (0.13)2 x π assumed in all calculations. 
Heart rate was determined by measuring the time between six consecutive cycles from 
the start of each Doppler trace. Cardiac output was calculated as the product of stroke 
volume and heart rate. Previous work from our lab found that six consecutive cycles was 
sufficient to account for any respiration-induced variability of heart rate.  
4.2.6 Blood pressure and blood gas analysis 
Surgical tracheostomy was performed in anaesthetized, spontaneously breathing 
animals. The previous surgical incision was re-opened and salivary glands and muscle 
overlying the trachea were separated using blunt dissection. The trachea was identified 
and cannulated using 1.57 mm external diameter polythene tubing (Portex Ltd). The 
tracheal tube was attached to a T-piece through which the anaesthetic vapour was 
passed. The left common carotid artery was isolated, cannulated with PVC tubing with an 
outer diameter of 0.96mm (Biocorp Ltd, Huntingdale, NSW, Australia), and secured with 
2.0 silk sutures. The arterial line was flushed with 0.1 ml n-saline and a small quantity of 
blood drawn back to ensure correct placement and line patency. The arterial line was 
connected to a pressure transducer (Powerlab, AD Instruments) for continuous 
monitoring of MAP and for intermittent blood sampling. The line was flushed with 0.5 ml 
n- saline after blood sampling.  
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The animal was then allowed 10-20 mins to stabilize to ensure normothermia, appropriate 
depth of anaesthesia, and adequate oxygenation and ventilation (Figure 8). Arterial blood 
gas analysis was performed with 0.2 ml taken into heparinized capillary tubes. 
Measurement was made of pH, sodium, potassium, ionized calcium, base excess, 
lactate, oxygen saturation (SaO2), partial pressure of carbon dioxide (PaCO2), and partial 
pressure of oxygen (PaO2) (ABL-70 analyser, Radiometer, Copenhagen, Denmark). 
 
Figure 8 Model of anaesthetized rat. An arterial line is placed in the common carotid 
artery for invasive blood pressure monitoring and arterial blood gas sampling. A surgical 
tracheostomy is performed and the urinary bladder catheterized.  
A lapatotomy incision was made from the lower abdomen in the midline extending to the 
left upper quadrant. A 22-gauge needle was used to aspirate urine via bladder puncture. 
The urine was snap-frozen in liquid nitrogen. The bladder apex was catheterized using 
polythene tubing (Portex Ltd, Hythe, Kent) of 1.57 mm external diameter inserted through 
a small incision at the apex and secured with 2.0 silk sutures. Moving overlying bowel to 
the right side of the abdominal cavity allowed access to the left kidney.  
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4.2.7 Organ collection and collection of serum 
The left kidney was isolated from surrounding tissue by careful blunt dissection. The left 
renal vasculature was clamped and the kidney immediately resected. The renal capsule 
was stripped and the kidney divided into approximately equal thirds. The upper pole was 
placed into formalin and the mid and lower poles snap-frozen into liquid nitrogen. The 
thoracic cavity was opened and cardiac puncture performed to obtain blood. The blood 
was placed in a heparinized tube and centrifuged at 6500 rpm for 10 min. The serum was 
divided into aliquots and snap-frozen in liquid nitrogen.  
4.3 In vitro techniques 
4.3.1 Protein Extraction 
Snap-frozen renal tissue was homogenized in radioimmunoprecipitation assay 
homogenizing buffer (RIPA buffer; 50 mM NaCl, 1.0% IGEPAL (Octylphenyl-polyethylene 
glycol, Sigma Aldrich), 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) 
at an approximate ratio of 0.3g tissue with 1 ml buffer. Tissue was homogenized with a 
sonicator. The homogenate was centrifuged for 10 min at 14,000x g in a cold microfuge 
to remove tissue debris. The supernatant was pipetted and protein concentration 
determined using the bicinchoninic acid assay (BCA) kit (Pierce, Rockford, IL, USA) 
according to the manufacturer’s protocol. Samples were stored at -80°C.  
4.3.2 Enzyme linked immunosorbent assay (ELISA) 
Serum samples were obtained during the experiment and centrifuged at 6500 g for 10 
min in a lithium-heparin tube. The serum was siphoned off, snap-frozen in liquid nitrogen, 
and stored at -80oC. Sandwich ELISA was performed to assess serum levels of various 
cytokines. DuoSet ELISA kits (R&D Systems, Minneapolis, MN, USA and BD 
Biosciences, Oxford, UK) were used according to the manufacturer’s instructions ( 
 95 
 
Table 8). ELISA was also performed to assess the presence of rat MCP-1, IL-10, IL-4, 
INF-γ and IL-1β in renal tissue homogenate. Tissue cytokine levels were expressed 
relative to the total protein content. Absorbance was read at 450 nm using a 
spectrophotometric ELISA plate reader (Anthos HTII; Anthos Labtec, Salzburg, Austria).  
Analyte Company Units Range- 
Minimum 
Range 
Maximum 
CV 
Intra-
assay 
CV 
inter-
assay 
Recovery 
(%) 
(Accuracy) 
IL-1β R&D pg/ml 62.5 4000 N.S N.S 40% 
decrease 
when 
incubated 
with IL-1R1 
IL-4 BD  pg/ml N.S 100 N.S N.S N.S 
IL-6 BD  pg/ml N.S 5000 N.S N.S N.S 
IL-10 BD  pg/ml N.S 1000 N.S N.S N.S 
INF-γ BD  pg/ml N.S 2000 N.S N.S N.S 
NGAL R&D pg/ml 
 
78.1 5000 N.S N.S N.S 
Cystatin C R&D pg/ml 125 8000 3.2 7.1 107 (98–113) 
MCP-1 BD  pg/ml N.S 2000 N.S N.S N.S 
Analyte Company Units Range- 
Minimum 
Range 
Maximum 
CV 
Intra-
assay 
CV 
inter-
assay 
Recovery 
(%) 
(Accuracy) 
IL-1β R&D pg/ml 62.5 4000 N.S N.S 40% 
decrease 
when 
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Table 8 ELISA analytes and specifications (N.S.: Not stated) 
incubated 
with IL-1R1 
IL-4 BD  pg/ml N.S 100 N.S N.S N.S 
IL-6 BD  pg/ml N.S 5000 N.S N.S N.S 
IL-10 BD  pg/ml N.S 1000 N.S N.S N.S 
INF-γ BD  pg/ml N.S 2000 N.S N.S N.S 
NGAL R&D pg/ml 
 
78.1 5000 N.S N.S N.S 
Cystatin C R&D pg/ml 125 8000 3.2 7.1 107 (98–113) 
MCP-1 BD  pg/ml N.S 2000 N.S N.S N.S 
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4.3.3 Multiplex 
MILLIPLEX®MAP multi-analyte panels (Merck Millipore, Watford, Hertfordshire, UK) were 
used for simultaneous detection and quantification of eight biomarkers and 
cytokines/chemokine in rat urine, including NGAL, cystatin C, IL-18, MCP-1, clusterin, 
calbindin, osteopontin, and KIM-1. The same technique was used to determine serum 
levels of IL-18 (Table 9). 
MILLIPLEX® is a magnetic bead-based Luminex® assay that utilizes distinct sets of 
microspheres (fluorescent-coded beads) coated with a specific capture antibody to target 
the corresponding cytokine/chemokine/biomarker. Bound antigen is detected by 
biotinylated antibody. On addition of conjugated streptavidin-phycoerythrin (PE), the 
fluorescent reporter molecule, fluorescent signals from individual microspheres are 
quantified.  
Assays were performed according to the manufacturer protocols. MILLIPEX®MAP contains 
a filter plate and reagents (assay buffer, Standard, Quality Controls, 10x wash Buffer, and 
relevant antibody-bead vials). Briefly, 200 microlitres of well assay buffer was added to 
the plate and incubated at room temperature for 10 minutes. Assay buffer was removed 
gently by inverting the plate. 25µl of standards (serial dilution from stock) or Quality 
Controls were transferred into wells followed by an additional 25 µl matrix solution. 25 µl 
assay buffer and 25 µl rat urine were added into the sample wells. 60 µl of each antibody-
bead was mixed together to a final volume of 3 ml with Bead Diluent. 25 µl of the mixed 
beads were transferred to each well and the plate incubated overnight at 4°C, or for 1hr 
at room temperature (depending on analytes). Contents apart from magnetic beads (with 
bound antigen) were removed and the plate washed twice. 25 µl detection antibody was 
added and incubated at room temperature for 2 hours. Following this, 25 µl Streptavidin-
PE was added and incubated for 30 minutes. After removing the fluids and a further 2 
washes, 150µl sheath fluid was added to resuspend the beads for 5 minutes. The plate 
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was read on a Bio-Plex 200 multiplex system (Bio-Rad, Hemel Hempstead, Hertfordshire, 
UK). 
 
Analyte Units Minimum 
detectable 
level 
Maximum 
detectable 
level 
Precision:  
CV Intra-
assay(%) 
Precision:  
CV inter-
assay(%) 
Accuracy: 
Recovery 
(%) 
IL-18 pg/ml 6.2 50,000 2.5 11.1 97.2 
MCP-1 pg/ml 9.0 120,000 2.3 9.2 80.2 
NGAL ng/ml 0.002 10.0 <10 <10 100 
Cystatin C ng/ml 0.003 8.0 <10 <10 100 
KIM-1 ng/ml 0.007 20.0 <10 <15 110 
Osteopontin ng/ml 0.008 20.0 <10 <15 92 
Clusterin ng/ml 0.307 1,500 <10 <15 126 
Calbindin ng/ml 0.079 250 <10 <15 70 
Table 9 Multiplex analytes.  
 
Recovery/ Accuracy: Represents mean percent recovery of spiked standards. Minimum 
detectable concentration (MinDC)/ Sensitivity: MinDC is calculated using MILLIPLEX 
Analyst. It measures the true limits of detection for an assay by mathematically 
determining what the empirical MinDC would be if an infinite number of standard 
concentrations were run for the assay under the same conditions 
Intra-assay precision is generated from the mean of the %CV (coefficient of variation) 
from 8 reportable results across two different concentrations of analytes in a single assay 
Inter-assay precision is generated from the mean of the %CVs across two different 
concentrations of analytes across 13 different assays 
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4.3.4 Biochemistry 
Serum obtained at the end of each experiment was analyzed for renal function (serum 
urea and creatinine) and liver function (albumin, alkaline phosphatase (ALP), aspartame 
amino transferase (AST) and alanine amino transferase (ALT)). Samples were analyzed 
by the Clinical Pathology laboratory at the Royal Free Hospital, London.  
4.3.5 Immunohistochemistry 
Kidneys were fixed for 24-72 hours in formalin, transferred to 70% ethanol, and 
embedded in paraffin. Sections were then cut into 5 µm slices and mounted onto glass 
slides. Sections were examined using an Olympus BX4 microscope (Olympus Optical, 
London, UK) at x20 magnification. Ten random fields of view of the cortex were analyzed 
for each section. All analyses were performed blind. 
4.3.5.1 Tubular injury 
All sections were stained with Periodic acid-Schiff (PAS). Ten random fields of view of the 
cortex were analyzed for each section at x20 magnification under a light microscope. 
Sections were scored for acute tubular injury, glomerular injury, and interstitial infiltrate. 
Features of tubular injury included tubular dilatation, brush border loss, and tubular cast 
formation. Each feature was scored 0-3 (0- absent, 1- <33%, 2- 33- 67%, 3- >67%). The 
average score of the ten fields of view were totaled, the maximum tubular injury score 
being 9. Glomerular injury included collapsed glomeruli or glomerular thrombosis. Ten 
random glomeruli were examined and a score of 0 (absent) or 1 (present) assigned. The 
average score of the 10 fields of view were totaled. Interstitial infiltrate was scored as 
being absent (0) or present (1). The average score of the 10 fields of view were totaled. 
Two timepoints were chosen for tubular injury scoring - the early pro-inflammatory phase 
and the point at which serum creatinine was significantly elevated. Renal tissue from a rat 
that was subject to prolonged hypotension secondary to haemorrhage was used as a 
positive control. 
 100 
4.3.5.2 Apoptosis 
Apoptosis was detected by DNA fragments in situ using the terminal deoxyribonucleotidyl 
transferse (TdT)-mediated biotin-16-dUTP nick-end labelling (TUNEL assay). The 
commercially available TACS® TdT In Situ Apoptosis Detection Kit (R&D Systems) was 
used and recommended protocols followed. Briefly, slides were dewaxed and rehydrated 
through graded xylene and ethanol, respectively. Slides were immersed in 1x PBS for 10 
min. Slides were covered with 50 µl of Proteinase K Solution for 30 minutes, then washed 
twice in deionized water for 2 min each time. Slides were immersed in Quenching 
Solution for 5 min, washed in 1x PBS for 1 min, then immersed in 1x TdT Labeling Buffer 
for 5 min before covering with 50 µl of Labeling Reaction Mix for 60 min at 37oC in a 
humidity chamber. Placing slides in 1x TdT Stop Buffer for 5 min stopped the reaction. 
Slides were then washed twice in deionized H2O for 5 min each, covered with 50 µl of 
Strep-HRP Solution and incubated for 10 min at 37oC in a Humidity Chamber to avoid 
evaporation. Slides were washed twice more then immersed in DAB solution for 7 min, . 
washed twice in deionized H2O, for 2 min each and finally immersed in 1% Methyl Green 
for up to 5 min. Each slide was dipped 10 times in two changes of deionized H2O, 
followed by 95%, then 100% ethanol, and finally 2 changes of o-xylene. Glass coverslips 
were mounted using mounting medium Eukitt (VWR International). Sections were 
examined using an Olympus microscope (Model, Olympus Optical, London, UK) at x20 
magnification. Ten random fields of view of the cortex were analyzed for each section. 
The total number of apoptotic bodies per x20 field were counted manually and an 
average taken for each group. A total of three slides for the septic groups (with at least 
one from the poor prognosis subgroup) and 2 from the naïve groups from timepoints 6, 
12, 24, 48, and 72 hours were selected. All analyses were performed blind. 
4.3.5.3 Macrophage infiltration 
Sections were stained to assess macrophage infiltration. Slides were dewaxed and 
rehydrated through graded xylene and ethanol, respectively. Antigen retrieval was 
performed by placing slides in 0.01M sodium citrate buffer heated to 90oC in a water bath 
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for 15 min. Following immersion in 50% methanol containing 0.3% H2O2 for 1 h to block 
endogenous peroxidase activity, non-specific binding was blocked by incubation with 
20% normal goat serum (NGS) diluted in PBS. The primary antibody (mAb ED-1 CD68 
mouse anti-rat, Serotec, Kidlington, Oxon) was diluted 1:500 in PBS and incubated for 1 
h at room temperature. Slides were then incubated with biotinylated goat anti-mouse 
(Dako) for 45 min, then washed in PBS-tween to remove excessive, unbound antibody. 
Antibody binding was visualized using 3,3’-diaminobenzidene (Dako). Sections were 
counterstained with haematoxylin, then dehydrated, mounted with Eukitt (VWR 
International) and left to dry overnight. One section from each sample was incubated with 
antibody diluent instead of primary antibody and served as control. Sections were 
examined at x20 magnification. Ten random fields of view of the cortex were analyzed 
per section. The total number of macrophages per x20 field and the number of 
macrophages per glomerular cross-section were assessed semi-quantitatively using a 
Color Coolview camera (Photonic Sciences, Robertsbridge, East Sussex) and Image Pro 
Plus software (Media Cybernetics, Silver Spring, MD, USA). A total of six slides for the 
septic groups and from the naïve groups from timepoints 3, 6, 12, 24, 48, and 72 h were 
selected. All analyses were performed blind. Spleen tissue from a septic animal at 6 h 
was used as a positive control. 
4.4 Statistics 
All statistical analyses were performed using SPSS (IBM. Version 20) and graphs drawn 
using Graphpad Prism (GraphPad Software, Version 5.0d). Normality of continuous data 
was assessed using the Shapiro-Wilk test. Continuous variables are presented as means 
(standard deviation) where parametric, and median (interquartile range) where non-
parametric. Parametric data were compared using unpaired Student’s t-test, whereas 
non-parametric data were compared using the Mann Whitney U test for comparison of 
continuous data between 2 groups. For comparison of continuous variables between 
more than two groups, one-way analysis of variance (ANOVA) with post hoc Tukey’s test 
is used. Cox-proportional regression was used to assess the sensitivity and specificity of 
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different haemodynamic parameters on survival. Pearson’s correlation was performed to 
assess the degree of correlation between serum and urine levels of biomarkers (cystatin 
C, NGAL, IL-18, and MCP-1). A p-value <0.05 was taken as statistically significant.  
4.5 Results 
4.5.1 Dose finding study 
Doses of slurry varied from 3 ml/kg (n=7), 4 ml/kg (n=7), 4.5 ml/kg (n=6), and 5 ml/kg 
(n=6). There was a stepwise dose-related decrease in 24 h survival, ranging from 100% 
with 3 ml/kg to 33% with a 5 ml/kg dose ( Table 10). Cox-proportional regression 
revealed that a SV of 0.195 ml at 6 h predicted mortality at 24 h with a sensitivity of 60%, 
specificity of 90% and an area under the receiver operator curve of 0.84 (hazard 
ratio=6.6; p=0.008). Based on these results, a faecal slurry dose of 4.5 ml/kg was used 
for the 72 hour characterization study.  
 
Slurry dose (ml/kg) Number Survival at 24hrs 
3 7 100% 
4  7 71% 
4.5 6 67% 
5 6 33% 
 Table 10 Mortality associated with different faecal slurry doses 
  
 
4.5.2 Systemic variables  
There were no significant differences in baseline data (weight, temperature, HR, SV, and 
CO) between groups. By 3hrs post induction of sepsis, there was a significant fall in 
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stroke volume and cardiac output. Septic animals mounted a significant tachycardia by 
6hrs, which persisted at 24hrs. This paralleled the increase in core body temperature. 
Mean arterial pressure remained relatively stable in the septic animals predicted to live 
but was higher at 6h and 12h in the septic animals predicted to die. This was associated 
with an increase systemic vascular resistance (SVR,) a lower global DO2 and elevated 
arterial lactate.   
The global DO2 was significantly elevated at early time points (3hr and 6hr) in animals 
that were predicted to survive compared to animals that were predicted to die. Along with 
SV, global DO2 and SVR were able to distinguish between septic animals that were 
predicted to live and those predicted to die (however SV and global DO2 are coupled). By 
48hrs, SV, CO, HR, and core temperature normalized among septic animals, and these 
remained stable till 72hrs (Figure 9).   
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Figure 9 72hour characterization - Systemic variables following induction of experimental 
sepsis in Wistar rats (sham, sepsis good prognosis, sepsis poor prognosis). Septic 
animals develop a tachycardia, fall in stroke volume, increase in systemic vascular 
resistance, and fever early (3-6hr), which resolves from 24hr to reach baseline values at 
72hr. Changes in global oxygen delivery and mean arterial pressure are smaller and 
more transient.  
(a: p<0.05 sham vs good prognosis; b: p<0.05 sham vs poor prognosis; c: p<0.05 good vs poor 
prognosis) 
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4.5.3 Biochemistry  
Biochemistry data are shown below (Figure 10). Serum albumin was significantly lower in 
septic animals predicted to die from the 3 h time point with a progressive fall thereafter. 
Among septic animals predicted to live, serum albumin was lower from 12 – 48 h 
compared to sham animals. Serum glucose was also lower from 6h, likely to be due to 
decreased carbohydrate consumption and depletion of liver glycogen stores. The fall in 
base excess is seen early (from 3 h) and similar to the clinical scenario. This is due to an 
increase in inorganic acids being formed (e.g. ketoacids in starvation and lactate) along 
with the impaired ability of the kidney to excrete acids. 
There was a very early peak (3 h) in serum urea in septic animals predicted to die 
compared to sham animals. This is consistent with urea as a marker of volume depletion 
and rising before serum creatinine rises. Once fluid resuscitation commenced (2 h) there 
was a progressive fall in urea that normalized by 12 h. However, once renal dysfunction 
(likely fall in GFR) ensues, serum urea rises but to a lesser amount. In contrast, serum 
creatinine, rises initially due to haemoconcentration/intravascular volume depletion (at 3 
h), falls back to baseline once fluid resuscitation is commenced, and rises once again (at 
24 h) likely due to a fall in GFR  
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Figure 10 72 hour characterization- Biochemistry following induction of experimental 
sepsis in Wistar rats (sham, sepsis good prognosis, sepsis poor prognosis). Biochemical 
changes occur from 3hr. Apart from serum urea, changes are maximal at 24hrs followed 
by recovery to baseline values till 72hr. The early rise in urea, creatinine, and lactate fall 
promptly after fluid resuscitation is commenced, demonstrating early 
haemoconcentration.  
(a: p<0.05 sham vs. good prognosis; b: p<0.05 sham vs. poor prognosis; c: p<0.05 good vs. poor 
prognosis) 
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4.5.4 Serum Cytokines  
The pro-inflammatory serum cytokine IL-1β was significantly elevated by 3 h. This was 
maintained until 12 h, followed by a gradual fall to normal by 48 h. There was no 
difference in IL-1β levels between animals predicted to survive or die. Serum IL-6 levels 
were elevated at 3 h only in animals predicted to die. By 6 h, IL-6 levels peaked and were 
significantly elevated in all septic animals. IL-6 levels fell earlier than IL-1β (6 h). By 24 h, 
IL-6 levels had returned to baseline values in animals predicted to survive. There were no 
clear differences in IL-18 levels between sham and septic animals, which were widely 
variable between animals. Serum INF-γ was only detectable at 6 h, after the peak rise in 
IL-18. Serum MCP-1 levels followed a similar pattern to IL-1β. The anti-inflammatory 
cytokine IL-10 was elevated from 3 h in the animals predicted to die and in all septic 
animals by 6 h. IL-10 levels stayed elevated till 72 h compared to sham animals. Serum 
IL-4 levels could not be detected at any point while INF-γ levels were detected in only a 
few septic animals at 6 h. Therefore the overall balance of cytokines changed from a pro- 
to an anti-inflammatory profile in the acute and resolution phases of sepsis, respectively 
(Figure 11) 
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Figure 11 Characterization- Serum cytokines following induction of experimental sepsis 
in Wistar rats (sham, sepsis good prognosis, sepsis poor prognosis). There is a variable 
pattern of proinflammatory cytokine kinetics. IL-1β and IL-6 rise early (3 h) and remain 
elevated for 24 h. INF-γ is elevated only at 6 h, whereas IL-18 is not significantly 
elevated. Anti-inflammatory cytokine IL-10 begins to rise by 3 h but remains elevated 
through to resolution of sepsis at 72 h.  
(a: p<0.05 sham vs good prognosis; b: p<0.05 sham vs poor prognosis; c: p<0.05 good vs poor 
prognosis) 
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4.5.5 Renal Cytokines  
 
Renal IL-β was elevated by 3 h and 6 h in septic animals predicted to die and survive, 
respectively. From 12 h there was no difference in renal cytokine levels between septic 
and sham animals. Renal MCP-1 demonstrated a rise from baseline to peak at 24 h, 
when it was higher in septic predicted survivors compared to sham animals. Renal INF-γ, 
IL-4, and IL-10 demonstrated no convincing trends or differences between sham and 
septic animals. Sham animals demonstrated variability in these renal cytokine values 
(Figure 12).  
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Figure 12 72 hour characterization - Renal cytokines following induction of experimental 
sepsis in Wistar rats (sham, sepsis good prognosis, sepsis poor prognosis). Renal IL-β 
was elevated by 3 h and 6 h in septic animals predicted to die and survive, respectively. 
From 12 h there was no difference in renal cytokine levels between septic and sham 
animals. Renal INF-γ, IL-4, and IL-10 levels were variable. 
(a: p<0.05 sham vs good prognosis; b: p<0.05 sham vs poor prognosis; c: p<0.05 good vs poor 
prognosis) 
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4.5.6 Biomarkers 
Eight different urine biomarkers were measured in addition to urine Na+ and creatinine 
concentrations (the latter two in fewer animals due to lack of urine volume) (Figure 13). 
All biomarkers related to PTEC injury were altered to varied degrees and with different 
kinetics. After a recovery period, all biomarkers returned to levels approaching those 
observed in sham animals. Apart from urine osteopontin and IL-18, all other urine 
biomarkers were elevated and at an earlier time point to serum creatinine (at 24 h).  
Urine NGAL was the most sensitive marker amongst those studied, rising from 3 h to 24 
h. Although other biomarkers were also elevated before the rise in serum creatinine, the 
magnitude of their rise was much less compared to NGAL. Urine NGAL was also the 
earliest biomarker to rise. Urine KIM-1 was the only biomarker to show a greater rise in 
animals predicted to die. This was seen at 12 h, when serum creatinine was identical 
between septic and sham animals. Urine IL-18 has been analyzed in septic AKI, but has 
been less promising than urine NGAL (Kashani et al. 2013). We demonstrated similar 
findings. The rise in urine IL-18 occurred at 12 h but did not reach significance. Urine 
cystatin C. a marker of GFR and intact tubular reabsorption, was raised between 12-48 h 
in septic animals.  
I also measured two markers of distal tubular injury, namely calbindin and osteopontin. 
Neither have been previously evaluated in septic AKI. Interestingly, urine calbindin was 
elevated at 6-12 h whereas urine ostopontin did not differ between septic and sham 
animals. Although septic AKI is typically associated with PTEC injury, there may be some 
DTEC injury. Urine MCP-1 has also not been characterized in septic AKI. I found a rise in 
urine MCP-1 levels between 12-18 h.  
A fall in urine KIM-1 and calbindin at 24 h may predict renal recovery. Although this 
timepoint coincided with the rise in serum creatinine, it was associated with improvement 
in clinical parameters (cardiovascular) and a fall in pro-inflammatory cytokines (Il-1β, IL-6, 
IL-18).  
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Figure 13 72 hour characterization - Urine biomarkers following induction of experimental 
sepsis in Wistar rats (sham, sepsis good prognosis, sepsis poor prognosis). Urine NGAL 
was the most sensitive marker, rising from 3 h to 24 h. Other biomarkers were also 
elevated before the rise in serum creatinine, though the magnitude of their rise was much 
less compared to NGAL. Urine KIM-1 was the only biomarker to show a greater rise in 
animals predicted to die. Urine IL-18 and osteopontin were not elevated in septic animals.  
(a: p<0.05 sham vs good prognosis; b: p<0.05 sham vs poor prognosis; c: p<0.05 good vs poor 
prognosis) 
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4.5.7 Serum biomarkers 
  
 
 
Figure 14 72 hour characterization - Serum biomarkers following induction of 
experimental sepsis in Wistar rats (sham, sepsis good prognosis, sepsis poor prognosis). 
Serum NGAL rose early at 3 h whereas serum cystatin C rises at 12 h. Both biomarkers 
were elevated till 24 h.  
(a: p<0.05 sham vs good prognosis; b: p<0.05 sham vs poor prognosis; c: p<0.05 good vs poor 
prognosis) 
 
Serum NGAL rose early at 3 h (Figure 14). However, this may reflect neutrophil activation 
rather than tubular injury. Serum cystatin C rises at 12 h at a point when serum creatinine 
falls towards baseline. This interesting finding may reflect a fall in GFR (and hence rise in 
serum cystatin C) along with decreased creatinine production.  
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4.5.7.1 Correlation between urine and serum biomarkers 
 
 All Septic animals only 
 r2 p- value r2 p- value 
MCP-1 0.122 0.356 0.051 0.756 
NGAL 0.713 <0.001 0.654 <0.001 
IL-18 0.014 0.908 0.016 0.914 
Cystatin C 0.059 0.655 0.072 0.660 
Table 11 Correlations between paired urine and serum biomarkers 
 
It is unclear to what extent the urine biomarkers reflect what is filtered from the circulation 
and eliminated in the urine, as opposed to de novo production within the kidney. There 
was no correlation between urine and serum levels of IL-18, MCP-1, and cystatin C 
(Table 11). There was, however, a positive correlation between urine and serum NGAL 
values, even when including only septic animals. Urine NGAL, Cystatin C, and Clusterin 
were the only biomarkers to correlate with serum creatinine. None of the urine biomarkers 
had a correlation defined as r2 > 0.5 with serum creatinine (Table 12). Correlations 
between different urine biomarkers were assessed. Of 16 positive correlations between 
the urine biomarkers, only four were positive as defined by an r2 value >0.5 (Table 13).  
 
Urine biomarker r2 p- value 
NGAL 0.318 0.008 
Cystatin C 0.304 0.008 
Clusterin 0.274 0.011 
Table 12 Positive correlations with serum creatinine 
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Urine biomarker r2 p- value 
Cystatin C vs. NGAL 0.766 < 0.001 
Cystatin C vs. KIM-1 0.516 < 0.001 
IL-18 vs. MCP-1 0.869 < 0.001 
Clusterin vs. KIM-1 0.628 < 0.001 
Table 13 Significantly positive correlations (r2 > 0.5) between urine biomarkers 
4.5.8 Renal Histology 
4.5.8.1 Tubular injury  
Histological sections were scored at two timepoints for assessment of tubular injury. The 
6 h point was chosen as an early phase and the 24 h point taken as the point at which 
serum creatinine was significantly elevated. The tubular injury score was similar between 
septic and sham-operated animals at 6 h (1.10±0.46 vs. 0.63±0.52; p=0.26). A higher 
tubular injury score at 24 h was seen in septic animals compared to sham (1.97±0.83 vs. 
0.63±0.52; p=0.001). Despite this higher score, the degree of injury was still relatively 
mild (the highest possible score being 9). Predominant findings included mild tubular 
dilatation and brush border loss. Tubular injury was patchy, among areas of normal 
histology. There was no evidence of tubular cell necrosis, interstitial cellular infiltrate, 
glomerular collapse, or glomerular thrombosis. Tubular cast formation, when present, 
was sporadic (Figure 15).  
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Figure 15 Histological assessment of rat kidneys for renal damage (PAS-staining, 
magnification x 20). A. Naive renal tissue without any significant damage. B. Renal tissue 
obtained from a haemorrhage-reperfusion model (A. Dyson, UCL), showing several 
characteristics of acute tubular injury including dilated tubules, ischemic glomeruli and 
tubular casts. C. Kidney section from a 24h sham-operated animal. D. Kidney section 
from a 24h septic rat. 
 
4.5.8.2 Apoptosis 
TUNEL stain revealed minimal presence of cell death, with an average of two TUNEL 
positive cells per 20x magnification field. Where present, TUNEL positive cells were 
within proximal tubular epithelial cells (Figure 16).  
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Figure 16 TUNEL stain of renal tissue. Apoptotic cells stain dark brown (arrow). 
Apoptotic bodies seen mainly in proximal tubular epithelial cells. No significant difference 
in apoptotic bodies seen between naïve and septic kidneys. (x20 magnification).  
 
4.5.8.3 Macrophage infiltration 
Naive kidneys revealed no or minimal staining of macrophages. When present, 
macrophages were found within the interstitium. There was significant infiltration of renal 
macrophages within the interstitium of septic animals at 72 h (Figure 17), though there 
was a trend towards an increase in renal macrophages from 24 h. Glomerular 
macrophages were significantly elevated at 72 h. There was wide variability in the 
presence of macrophages among septic animals. The rise in renal macrophages was 
associated with a fall in serum-renal MCP-1 ratio  (ratio between serum MCP-1 (ng/ml) 
and renal MCP-1 (pg/mg protein) (Figure 18). This chemokine gradient may be 
responsible for local macrophage recruitment.  
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Figure 17 Macrophage infiltration. (a).Macrophages (stained brown colour) are seen 
within the renal interstitium and glomeruli of naïve and (b). septic animals (black arrows) 
(x10 magnification). The quantity and intensity of macrophage infiltration is much greater 
in the septic kidney. (c). Higher magnification of macrophages seen within the interstitium 
and glomeruli (x20 magnification). (d). Septic spleen used as a positive control (x10 
magnification).   
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Figure 18 72 hour characterization - Renal macrophages and MCP-1 levels following 
induction of experimental sepsis in Wistar rats (sham, sepsis good prognosis, sepsis poor 
prognosis). Maximal renal macrophage infiltration is associated with clinical recovery. The 
amount of renal macrophage infiltration in inversely proportional to the gradient of MCP-1 
between serum and renal tissue.  
(a: p<0.05 sham vs good prognosis; b: p<0.05 sham vs poor prognosis; c: p<0.05 good vs poor 
prognosis) 
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4.5.9 Effect of Fluid Resuscitation 
A separate experiment was carried out in which fluid resuscitation was not given to a 
group of animals. Compared to the animals that received fluid resuscitation (as per 
protocol), animals without fluid resuscitation had a significantly higher urea, creatinine, 
and lactate (Figure 19). Despite this, there was no difference between groups in global 
haemodynamic parameters including change in cardiac output, change in stroke volume, 
change in heart rate, global oxygen delivery, and mean arterial pressure.  
Core body temperature and the tubular injury score were higher in animals that did not 
receive fluid resuscitation, although this did not reach statistical significance. 
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Figure 19 Effect of fluid resuscitation on haemodynamic and biochemical parameters at 
6hrs following induction of experimental sepsis in Wistar rats. Septic rats that are fluid 
resuscitated have a lower serum urea and creatinine, arterial lactate, and core 
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temperature compared to septic rats without fluid resuscitation. Global haemodynamic 
variables do are not significantly different between groups.  
(* p<0.05 compared to fluid resuscitated animals) 
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4.6 Discussion 
4.6.1 Characterization  
In this clinically relevant rat model of polymicrobial sepsis, features of inflammation such 
as temperature and tachycardia become evident from 3 h, although many parameters do 
not reach statistical significance at that early time point. By 6h, clinical features of sepsis 
were fairly evident and sustained until 24 h. From 24 h, there was clinical recovery (fall in 
temperature towards baseline, resolution of tachycardia and recovery of SV). 
Temperature and cardiac indices follow a similar temporal trend throughout sepsis and 
recovery.  
Consistent with previous work in our laboratory, echocardiographic findings at 6 h could 
predict survival in the septic animals (Rudiger et al. 2013). Myocardial depression in early 
sepsis was associated with transcriptomic changes in pathways controlling JAK/STAT, 
TLR2/MYD88, β-adrenergic signaling and intracellular calcium cycling (Rudiger et al. 
2013). 
Despite significant volume fluid resuscitation, there is a significant reduction in SV 
between 3 and 24 h. This may be due to capillary leak and myocardial depression 
(Rudiger et al. 2013). In animals predicated to die, MAP is maintained for the initial 12 h 
due to a rise in SVR. This increase in SVR is likely to be a consequence of increased 
sympathetic drive. As MAP is maintained at the expense of intense vasoconstriction, flow 
is not maintained as evidenced by a fall in global DO2 and a greater rise in serum lactate 
compared to septic animals predicted to live. Animals predicted to live have an early rise 
in global DO2. This mirrors the clinical picture where septic patients often have a 
hyperdynamic circulation in early sepsis, unless peri-mortem (Groeneveld et al. 1988). 
However, in contrast to what is often seen clinically, patients who die from overwhelming 
sepsis often have significant vasoplegia rather than the increase in SVR seen in this 
rodent model of sepsis (Groeneveld et al. 1988). This may relate to the age of the 
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animals used and within-species differences. Older mice exposed to LPS treatment 
demonstrate excessive TNF-α and nitric oxide production compared to younger mice 
(Chorinchath et al. 1996). This has not been demonstrated in rats, but might explain why 
the relatively young rats used in my studies maintained mean arterial pressure until the 
hour or so pre-mortem. It would thus be also important to measure key markers and 
mediators of cardiovascular dysfunction in sepsis, including troponin, cateocholamines, 
vasopressin and nitric oxide. 
4.6.2 Immunology (systemic) 
Serum pro-inflammatory (IL-1β, IL-6, IL-18, INFγ) and anti-inflammatory (IL-10) cytokines 
were measured. Most pro-inflammatory cytokines were elevated early, with peaks in IL-
1β and IL-18 as early as 3 h. Serum INF-γ was only detectable at 6 h. The peak in INF-γ 
followed the peak in IL-18 (a potent stimulant of INF-γ release previously known as INF-γ 
inducing factor) (Tomura et al. 1998). Furthermore, we demonstrated a correlation 
between peak serum IL-1β and IL-18 levels. Release of IL-1β and IL-18 is tightly coupled, 
supporting NLRP3 inflammasome activation early in sepsis. The pattern of temporal 
change in serum IL-10 was very similar to that seen with the pro-inflammatory cytokine 
profiles, though elevated IL-10 levels persisted throughout recovery. Animals predicted to 
die had higher pro- and anti-inflammatory cytokine levels compared to sham animals.  
In a large cohort study of 1886 subjects hospitalized with community-acquired 
pneumonia, cytokine concentrations (IL-6, IL-10, TNF-α) were highest at presentation 
and declined rapidly over the first few days (Kellum et al. 2007). Temporal changes in 
cytokines were similar (early peak of both pro- and anti-inflammatory cytokines followed 
by decline). Furthermore, these levels were highest in those who were sicker and 
proceeded to eventually die, and lowest in those without severe sepsis. A similar pattern 
was seen in my animal model of sepsis. The pro-inflammatory cytokines mirrored illness 
severity, falling towards baseline as the animal recovered clinically. This was in contrast 
to the clinical study where cytokines remained elevated throughout the first week, beyond 
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resolution of the clinical signs of infection. However, the illness time in young rodent 
models of sepsis may not be directly comparable to that seen in generally elderly 
humans.  
4.6.3 Renal Inflammation 
I found an increase in renal IL-1β levels from 3 h that peaked at 24h. The source of IL-1β 
has not been determined. In a porcine model of endotoxaemia, renal IL-1β was 
expressed in renal arteriolar endothelial cells but not tubular epithelial cells (Granfeldt et 
al. 2008). IL-1β administered to mice resulted in decreased renal function and expression 
of functional renal transporters, including the epithelial sodium channel (ENaC), the renal 
outer medullary potassium channel (ROMK), and the Na+/K+-ATPase (Schmidt et al. 
2007). LPS-induced downregulation of sodium transporters was unaltered in cytokine-
deficient mice.  
I measured renal levels of cytokines hypothesizing an increase in renal IL-4 and IL-10 
during the resolution phase of AKI. IL-4-stimulated macrophages with an M2 phenotype 
promoted renal tubular cell proliferation (Lee et al. 2011). M2 macrophages produce IL-10 
which decreases the local inflammatory profile and increases expression of pro-
regenerative lipocalin-2 and its receptors in a model of renal ischaemia reperfusion (Jung 
et al. 2012). However, I could not find any convincing trend or difference between sham 
and septic rats.  
4.6.4 Renal Histology 
Despite a higher tubular injury score in septic compared to sham-operated animals at 24 
h, the degree of tubular injury was mild (mean score of 1.9 out of a maximum of 9 in 
septic animals at 24 h). Consistent with other studies, our renal histology findings show 
that histological injury is disproportionately low for the degree of functional impairment, 
and with minimal apoptosis (Langenberg et al. 2008, Lerolle et al. 2010, Takasu et al. 
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2013). There was no evidence of interstitial hypercellularity at any point to suggest 
significant immune cell infiltration.  
We demonstrated significant renal macrophage infiltration at 48 h, subsequent to a rise in 
renal MCP-1 at 24 h. This was coincident with clinical recovery. I speculate that the 
phenotype of this macrophage may be of the ‘M2’ pro-resolution phenotype. However, 
co-staining with ED-1 and markers of macrophage subtype is required to demonstrate 
this (iNOS and mannose receptor for M1 and M2 subtypes, respectively) (Lee et al. 
2011). During the resolution phase of sepsis, renal macrophages may play a different 
role. Endotoxin exposure confers renal protection from subsequent damage 
(preconditioning), mediated via the anti-inflammatory (M2) effect of renal macrophages 
(Hato et al. 2014). In renal tubules, preconditioning resulted in increased macrophage 
number and trafficking within the kidney, clustering of macrophages around S1 proximal 
tubules, and amelioration of peroxisomal damage and oxidative stress and injury to S2 
and S3 tubules. 
Patients with septic AKI who died had significantly greater renal macrophage and 
polymorphonuclear leucocyte infiltration in addition to tubular apoptosis compared to 
patients without severe AKI who die from causes other than septic shock (Lerolle et al. 
2010). The role of the renal macrophage in clinical AKI is difficult to entangle, as clinical 
data are often limited to post- mortem renal biopsies in patients with established septic 
AKI.  
4.6.5 Renal function  
Serum urea and creatinine are elevated at 3 and 6 h, and fell towards baseline values at 
12 h with IV fluid resuscitation. This is consistent with early haemoconcentration followed 
by an dilution effect. A correction factor can be applied to measured serum creatinine to 
correct for the fluid bolus given using the following formula (Macedo et al. 2010): 
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Corrected pCr = pCr x 0.6 x (admission weight) + ε (daily cumulative fluid balance) 
     0.6 x admission weight 
(Where pCr = plasma creatinine) 
Acute haemodilution may mask the creatinine rise in early AKI (Liu et al. 2011). Applying 
the correction factor for cumulative fluid balance over periods longer than a few hours 
after volume expansion lacks a physiological rationale or any objective evidence to 
support its accuracy (Prowle et al. 2015). The formula assumes all cumulative volume 
expansion occurs instantaneously at the point of serum creatinine measurement, failing 
to account for the actual kinetics of creatinine excretion. When volume expansion acutely 
reduces serum creatinine, the filtration of creatinine falls in parallel, and creatinine 
clearance will therefore also fall. Assuming that creatinine generation remains constant, 
creatinine will then accumulate in the body water until serum creatinine rises again to its 
baseline value. Modelling shows that after a large fluid bolus that increases circulating 
volume by 25%, 24 h serum creatinine is only 2% below expected (Prowle et al. 2015).  
In addition to haemodilution, the fall in serum creatinine at 12 h may be due to reduced 
creatinine production. At 14 h in a mouse model of sepsis, creatinine production was 
decreased (Doi et al. 2009). Creatinine is produced from creatine by non-enzymatic 
cyclization. This occurs throughout the body but especially in muscles where creatine 
concentrations are high. Creatinine production itself occurs in the liver (Cocchetto et al. 
1983). Creatinine production can therefore fall as lean muscle mass falls, or during liver 
disease/dysfunction. Loss of muscle mass and subclinical liver disease is common in 
critically ill septic patients. The rise in serum cystatin C (suggestive of decreased GFR) 
from 6 to 12 h with concurrent falls in serum creatinine may be a consequence of 
decreased creatinine production.  
4.6.6 Renal Biomarkers 
There are numerous studies investigating the utility of biomarkers to predict the onset of 
AKI prior to a rise in serum creatinine (Vanmassenhove et al. 2013). Several studies have 
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utilized more than one biomarker and have also looked at serial measures. However, a 
major limitation of clinical studies is that the exact timing of onset of illness is unclear. 
Furthermore, use of nephrotoxic drugs, significant hypovolaemia, comorbid illness, and 
heterogeneity in underlying diagnoses places limitations in interpretation of results. I have 
shown a clear trend in the kinetics of renal biomarkers. It needs to be determined if the 
same holds in the clinical setting where there are significant confounding factors (drug-
induced AKI, hypovolaemia, etc.). The use of diuretics and pre-existing CKD may also 
confound the results. Furthermore, the time course of sepsis in individual patients can 
vary markedly.  
Inducers of cell cycle arrest, TIPM-2 and IGFBP-7, have shown promise as novel AKI 
biomarkers (Kashani et al. 2013). Urine TIPM-2 and IGFBP-7 may be more sensitive and 
specific in diagnosing AKI than NGAL in critically ill patients, including patients with 
sepsis. The combined AUROC was 0.80 in prediction of KDIGO stage 2-3 AKI 12 h 
following ICU admission. Commercial Multiplex kits to measure rat TIMP-2 and IGFBP-7 
are not available however, the University of Pittsburgh has an in–house version using 
ELISA kit (Professor Kellum’s lab; personal communication). At the time of writing we are 
collaborating on order that he measure these analytes. 
Novel biomarkers are often assessed to predict a subsequent rise in creatinine. The 
diagnostic performance of a biomarker depends on the disease prevalence, and the 
sensitivity and specificity of an often imperfect gold standard. It has therefore been 
argued that an inherent flaw in the analysis of biomarkers is that a rise in serum 
creatinine is used as a ‘gold standard’ for AKI and all other biomarkers are compared to 
this. Apparent diagnostic errors using a new biomarker may be a reflection of errors in the 
imperfect gold standard itself, rather than poor performance of the biomarker (Waikar et 
al. 2012).  
To improve the assessment of the diagnostic performance of a novel biomarker, stricter 
criteria for the definition of AKI can be applied. Small changes in serum creatinine alone 
should not be used to define AKI in biomarker or interventional studies. A combination of 
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≥2 criteria may be a more appropriate standard. Although the KDIGO staging of AKI 
includes both serum creatinine and urine output, virtually all biomarker studies only use 
serum creatinine (KDIGO 2012). Furthermore, serum creatinine is a continuous variable 
but AKI is often categorized into absence/presence or ordinal stages. 
The clinical utility of a biomarker may be demonstrated by improvements in clinical 
outcome from biomarker-guided therapy. However, there is no proven specific treatment 
nor treatment algorithm for septic AKI so it may be difficult to demonstrate that biomarker-
guided treatment would result in a better outcome compared to creatinine.  
4.6.7 Effect of Fluid Resuscitation 
Haemodynamic instability during the early phase of septic shock is primarily the 
consequence of intravascular volume depletion and cardiac impairment. 
Pathophysiological changes are characterized by profound vasodilation due to relative 
deficiencies in vasoactive mediators and increased nitric oxide. This, results in a reduced 
venous return and cardiac output, often confounded by associated mitochondrial 
dysfunction in myocytes (Kumar et al. 2004, Pedoto et al. 1999). Tissue hypoxia may 
develop due to low blood flow and/or perfusion pressure. Fluid resuscitation is therefore 
the cornerstone of resuscitation in sepsis, and should be initiated promptly in patients 
with haemodynamic instability or evidence suggestive of tissue hypoperfusion, such as 
an elevated lactate, to achieve an adequate oxygen delivery. In critically ill patients, 
lactate is a surrogate marker of inadequate tissue oxygenation. Though not strictly 
accurate, a good relationship is nevertheless seen between hyperlactaemia and mortality 
(Aduen et al. 1994, Soliman and Vincent 2010). 
I also demonstrated the importance of fluid resuscitation as evidenced by the elevated 
serum urea and creatinine at 6 h compared to the rise in serum creatinine occurring at 24 
h when fluid resuscitation was administered. Fluid resuscitation is particularly important 
for studies assessing organ perfusion and renal function in sepsis, as renal ion 
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transporter expression in response to sepsis and hypotension are dissimilar (Schmidt et 
al. 2007).  
Despite this , a significant proportion of preclinical studies investigating renal blood flow 
did not administer fluid (Langenberg et al. 2005). As would be expected, fluid 
resuscitation in endotoxin- or CLP-treated rats is associated with improved survival 
(Smith et al. 1993). A reduction in serum TNF-α levels was also seen, though dilution 
may have had an effect. The lack of fluid resuscitation is associated with markedly 
reduced microvascular perfusion, increased leukocyte-endothelium interactions and 
sequestration (Villela et al. 2014).  
4.6.8 Limitations and future work 
My findings are applicable to this 72 h rat model of acute sepsis that represents a two-hit 
model where animals are instrumented under general anaesthesia 24 h prior to the onset 
of sepsis. While I made every attempt to recapitulate clinical sepsis, there are several 
limitations. This model is performed in relatively young rats, whereas patients with sepsis 
are usually older with co-existing comorbid illness. Other than haemodynamics, I 
generally did not make serial measurements in the same animal. Each time point 
represents the terminal experiment. However, this was required so that I could analyze 
histology. The most unwell animals were anuric and therefore it was not possible to 
measure urine biomarkers. 
The serum creatinine in the septic animals rose by only 30%, which is less than what is 
seen clinically. This raises potential questions as to the validity of the model to study AKI. 
However, in this fluid-resuscitated model of sepsis, animals with a >50% rise in serum 
creatinine at 24 h tended to not survive much longer. It is therefore not possible to study a 
recovery model of septic AKI with significant rises in serum creatinine. The creatinine rise 
seen at 24 h can be reached by 6 h in the absence of fluid resuscitation. However, this 
would not be clinically relevant and introduces the confounding variable of hypovolaemia. 
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The utility of biomarkers is dependent on their quantification; absolute concentration, 
biomarker normalized to urinary creatinine concentration, and biomarker excretion rate. In 
a prospective study of 529 critically ill patients, urine alkaline phosphatase, γ-glutamyl 
transpeptidase, cystatin C, NGAL, KIM-1, and IL-18 were measured on admission and 
after 12 and 24 h (Ralib et al. 2012). .Normalization to urinary creatinine concentration 
improved the prediction of developing AKI and outcome but provided no advantage in 
diagnosing established AKI. Similar findings were described in a rat model of drug-
induced AKI (Tonomura et al. 2011). I attempted to correct biomarker levels to the urine 
creatinine concentration, however this was not possible in many samples as urine output 
was limited, particularly in the most severely affected animals.  
Many cytokines are produced along with endogenous receptor inhibitors. IL-1β and IL-18 
have endogenously occurring inhibitors, IL-1Ra (Lamacchia et al. 2010) and IL-18 binding 
protein (Novick et al. 1999) respectively. The techniques used to measure cytokines 
cannot differentiate between total and unbound cytokines. Furthermore, there may be 
inaccuracies in measuring the pro-form of the cytokines and also partially degraded 
cytokines. Other proteins, both cytokines and other proteins, may also interact to give 
false positive results. This appears to be a problem in the tissue homogenates, where 
sham animals had variable levels of detectable cytokines both at the same timepoint and 
also across different timepoints. This was particularly a problem with tissue IL-6 (data not 
shown), where results could not be replicated on two separate occasions. 
I used a multiplex kit to measure urine NGAL and an ELISA based kit to measure serum 
NGAL. The monomeric (25kD) form is the predominant form secreted by tubular epithelial 
cells, and the dimeric (45kD) form is the predominant form secreted by neutrophils. NGAL 
is covalently conjugated with gelatinase (matrix metalloproteinase 9) via an 
intermolecular disulfide bridge as a 135-kD heterodimeric form. Western blot, but not 
ELISA based-techniquescan differentiate between the two. The development of 
molecular form-specific assays for NGAL may be a means to identify the origin of 
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HNL/NGAL in urine and construct more specific tools for the diagnosis of AKI (Cai et al. 
2010). 
The analysis of renal histology requires further work. This includes detailed histological 
characterization of the renal medulla and comparison to the renal cortex. Furthermore, 
the use of a control irrelevant isotype antibody in place of the primary antibody should be 
performed to demonstrate antibody specificity. Treatment of histology slices with DNase 
should be performed as a positive control for TUNEL stain.  
4.6.9 Summary and conclusion 
In this clinically relevant model of sepsis and recovery, I found many haemodynamic, 
biochemical, and immunological features consistent with clinical sepsis. Renal histology 
demonstrates minimal histological injury while renal recovery was associated with an 
increase in renal macrophages.  
For the first time, the temporal profile of a panel of renal biomarkers in sepsis in the 
context of systemic and renal inflammation and recovery has been characterized. All 
biomarkers related to PTEC injury were altered to varied degrees and with different 
kinetics. After a recovery period, all biomarkers returned to levels approaching those 
observed in sham animals. Apart from urine osteopontin and IL-18, all other urine 
biomarkers were elevated and at an earlier timepoint to serum creatinine (raised at 24 h). 
Urine NGAL was the most sensitive marker among those studied, rising from 3 to 24 h. 
Urine KIM-1 was the only biomarker to show a greater rise in animals predicted to die. 
While serum creatinine fell at 12 h, serum cystatin C increased, suggestive of decreased 
creatinine production.  
These clinically relevant findings could inform future clinical testing. 
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5 Renal haemodynamics and bioenergetics 
 
5.1 Background 
The haemodynamic instability associated with severe sepsis and septic shock has led to 
the dogma that sepsis-induced AKI is primarily a consequence of renal ischaemia and 
ensuing acute tubular necrosis (ATN) (Schrier and Wang 2004). Profound and rapid 
alterations in blood pressure and regional blood flow during septic shock may lead to loss 
of renal autoregulation, renal hypoperfusion and ischaemia. However, early studies using 
indwelling renal vein catheters to measure renal blood flow (RBF) in septic patients with 
AKI revealed preserved or even elevated renal blood flow (Brenner et al. 1990, Lucas et 
al. 1973, Rector et al. 1973). An early study using indwelling renal vein thermodilution 
catheters in septic patients with AKI demonstrated that RBF was maintained within 
normal limits (Brenner et al. 1990). A systematic review of RBF in experimental sepsis 
recorded 159 separate studies (Langenberg et al. 2005). The method of sepsis induction, 
size and conscious level of the animal, time of measurement, use of fluid resuscitation, 
and systemic haemodynamics were important covariates. Such models of sepsis have 
confirmed that creatinine clearance and RBF may not correlate (Prowle et al. 2012, Wan 
et al. 2009).  
I have demonstrated in my clinically relevant fluid-resuscitated rat model of sepsis that 
systemic inflammation occurs as early as 6 h while renal dysfunction, as defined by 
elevated serum creatinine, occurs at 24 h. Renal histology remains relatively normal with 
mild acute tubular injury at 24 h.  
I hypothesized that the rise in serum creatinine at 24 h is not secondary to a 
reduction in renal blood flow but rather to bioenergetic dysfunction. As data on 
mitochondrial dysfunction in sepsis are conflicting (Section 2.7), I investigated the 
effects of sepsis-induced inflammation on renal tubular mitochondria, without any 
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influence from renal blood flow or oxygen delivery, using multiphoton imaging of a 
live kidney slice.   
  
5.2 Methods 
5.2.1 Renal cortical oxygen tension 
To ascertain renal blood flow and tissue oxygen tension within the kidney, I performed a 
laparotomy under anaesthesia (as described earlier) at either 6 or 24 h post-induction of 
sepsis with an echocardiogram and renal ultrasound scan performed beforehand. The 
fluid infusion of 10 ml/kg/h was continued until the abdominal cavity was opened, after 
which the infusion rate was increased to 20 ml/kg/h to compensate for evaporative 
losses. 
A 22-gauge needle was used to puncture the renal capsule at the mid-pole. A fibreoptic 
optode (250µm diameter) connected to an Oxylite tissue monitoring system (Oxford 
Optronix, Didcot, Oxon UK) was inserted into the kidney to a depth of 4-5 mm and 
subsequently withdrawn to a depth of 1-2 mm to prevent anomalous measurements due 
to any local haematoma (Figure 20). This sensor enabled continuous tissue oxygen 
tension (tPO2) monitoring within the renal cortex (Whitehouse et al. 2006).  
The oxygen sensors are pre-calibrated within the range 0- 26.7 kPa. Short excitatory 
pulses of light (475 nm) are emitted along the fibre-optic cable to a platinum-complex 
fluorophore situated at the sensor tip. Upon interaction with oxygen, the fluorophore emits 
light (600 nm) that is recorded at the detection unit. The lifetime of the returned light is 
inversely proportional to local PO2, according to the Stern-Volmer equation: 
τ0/ τ1 = 1 + (κq x τ0 x {O2}) 
where τ0 is the decay time at zero oxygen, τ1 is the decay time at a specific oxygen 
concentration (O2) and κq is a quenching rate constant that denotes the probability of a 
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photoluminescent molecule and oxygen molecule colliding. As luminescence decay is 
longer at a lower PO2, accurate measurements can be made within the physiological 
range (0-8 mmHg). Continuous tPO2 measurements were recorded onto a computer 
using a 16-channel Powerlab system and Chart 5 acquisition software (AD Instruments, 
Chalgrove, Oxon, UK). At least five minutes were allowed prior to obtaining a reading to 
allow for any local oedema surrounding the sensor tip to resolve. 
 
Figure 20 Picture taken at laparotomy demonstrating oxygen sensor in situ. The 
fibreoptic optode is inserted into the renal cortex at the level of the mid pole of the left 
kidney. 
5.2.2 Renal Blood flow 
The left renal artery was isolated by careful blunt dissection. An ultrasonic flow probe 
(Transonic Systems, Ithaca, NY, USA) of 1 mm diameter was coated in a water-soluble 
lubricant and placed around the left renal artery to measure renal blood flow (RBF) 
(Figure 21). Renal oxygen delivery (DO2 renal) was calculated using the following 
formula: 
DO2 (renal) = 1.34 x RBF (L/min) x Hb (g/dl) x SaO2 
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Figure 21: Picture taken at laparotomy demonstrating renal artery ultrasonic flow probe 
and large area oxygen sensor in situ. The ultrasonic flow probe of 1 mm diameter was 
coated in a water-soluble lubricant and placed around the left renal artery to measure 
renal blood flow. 
5.2.3 Renal oxygen extraction ratio 
The left renal vein was isolated from surrounding tissue by careful blunt dissection. One 
ligature was placed around the renal vein, and another around the renal artery and vein. 
The renal vein was kinked using the ligature, punctured with an 18-gauge needle, and 
approximately 0.3 ml of blood was aspirated. The renal vein and artery were then ligated 
to prevent blood loss. A simultaneous blood sample was taken from the arterial line. Both 
were analyzed in an ABL-70 blood gas analyser (Radiometer, Copenhagen, Denmark). 
The renal oxygen extraction ratio (ERO2) was calculated using the following formula: 
ERO2 = (SaO2- RVO2) x 100 
SaO2 
where RVO2 is renal vein oxygen saturation and SaO2 the arterial blood oxygen 
saturation. 
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5.2.4 Electron microscopy  
As the renal instrumentation methodologies described below are likely to affect serum 
creatinine and histology, samples for electron microscopy and biochemistry were taken in 
repeat experiments at 24h where instrumentation was not performed. A kidney was 
obtained from a septic and a sham animal under anaesthesia. The septic animal had 
significant renal dysfunction (serum creatinine 42 µmol/l) but was not conisdered peri-
mortem. Renal tissue was cut into sections of approximately 1 x 1 x 1 mm using a 
surgical scalpel and placed immediately into glutaraldehyde fixative. The histopathology 
laboratory at the Royal Free Hospital, London performed electron microscopy. Analysis 
was qualitative and focused on mitochondrial structure within proximal tubular epithelial 
cells. Ten random fields were examined at x2,650 magnification in a blinded manner. 
Tubules at the cortico-medullary junction and within the cortex were assessed. Higher 
magnifications (x15,000) were used to evaluate changes within the mitochondria.  
5.2.5 Ex-vivo assessment of mitochondrial function -       
confocal microscopy 
Using dyes or natural flurophores, confocal microscopy allows detailed imaging of cellular 
physiological processes in intact renal tissue sections. Multiphoton imaging uses a long 
wavelength excitation laser that permits significantly greater tissue penetration compared 
to conventional single-laser confocal fluorescence microscopy. This results in less 
phototoxicity and is therefore a better technique for imaging live kidney sections. This 
technique can image live kidney slices in real-time in response to various insults or drugs. 
Multiphoton imaging of freshly prepared rat kidney slices has been previously used to 
investigate mitochondrial function in cells along the nephron, both at rest and in response 
to toxic stimuli, including chemical anoxia (Hall et al. 2009).  
The left kidney was removed from an anaesthetized healthy male Wistar rat and 
immediately placed in oxygenated ice-cold HEPES-buffered solution (118mM NaCl, 
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10mM NaHCO3, 4.7mM KCl, 1.44mM MgSO4 , 1.2mM KH2 PO4 , 1.8mM CaCl2 , 10mM 
HEPES, 5mM glucose, 5 mM sodium butyrate, and 5mM pyruvate). The kidney was 
sliced in half along the transverse plane and mounted on a stage. Slices were cut at 200 
µm in oxygenated ice-cold HEPES-buffered solution using a Microm 650V tissue slicer.  
Slices were incubated in oxygenated HEPES-buffered solution at room temperature until 
used. Kidney slices were placed in an open bath chamber (Harvard Apparatus, 
Edenbridge, Kent, UK) and secured with a slice anchor. Dyes and reagents were loaded 
using an on-stage perfusion system, and changes in signal imaged in real-time in 
response to reagents. Kidney sections were studied up to 6 hours following resection. 
Structures were identified by their characteristic morphology and location. 
Slices were imaged using a Zeiss LSM 510 NLO axiovert microscope coupled to a 
tunable Coherent Chameleon laser. For all probes used, the optimal excitation 
wavelength was based on two-photon excitation spectra (Hall et al. 2009). An internal 
detector captured emitted light. Image processing and analysis was performed using 
Zeiss LSM software (Carl Zeiss Ltd., Welwyn Garden City, Herts, UK) and Image J 
software (National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/). To 
quantify fluorescence signals, regions of interest were drawn around tubules in a 
minimum of three different fields (imaged using a x40 objective). All values are expressed 
as the mean fluorescence intensity, per image pixel (arbitrary units, AU), within the 
relevant region of interest.  
The cationic lipophilic indicator tetramethyl rhodamine methyl ester (TMRM) was used to 
determine mitochondrial membrane potential, at a concentration of 50 nM. The greater 
the potential, the more dye that accumulates and the greater the signal intensity at any 
given pixel. ROS generation in tubules was measured using dihydroethidium (HEt), at a 
concentration of 5 µM. As HEt fluoresces on oxidization by superoxide, the fluorescence 
signal thus increases in proportion to the rate of ROS production. At 720 nm excitation, 
the autofluorescence signal emitted between 435-485 nm (cyan) arises predominantly 
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from mitochondrial NADH. The resulting image consists of striations of signal at the basal 
pole of the cell, matching the known distribution of mitochondria in the tubule and the 
signal seen with TMRM (Table 14) (Figure 22). 
 
Fluorophore Function Final 
concentration 
Excitation 
wavelength 
(nm) 
Emission 
wavelength 
(nm) 
Tetramethyl 
rhodamine methyl 
ester (TMRM) 
Mitochondrial 
membrane 
potential 
50nM 860 575-640 
Dihydroethidium 
(HEt) 
ROS generation 5µM 720 575-640 
NADH 
autofluoresence 
Redox state N.A 720 435-485 
 Table 14 Mitochondrial fluorophores 
 
Figure 22 Confocal images of the proximal tubule NADH, TMRM and Het. NADH is auto-
fluorescent at 720nm and emits a wavelength of 435- 485nm, appearing cyan. TMRM is 
excited at 860nm, and Het is excited at 720nm. Both TMRM and HEt emit wavelengths of 
575- 640nm, appearing red.   
I studied changes in mitochondrial membrane potential, reactive oxygen species (ROS) 
production, and the redox state of PCTs and DCTs. Images were obtained in 
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physiological saline solution (PSS), 24h sham serum, and 24h septic serum. I chose this 
timepoint to collect serum as it corresponded to measurement of significant differences in 
renal VO2 in vivo. Serum was diluted to a 1:3 ratio in PSS to minimize the total amount of 
serum required. Images were taken every 5 min for a total of 45 min. A total of six sets of 
images were taken in PSS, three in sham serum, and three in septic serum.  
Kidney slices were imaged up to 60 min. The mean fluorescent intensity at 60 min was 
expressed as a percentage of mean fluorescent intensity at baseline. Images were taken 
at 15-min intervals, focusing on different areas of the slice to avoid damage (bleaching) to 
the slice from repeated imaging of the same field.  
5.2.6 Protein extraction and quantification 
Snap-frozen renal tissue was homogenized in radioimmunoprecipitation assay 
homogenizing buffer (RIPA buffer; 50 mM NaCl, 1.0% IGEPAL (Octylphenyl-polyethylene 
glycol, Sigma Aldrich), 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) 
at an approximate ratio of 0.3g tissue with 1 ml buffer. Tissue was homogenized with a 
sonicator. The homogenate was centrifuged for 10 min at 14,000g in a cold microfuge to 
remove tissue debris. The supernatant was pipetted and protein concentration 
determined using the bicinchoninic acid assay kit (Pierce, Rockford, IL, USA) according 
to the manufacturer’s protocol. Samples were stored at -80°C.  
In preparation for Western blot analysis, samples were diluted to a concentration of 6 
mg/ml in RIPA buffer and reduced by adding an equal volume of β-mercapthethanol and 
sodium dodecyl sulfate (SDS) buffer (50 µl β-mercapthethanol added to 950 µl SDS) 
buffer) and heated in a heating block for 5 min at 95oC. The final protein concentration 
used for Western blot was therefore 3 mg/ml. Samples were stored at -80°C. 
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5.2.7 Western blot 
Protein was extracted and estimated from renal tissue as described. Samples (20 µg 
protein) were electrophoresed at 100V for 1 h through a 12% or 15% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel under reducing conditions. 
Proteins were transferred to a polyvinylidine difluoride (PVDF) membrane (GE 
Healthcare) at 10V for 45 min, and then blocked for 1 h in 5% milk/1% TBST. This 
membrane was then incubated with goat anti-mouse IgG polyclonal UCP-2 antibody 
(Santa Cruz) at 1:250 in 5% bovine serum albumin (BSA; Sigma) in PBS overnight at 
4oC. Following incubation with the primary antibody, HRP rabbit anti-goat IgG (Sigma) 
was added at 1:3000 in 5% milk for 1 h. Activity was detected using ECL Plus substrate 
(GE Healthcare). Two animals were randomly selected from each of the naïve, sham and 
sepsis (6, 12, and 24 h) groups for analysis. Naïve kidney was used as a relevant 
negative control. 
5.3 Statistics 
All statistical analyses were performed using SPSS (IBM. Version 20) and graphs drawn 
using Graphpad Prism (GraphPad Software, Version 5.0d). Normality of continuous data 
was assessed using the Shapiro-Wilk test. Continuous variables are presented as means 
(standard deviation) where parametric, and median (interquartile range) where non-
parametric. Parametric data were compared using unpaired Student’s t-test, whereas 
non-parametric data were compared using the Mann Whitney U test for comparison of 
continuous data between 2 groups. For comparison of continuous variables between 
more than two groups, one-way analysis of variance (ANOVA) with post hoc Tukey’s test 
is used. A p-value <0.05 was taken as statistically significant. 
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5.4 Results 
5.4.1 Baseline Variables 
At baseline (before central venous catheter insertion), all variables including body weight, 
haemodynamics and renal resistive index of each study group were similar (p>0.05) 
(Appendix). All instrumented animals recovered fully prior to induction of faecal slurry. 
Sham-operated animals remained active throughout. All animals in the sham-operated 
groups survived the 6- and 24 h experiments. All animals in the septic group survived the 
6 and 24 h experiments but two animals in the 24 h group were peri-mortem and 
excluded from analysis.  
5.4.2 Systemic variables 
At 6 and 24h, septic animals had a significantly higher core body temperature compared 
to sham-operated animals. Despite fluid replacement, there was a significant fall in SV 
and CO in septic animals at both 6 and 24 h compared to baseline values. Septic animals 
had a significant increase in HR at 6 h that returned to baseline values by 24 hr. Mean 
arterial pressure and global oxygen delivery were similar at 6 and 24 h compared to naïve 
and sham animals (Figure 23). Changes in systemic haemodynamics, biochemistry, acid-
base balance, and systemic cytokines are described in detail in Chapter 4.  
 
  
Temperature (oC)
Na
ive 6 24
36
37
38
39
40
Naive
Sham
Sepsis
Naive 6hr 24hr
* § * §
Change in SV (%)
0 6 24
-100
-80
-60
-40
-20
0
20
Sham
Sepsis
Baseline 6hr 24hr
§
§*
 144 
  
  
 
Figure 23 Systemic variables following induction of experimental sepsis in Wistar rats (at 
6 h and 24 h) compared to naïve Wistar rats. Septic animals develop fever, tachycardia, 
and impaired SV by 6hrs, which persists through to 24 h. Mean arterial pressure and 
global oxygen delivery remain unchanged. 
(* p<0.05 for sham vs. sepsis (corresponding time points); § p<0.05 for Naïve vs. sepsis) 
5.4.3 Renal haemodynamic variables 
Renal blood flow, renal oxygen delivery, and the proportion of global O2 delivery to the 
kidneys remained unchanged in septic compared to naïve rats. Renal oxygen extraction 
ratio and consumption were significantly lower at 6 h and recovered by 24 h (septic vs. 
naïve animals) (Figure 24). At 24 h, there was a significant increase in lactate being 
produced by the kidneys, despite renal DO2 and VO2 being similar to naïve animals. This 
was associated with a significant fall in renal cortical oxygenation. The urinary fractional 
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excretion of sodium fell at 6 and 24 h, though serum creatinine was elevated only at 24 h 
in septic animals compared to naïve animals (Figure 25). (See Appendix for tables).  
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Figure 24 Renal haemodynamics following induction of experimental sepsis in Wistar 
rats (at 6 hr and 24hr) compared to naïve Wistar rats. Compared to naïve animals, renal 
blood flow and oxygen delivery is maintained in sepsis. Despite this, there is an early fall 
in renal oxygen consumption which recovers to baseline by 24 h.   
(* p<0.05 for sham vs. sepsis (corresponding time points); § p<0.05 for Naïve vs. sepsis) 
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Figure 25 Renal metabolism and function following induction of experimental sepsis in 
Wistar rats (at 6 hr and 24hr) compared to naïve Wistar rats. At 24 h, lactate clearance 
falls in septic animals. This is associated with a fall in cortical oxygen tension and a rise in 
serum creatinine. Fractional excretion of sodium falls at 6 h and remains low at 24 h.  
(* p<0.05 for sham vs. sepsis (corresponding time points); § p<0.05 for Naïve vs. sepsis) 
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5.4.4 Mitochondrial ultrastructure 
 
Figure 26 Electron microscopy of proximal tubule epithelial cell mitochondria (obtained 
from septic animal at 24 h) reveals normal mitochondrial ultrastructure (x15,000).  
 
Mitochondria within the septic kidney appeared normal (Figure 26). There were no 
features of isometric vacuolization, hydropic mitochondria, or structural loss of 
mitochondrial cristae.  
5.4.5 Confocal Microscopy 
Mitochondrial NADH redox state, membrane potential, and tubular reactive oxygen 
species levels remained stable over the 60 min time period in both PSS and sham serum 
(Figure 27). There was a significant drop in NADH redox state in the proximal tubules 
when incubated in septic serum, which was abrogated by pre-incubation with 4-OH-
TEMPO. 
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Figure 27 Changes to mitochondrial redox state, reactive oxygen species (ROS), and 
membrane potential in response to physiological saline solution (PSS) sham serum, 
septic serum, and pre-treatment with 4-OH-TEMPO and septic serum. Exposure to septic 
serum results in an increase in proximal tubular reactive oxygen species and a 
concurrent fall in NADH and mitochondrial membrane potential compared to incubation in 
PSS for 45min. Similar changes are seen in the distal tubules, apart from the fall in 
NADH. These changes are abrogated with 4-OH-TEMPO pre-treatment. Bar graphs and 
error bars represent mean and standard deviation respectively of > 6 replicates. 
(* p<0.05 sham serum vs. septic serum. § p<0.05 septic serum vs. septic serum + 
TEMPO.)  
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The change in redox state was not evident in distal tubular cells. The fall in mitochondrial 
membrane potential when incubated in septic serum approached statistical significance in 
the PTECs and was significantly reduced in DTECs. This change was not prevented by 
4-OH-TEMPO. Both PTEC and DTEC ROS levels were significantly increased in kidney 
slices incubated in septic serum, and were completely prevented by pre-incubation with 
4-OH-TEMPO (Figure 27).  
5.4.6 Western blot for UCP-2 
 
Figure 28 Western blot for Uncoupling Protein (UCP-2) in renal homogenate. Expression 
of UCP-2 (35kDa) and alpha-tubulin (55kDa).  
 
Figure 29 Relative expression of renal uncoupling protein-2 (n=2 per group). There was 
a trend towards an increase in renal UCP-2 expressed in septic compared to sham 
animals at 24 h. 
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The relative expression of UCP-2 was increased in kidney homogenates from septic 
animals at 24 h compared to sham-operated animals and naïve animals (Figure 28). 
There was no differences in UCP-2 levels at either 6 or 12 h. At 24 h, there was a trend 
towards an increase in renal UCP-2 expressed in septic compared to sham animals 
(Figure 29).  However, as only n=2 per group was performed, it was not possible to 
assess for statistical significance.  
5.5 Discussion 
5.5.1 Systemic features 
Blood pressure remained relatively constant throughout the 24 h study period. Despite 
the similar MAP, lactate was elevated at 24 h, suggestive of tissue hypoperfusion and/or 
mitochondrial dysfunction. Despite a higher tubular injury score in septic animals at 24 h, 
the degree of tubular injury was mild with a mean score 1.9 (maximum of 9). Renal 
histology was consistent with other septic AKI studies (Langenberg et al. 2008, Lerolle et 
al. 2010, Takasu et al. 2013), being disproportionately low for the degree of functional 
impairment. RBF remained stable in this model of sepsis. My results suggest that 
structural tubular injury or falls in RBF are not the predominant pathological process 
underlying septic AKI.  
5.5.2 Renal haemodynamics 
GFR, tubular sodium transport and renal VO2 are closely linked. Tubular reabsorption of 
filtered sodium is the major determinant of renal VO2 (Kiil et al. 1961), and tubular 
transport processes are dependent upon the filtered load (Sward et al. 2005, Torelli et al. 
1966). At 6 h there was no alteration in serum creatinine, possibly because creatinine 
would take some time to rise from the point of a decreased GFR. Furthermore, in early 
sepsis, there is a decreased production of creatinine (Doi et al. 2009). At 6 h, renal DO2 
and cortical oxygenation are maintained but renal VO2 falls. The fall in FeNa+ suggests 
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that tubular workload and VO2 should be increased. I therefore postulate that GFR falls 
and the (absolute) amount of solute reabsorbed by the tubules falls, though the 
proportion of filtered solute reabsorbed is increased, as reflected by the fall in FeNa+. 
Tubuloglomerular feedback (TGF) allows each nephron to regulate its GFR in 
accordance with the capacity of its proximal tubule to reabsorb NaCl. Extracellular 
adenosine contributes to the regulation of GFR. Renal interstitial adenosine is mainly 
derived from dephosphorylation of released ATP, AMP, or cAMP by the enzyme ecto-5'-
nucleotidase (Le Hir and Kaissling). This enzyme is located primarily on external 
membranes and on mitochondria of proximal tubule cells (Miller et al. 1978). Extracellular 
adenosine activates A1AR adenosine receptors on vascular afferent arteriolar smooth 
muscle cells, resulting in vasoconstriction, reduced GFR, a reduced need for tubular 
reabsorption and preservation of renal bioenergetics (Schnermann et al. 1990). I 
speculate that the increased workload of the PTECs from 6 h results in ATP depletion 
and accumulation of adenosine. 
At 24 h, serum creatinine rose in septic animals despite a stable RBF. This suggests 
intra-renal shunting, with either less blood flowing through the glomerulus and/or 
dilatation of the efferent arteriole to reduce glomerular filtration. Selective augmentation of 
adenosine around afferent arterioles causes persistent vasoconstriction and a reduction 
in glomerular blood flow. Concurrent global elevation of renal adenosine causes steady-
state vasodilatation resulting from A2AR-mediated generation of nitric oxide (NO) 
(Hansen et al. 2005). The A2AR mediates vasodilatation in deep cortical glomerular 
vessels, increasing medullary blood flow and oxygenation (Vallon and Osswald 2009). 
Therefore, adenosine may maintain renal perfusion via A2 generation of NO, while 
allowing a compensatory reduction in tubular workload mediated by a reduction in A1 
receptor activation. Antagonism of the A1AR decreased renal blood flow during endotoxic 
shock (Nishiyama et al. 1999). 
Renal oxygenation depends on the balance between renal DO2 and VO2. In health, renal 
VO2 depends on renal DO2, and oxygen extraction remains stable over a wide range of 
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RBF (Levy 1960). Any reduction in renal DO2 should be accompanied by a corresponding 
fall in renal VO2 to maintain renal cortical PO2. At 24 h, cortical PO2 fell in the septic 
animals despite renal DO2 and VO2 values that were similar to baseline. The rise in 
serum creatinine at 24 h implies a reduction in GFR. Tubular workload and renal VO2 
should therefore be reduced. However, during hypovolaemic states, the proportion of 
filtered solute reabsorbed by the tubules is increased in an effort to conserve fluid. This 
will increase renal VO2 which, when combined with a stable renal DO2, results in a fall in 
cortical oxygenation. This may be compounded by the diversion of oxygen from ATP 
production as a consequence of uncoupling (Crouser et al. 2002).  
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5.5.3 Mitochondrial structure and function 
 
Figure 30 Electron transport chain and oxidative phosphorylation. During oxidative 
phosphorylation, the main process of ATP production in most body cell types, electrons 
are donated from the Krebs’ cycle to NADH and FADH2, and then pass down the electron 
transport chain (ETC). O2 is the terminal electron acceptor at Complex IV. As electrons 
move down the ETC, H+ ions are driven into the intermembrane space, generating a 
chemiosmotic proton gradient to generate ATP from ADP and inorganic phosphate at 
complex V (ATP synthase). The use of O2 to drive ATP production is known as coupled 
respiration.  
 
Superoxide is the primary reactive oxygen species produced by mitochondria; this arises 
from respiratory complexes I and III (semiubiquinone pathway). In health, the small 
amount of superoxide generated has a signaling role. These levels are kept low by 
mitochondrial antioxidants such as manganese superoxide dismutase (MnSOD). 
Relatively low levels of ROS may also be beneficial with important signaling (hypoxic 
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pulmonary vasoconctriction), biosynthetic (HIF-1 production) and immune functions (TLR 
signaling and post-transcriptional modifications in TNF signaling). 
During sepsis, harmful levels of ROS and reactive nitrogen species (RNS) are produced 
and these can overwhelm the antioxidant capacity. The reaction of NO with superoxide 
generates peroxynitrite, a potent oxidizing agent that causes protein nitration, DNA 
damage and mitochondrial dysfunction (Cuzzocrea et al. 2006). Features of hydropic 
mitochondria and increased autophagosomes in critically ill septic patients are more 
prevalent in septic than in non-septic patients (Takasu et al. 2013). Furthermore, 
mitochondria exposed to non-mitochondrial ROS become a source of ROS themselves. 
Renal tubular cells increase their expression of inducible nitric oxide synthase (iNOS) and 
NADPH oxidase 4 (NOX-4) in response to LPS. This culminates in cytosolic 
overexpression of NO and superoxide,,respectively (Quoilin et al. 2014). This positive 
feedback loop of ROS-induced-ROS is likely to culminate in inhibition, dysregulation and 
damage to mitochondria.  
Uncoupling can occur in various physiological states such as heat production in brown 
fat. Protons pumped across the mitochondrial membrane can ‘leak’ back into the 
mitochondrial matrix and the energy is dissipated as heat. In this situation, NADH is 
oxidized, the mitochondrial membrane potential falls, and O2 is used but ATP is not 
produced (Figure 30). The reduction in mitochondrial membrane potential limits the 
amount of electrons passing along the mitochondrial membrane, and thus the amount of 
ROS produced, however, this is at the expense of ATP production.  
I speculate that a decrease in ATP synthesis (mediated in part via mitochondrial 
uncoupling) would increase the relative amount of renal adenosine. Extracellular 
adenosine activates A1 receptors on afferent arteriolar smooth muscle cells, resulting in 
vasoconstriction and a reduction in GFR (thereby conserving circulating volume). 
Concurrent activation of A2 receptors maintains renal perfusion and facilitates blood 
shunting from the glomeruli. Renal inflammation in sepsis (detailed in section 2.8) 
decreases PTEC ion transporters. This ‘functional shut down’ of GFR, tubular function 
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and ATP production triggers various protective mechanisms, though at the expense of 
renal function. These include conservation of circulating volume, reduction in ROS, and 
‘energy conservation’. This also explains the relatively well-preserved renal histology 
seen in sepsis despite an increase in serum creatinine, 
Treatment with antioxidants ameliorates organ injury in experimental models of sepsis. 
Several therapeutic agents have been tried, including n-acetyl cysteine (NAC) to reduce 
hepatic oxidative stress (Zapelini et al. 2008), MITO-Tempo to reduce renal injury (Patil et 
al. 2014), and inhibiting peroxynitrite with MnTMPyP or inducible nitric oxide synthase 
with aminoguanidine and to prevent renal injury (Seija et al. 2012).The lack of clear 
clinical benefit of antioxidants in sepsis may be due to late initiation (preventative 
therapies have greater benefit), inadequate dosing (particularly with respect to tissue 
levels), and the need to target mitochondrial ROS. 
By incubating fresh kidney slices with septic serum, I demonstrated that “circulating 
humors” rather than RBF or oxygen delivery could induce mitochondrial dysfunction. As 
such, therapies using extracorporeal blood purification may be beneficial. Methods of 
extracorporeal blood purification include high volume haemofiltration, combined plasma 
filtration and absorption, haemoabsorption (using polymyxin B or Cytosorb columns), 
plasma exchange, and now selective removal of cytokines using the biospleen (Zhou et 
al. 2013). Trials of high volume haemofiltration have not shown clinical benefit and blood 
purification strategies may also remove useful molecules including amino acids and 
drugs. Promising results were seen from a pilot study of polymyxin haemoabsorption in 
septic patients (Cruz et al. 2009) and a larger trial is ongoing.  
5.5.4 Limitations and future work 
All BP recordings were obtained in anaesthetized animals and the severity of sepsis was 
relatively modest (100% survival). Increasing severity to include peri-mortem animals was 
not possible, as they deteriorated and sometimes died during invasive measurements.  
The interpretation of experimental results requires appropriate sham animals. I conducted 
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parallel experiments in animals without faecal peritonitis, but which had received a similar 
volume of intravenous fluid. This increased RBF, renal DO2, and cortical oxygenation at 
24 h. The workload of the PTECs would have increased in view of the need to eliminate 
the large volume of free water and to reabsorb a significant proportion of filtered sodium 
(animals were given solutions with low Na+ concentrations).  
High-volume resuscitation itself is associated with renal impairment. The kidney lies 
within a capsule and increased venous pressures may result in a ‘renal compartment 
syndrome’ (Cruces et al. 2014). Clinical data suggest that critically ill patients with 
increased positive fluid balance are at greater risk of AKI (Payen et al. 2008). However, 
causality is difficult to prove as sicker patients are more likely to require fluid resuscitation 
and develop AKI from the underlying disease. I therefore compared values of septic to 
sham animals without any intravenous fluid (but the other invasive procedures were 
performed).  
The invasive nature of the techniques places limitations on data interpretation. 
Instrumentation of the kidney and its vasculature is highly invasive and, in itself, was 
associated with a rise in serum creatinine (data not shown). The model was repeated 
without renal instrumentation to obtain histology and measurement of serum urea and 
electrolytes. The methodology cannot offer information on specific functional anatomical 
structures (e.g., glomerulus, peritubular area, outer versus inner medulla). The renal 
microvascular anatomy of the rat differs from large animals. Thus, observed distributive 
effects of sepsis on renal oxygenation may differ in humans. 
Mitochondrial work was performed at levels of oxygen that are ‘non-physiological’. 
Although differences were seen between kidney slices incubated with either septic or 
sham serum, it is yet to be determined whether the same hold true in physiological levels 
of oxygen. I demonstrated an upregulation in UCP-2 protein in the kidney. However, I 
have not demonstrated the functional significance of this, e.g. a reduction in ATP 
production. The role of uncoupling within the kidney needs to be better characterized with 
knowledge of the time course and the impact on of ATP turnover. The effect of 
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uncoupling can be determined either by inhibiting uncoupling (e.g. with genipin or siRNA) 
or by augmenting it (e.g. with dinitrophenol). Inhibition of uncoupling may result in greater 
ROS formation, the by-products of which could be measured.  
 
5.6 Conclusion 
Renal blood flow is maintained in fluid-resuscitated experimental sepsis. Renal cortical 
oxygenation falls despite similar renal oxygen delivery and utilization at 24 h. The 
presence of UCP-2 in the kidney at this timepoint suggests that mitochondrial uncoupling 
may account for the similar renal oxygen consumption despite less tubular workload (as 
reflected by a rise in GFR). I used multiphoton imaging of the live kidney slice to 
investigate the effect of systemically produced circulating factors on renal tubular 
bioenergetics. This resulted in a fall in tubular NADH and mitochondrial membrane 
potential that are consistent with mitochondrial uncoupling. Furthermore, the amount of 
tubular ROS production is increased. These changes may be driven by ROS as in vivo 
treatment with the ROS scavenger TEMPO abrogated the changes. Mitochondrial 
uncoupling itself may be an adaptive mechanism in which ROS production is limited. I 
have demonstrated that “circulating humors” and not RBF/ DO2, may be causative in 
inducing mitochondrial dysfunction. If renal dysfunction (reduction in GFR) and decreased 
oxidative phosphorylation are adaptive phenomena to decrease reactive oxygen species 
production, then targeting global or renal DO2 may not ameliorate organ injury.  
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6 The role of the NLRP3 inflammasome in sepsis-
induced acute kidney injury 
 
6.1 Background 
 
The NLRP3 inflammasome has been best characterized in immune cells including 
monocytes and macrophages. However, intrinsic renal cells also demonstrate 
components of the inflammasome in various pro-inflammatory diseases, while 
pharmacological inhibition and/or genetic deletion have shown protective effects in many 
preclinical models of AKI.  
The presence of inflammasome components in epithelial cells in closer proximity to the 
ureters and bladder suggests that the renal tubular epithelial inflammasome may have 
evolved to deal with local (ascending) Gram-negative infections. The late distal 
convoluted tubule, the connecting tubule, and the collecting duct epithelial cells express 
P2X7, IL-18 and caspase-1 under basal conditions (Gauer et al. 2007). Similarly, 
medullary collecting ducts express TLR4 and its accessory molecules MD2, MyD88, and 
CD14 in response to LPS (Chassin et al. 2006). Uropathogenic E coli strains bind 
preferentially to intercalated cells of the collecting duct (Chassin et al. 2006) that can 
mount an appropriate immune response. A deficient TLR4/ inflammasome response, as 
seen in patients with TLR4 polymorphisms associated with hyporeactivity to LPS, 
predisposes to Gram-negative sepsis (Lorenz et al. 2002).  
While the NLRP3 inflammasome is crucial for host immunity, it is unclear if excessive 
activation of the inflammasome in sepsis may have detrimental effects on organ function 
and survival. Several preclinical and clinical studies have investigated the role of 
inhibiting the inflammasome pathway in endotoxaemia and sepsis. There are clear 
benefits from preclinical models demonstrating the protective effect of Caspase-1 (ICE) 
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deficiency in a mouse model of endotoxic shock (Li et al. 1995). Similarly, NLRP3 
deficient mice had markedly better survival compared to wildtype mice and produced 
significantly less IL-1β and IL-18 (Mariathasan et al. 2006). Pharmacological agents with 
inhibitory effects on the NLRP3 inflammasome, including dimethylsulphoxide, have also 
demonstrated survival benefit when mice were pre-treated (Ahn et al. 2014). 
The effect of IL-1β blockade in sepsis has been evaluated in humans. A series of 
multicentre randomized clinical trials (RCT) in the 1990s investigated the therapeutic 
effect of human recombinant IL-1 receptor antagonist (IL-1ra) in sepsis. A dose-
dependent 28- day survival benefit was seen in patients with septic shock due to Gram-
negative infection (Fisher et al. 1994). Post- hoc analysis revealed an increased survival 
time in patients with sepsis and secondary organ dysfunction and a predicted mortality 
≥24%. However, interim analysis of a subsequent multicentre RCT suggested it was 
unlikely that the primary efficacy endpoints would be met, so the study was terminated 
early (Opal et al. 1997).  
The functional significance of de novo organ-specific inflammasome expression in 
systemic inflammatory diseases such as sepsis is unclear. The notion that NLRP3 
inhibition may be beneficial in sepsis-induced AKI was demonstrated by caspase-1 
deficiency in a LPS model of endotoxaemia (Wang et al. 2005). With the use of global 
KOs and receptor antagonists, it is difficult to ascertain the relative contribution of 
systemic versus renal inflammasome activation in sepsis-induced AKI. The role of TLR4 
signaling in sepsis-induced AKI has been investigated in mice with functional TLR4 
deficiency (C3H/HeJ mice). These mice transplanted with wild-type kidneys were 
protected from LPS-induced AKI, whereas wild-type mice transplanted with C3H/HeJ 
kidneys developed severe LPS-induced AKI. This suggests that TLR4 expression in 
circulating cells propagates injury in septic AKI rather than intra-renal TLR4 (Cunningham 
et al. 2004). However, in a murine model of UUO, use of bone marrow chimeras revealed 
that NLRP3 mediates injurious/inflammatory processes in both hematopoietic and non-
hematopoietic cellular compartments (Vilaysane et al. 2010). 
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In another murine model of UUO, P2X7 was upregulated in cortical tubular epithelial cells; 
genetic deletion protected against macrophage infiltration, collagen deposition and 
apoptosis (Goncalves et al. 2006). This contrasts with the predominant glomerular P2X7 
expression seen in a glomerulonephritis model, which was also protected by genetic 
deletion or by P2X7 receptor antagonism (Taylor et al. 2009). The close association 
between the site of renal injury in and the presence of P2X7, along with the protective 
effect of a P2X7 antagonist or genetic deletion, strongly supports a role for P2X7 in AKI 
pathogenesis.  
A similar relationship may hold for sepsis-induced AKI. Pilot data from the rat sepsis 
model showed upregulation of proximal tubular epithelial P2X7 at 6 hours, associated with 
(mild) acute tubular injury, while glomerular P2X7 expression and damage were minimal 
(Figure 31).  
 
Figure 31 Renal tissues sampled at 6 h post-induction of faecal peritonitis (or control) 
were stained for the presence of the P2X7. Significant acute tubular injury was seen in 
rats subjected to sepsis; this correlated with increased P2X7 expression in the renal 
tubules. (x20 magnification). On PAS sections there was little evidence of infiltrating cells 
while staining for macrophages (CD68) was negative at this early timepoint (Chapter 4).  
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I therefore hypothesized that upregulation of the ATP-sensitive P2X7 receptor 
causes renal injury in sepsis through local production of cytokines and 
chemokines, and cell death. The aim of the work in this chapter was to define the 
role of the P2X7 in septic AKI, specifically to:  
1. Define patterns of expression of this receptor within the kidney, its 
relationship to inflammasome expression within the kidney, and to 
histological changes; 
2. Assess effects of P2X7 antagonism in a rat model of sepsis-induced AKI 
 
6.2 Methods 
6.2.1 Natural history of the renal inflammasome in sepsis 
6.2.1.1 Live kidney slice incubation and immunoflurosence 
The left kidney was removed from anaesthetized healthy male Wistar rats and 
immediately placed in oxygenated ice-cold HEPES-buffered solution (118mM NaCl, 
10mM NaHCO3, 4.7mM KCl, 1.44mM MgSO4, 1.2mM KH2 PO4, 1.8mM CaCl2, 10mM 
HEPES, 5mM glucose, 5 mM sodium butyrate, and 5mM pyruvate). The kidney was 
sliced in half along the transverse plane and mounted on a stage. Slices were cut at 200 
µm in oxygenated ice-cold HEPES-buffered solution using a Microm 650V tissue slicer 
(OTS 5000 tissue slicer, Electron microscopy sciences, Hatfield, UK).  
The slices were then placed in each well of a 6-well cell culture plate. (6-well Corning® 
Costar® cell culture plate (VWR, Lutterworth, Leicestershire, UK). Slices were washed 3 
times with 1x PBS (1 ml per well). Slices were incubated in either sham serum (1:3 sham 
serum and 2:3 PSS) or septic serum sampled at the 24 h timepoint (1:3 septic serum and 
2:3 PSS). Slices were then incubated in 5% CO2/ 95% O2 at 37oC for 90 mins.  
Live kidney slices were fixed with 4% methanol free PFA (about 500 µl per well) in 1x 
PBS for 15 min at room temperature. Slices were washed 3 times with 1x PBS (1 ml PBS 
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added per slice and washed for 1 min each time). Kidney slices were permeablized with 
0.5% Triton-x 100 in 1x PBS (about 500 µl per well) at room temperature for 10 min on a 
plate shaker. Slices were washed three times as described. Slices were blocked with 
10% BSA in 1x PBS for 2 h at room temperature followed by another three washes. 
Slices were incubated with primary antibody rabbit anti-mouse caspase-1 (Santa Cruz 
Biotechnology) diluted 1:500 in 1% BSA overnight at 4°C (1ml per well). The next day, 
slices were washed three times and the secondary antibody (Alexa Fluor® 568 goat anti- 
rabbit with excitation/emission wavelengths of 578⁄603nM, ThermoFisher Scientific. 
Waltham, MA USA) diluted 1:500 in 1% BSA in 1xPBS was added and slices incubated 
for 2 h incubation at room temperature in the dark. Slices were washed and nuclei were 
stained using DAPI (4',6-Diamidino-2-Phenylindole, Dilactate) with excitation/emission 
wavelengths of 360⁄460nM (ThermoFisher). Two drops of DAPI were added per ml of 1x 
PBS and slices incubated for 5 min at room temperature in the dark. Slices were washed 
three times and then washed with ddH2O. Slices were mounted on glass slides and 
excess water removed using a pipette. 50µL of Mowiol mounting medium (made in 
laboratory using Chemicals from Sigma Aldrich) was added as a droplet to cover the slice 
and a coverslip was placed over the slices. The Mowiol mounting medium was allowed to 
dry at room temperature for 30 min. Slides were stored at 4oC. 
All procedures following addition of the secondary antibody were performed in a room 
with minimal light so as to avoid bleaching of the fluorescent probes. All steps with 
incubations and washing were performed with the cell culture plate on a plate shaker with 
gentle agitation. One ml of reagent or wash solution was added per well to ensure the 
slice was covered adequately.  
Slices were imaged using a Zeiss LSM 510 NLO axiovert microscope coupled to a 
tunable Coherent Chameleon laser. An internal detector captured emitted light. Image 
processing and analysis were performed using LSM software (Carl Zeiss, Welwyn 
Garden City, Herts). 
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6.2.1.2 Immunohistochemistry (Paraffin embedded sections) 
Sections from the in vivo experiments (Chapter 4: Animal models of sepsis and recovery) 
were fixed in 10% formalin and embedded in paraffin. Sections were cut 5µm thick and 
then mounted on glass slides (performed by histopathology lab at Imperial College, 
London).  
For detection of P2X7, slides were dewaxed and rehydrated through graded xylene and 
ethanol, respectively. Antigen retrieval was performed by placing slides in 0.01M sodium 
citrate buffer heated to 90oC in a water bath for 15 min. Slides were then immersed in 
50% methanol containing 0.3% H2O2 for 1 h to block endogenous peroxidase activity. 
Slides were washed with PBS then incubated with 20% normal goat serum for 30 min to 
prevent non-specific binding. The primary antibody (mAb P2X7, APR-004, Alamone, 
Jerusalem, Israel) was diluted in 1% BSA/0.05M Tris-HCL (pH 7.2) and incubated at 
room temperature for 1 h. Slides were rinsed in PBS for 15 min and incubated with 
peroxidase-labelled polymer conjugated to goat anti-mouse immunoglobulins (Dako, Ely, 
Cambs) for 1 h. Antibody binding was visualized using 3,3’-diaminobenzidene (Dako) and 
counterstained with hematoxylin. Spleen tissue from a septic animal at 6 h was used as a 
positive control.  
Sections were examined using a light microscope (Olympus Optical, London, UK) at x20 
magnification. All sections were scored in a blinded manner. Ten random fields of view of 
the cortex were analyzed for each section at x20 magnification. P2X7 staining was 
assessed semi-quantitatively using a Color Coolview camera (Photonic Sciences, 
Robertsbridge, UK) and analyzed using Image Pro Plus software (Media Cybernetics, 
Silver Spring, MD, USA). For each section, ten random fields of view were analyzed and 
mean fluorescence intensity calculated (Figure 32). One section from each sample was 
incubated with antibody diluent instead of primary antibody and served as control. 
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ImagePro Score:   Area of P2X7 Expression x Density of P2X7 staining 
Total Area 
 
Figure 32: Localization of P2X7 by Image Pro software. Increased P2X7 is seen in 
cortical distal tubules and occasional proximal tubular cells, (x20 magnification).  
6.2.1.3 Proximal tubular cell culture 
NRK 52E rat tubular epithelial cells (Sigma Aldrich), derived from a primary cell line, were 
cultured in DMEM medium (Invitrogen, Paisley UK) supplemented with 10% fetal calf 
serum (FCS), 2 mM glutamine, 0.1 mM non-essential amino acids, 100 U/ml penicillin 
and 100 mg streptomycin. Cells were cultured in T75 flasks (TPP Techno Plastic 
Products AG, Trasadingen, Switzerland) at 37oC in 5% CO2 / 95% O2. Once confluent, 
cells were re-suspended (by adding 5 ml trypsin and placing in 5% CO2 / 95% O2 at 37oC 
for up to 5 min). The cells were then washed in Hank’s buffered saline solution (HBSS; 
Invitrogen), counted using a haematocytometer (Bright-Line Hemacytometer, Sigma-
Aldrich, Gillingham, Dorset, UK), and transferred to 6-well Corning® Costar® cell culture 
plates to achieve a concentration of half a million cells per well. Once confluent, complete 
medium was changed to serum-free medium for 24 h. Before stimulation, cells were 
washed with HBSS.  
Two wells of cells were used as controls. Control cells were not exposed to 
lipopolysaccharide (from Escherichia coli 0111:B4, Sigma Aldrich) or the P2X7 partial 
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agonist 2′(3′)-O-(4-Benzoylbenzoyl)adenosine 5′-triphosphate triethylammonium (BzATP; 
Sigma Aldrich). The four remaining wells of cells were primed with LPS (1 µg/ml) for 5.5 
hours. Two wells had BzATP added at a concentration of 200 ng/ml for 30 minutes. At the 
end of this period, the supernatant was collected. Cells were treated with 0.5 ml 2-
Mercaptoethanol (Sigma) and collected. The cells were stored at -80oC and supernatant 
stored at -20oC. Cells were analyzed for expression of IL-1β and P2X7 protein using 
Western blot. IL-1β and MCP-1 were quantified in the supernatant using ELISA. 
6.2.1.4 Monocyte isolation and culture 
Naïve male Wistar rats were given 1000 units heparin intraperitoneally 30 min prior to 
culling. Animals were anaesthetized as described and blood obtained via cardiac 
puncture. Blood was stored in a sterile Falcon tube on ice. Fifteen ml blood was added to 
30 ml volume of sterile PBS and mixed. Twenty ml was transferred onto 15 ml of Ficoll 
very slowly using a 1ml pipette to ensure the Ficoll-blood layer was not broken. The 
suspension was centrifuged for 30 min at 1400 rpm at room temperature ensuring the 
centrifuge break was off (to avoid disrupting the layer). Three layers were formed - the 
lowermost Ficoll layer, followed by the thin layer of monocytes, and the layer of PBS. 
Cells were re-suspended in 30 ml complete culture medium (RPMI with 10% FBS and 1% 
Pen/Strep) and centrifuged at 1200 rpm for 8 min at room temperature. The monocyte 
pellet was re-suspended once again and placed in 30 ml complete medium at 37oC in 5% 
CO2 / 95% O2 for 24 h. The next day, cells were centrifuged at 1200 rpm for 8 min at 
room temperature, re-suspended in 2 ml serum-free culture medium, and counted. 
Serum-free medium was added to give a total cell count of 4 x 106 cells per 1 ml. One ml 
was added per well in a 6 well plate and left overnight at 37oC in 5% CO2/ 95% O2. 
The next day, cell culture was started. Macrophages and monocytes require priming with 
LPS (signal 1) prior to release of IL-1β by co-stimulation with LPS (signal 2). The duration 
of LPS-priming is variable, though 4 h has been shown to be adequate (Qu et al. 2007). 
Stimulation by ATP is only required for 30 min after LPS priming (Mehta et al. 2001).  
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The following conditions were used:  
• control (unstimulated) 
• LPS: 1 µg/ml LPS per well for 6 h 
• LPS + ATP: 1 µg/ml LPS per well incubated for 5.5 h followed by 5 nM ATP for 
30 min 
• LPS + ATP + DMSO/P2X7A: 1µg/ml LPS per well incubated for 5.5 h followed by 
10 µM P2X7 antagonist dissolved in DMSO (final concentration 2%) followed by 5 
nM ATP for 30 min  
• LPS + ATP + DMSO: 1 µg/ml LPS per well was incubated for 5.5 h followed by 
DMSO (final concentration 2%) followed by 5 nM ATP for 30 min  
• Positive control BBG: 1 µg/ml LPS per well incubated for 5.5 h followed by 5 µM 
BBG and then 5 nM ATP for 30min  
Cell suspension was collected in a 1.5 ml tube and centrifuged at 1200g for 5 min at room 
temperature. Medium was transferred to new tubes and the pellets dissolved in 50 µl 
RIPA. Samples were stored at -80oC. 
6.2.1.5 Western Blot 
Protein was extracted and estimated from cultured cells or from whole kidney tissue as 
described (sections 4.3.1, 6.2.1.3). Samples (20 µg protein) were electrophoresed at 100 
V for 1 h through a 12% or 15% SDS-PAGE gel under reducing conditions. Proteins were 
transferred to a polyvinylidine difluoride (PVDF) membrane (GE Healthcare, Amersham, 
Bucks) at 10V for 45 min, and then blocked for 1 h in 5% milk/1% TBST. This membrane 
was then incubated with goat anti-mouse IL-1β (Santa Cruz Biotechnology) at 1:1000 
overnight at 4oC. Following incubation with the primary antibody, HRP rabbit anti-goat 
IgG (Sigma) was added at 1:3000 in 5% milk for 1 h. Activity was detected using ECL 
Plus substrate (GE Healthcare).  
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6.2.1.6 ELISA 
Serum samples were obtained during the experiment and centrifuged at 6500 rpm for 10 
min in a lithium-heparin tube. The serum was siphoned off, snap-frozen in liquid nitrogen, 
and stored at -80oC. Supernatants from cell culture experiments were collected and 
stored in -80oC freezer. Sandwich ELISA was performed to assess serum levels of IL-1β 
and MCP-1 from cell culture experiments. DuoSet ELISA kits (R&D Systems, 
Minneapolis, MN, USA) were used according to the manufacturer’s instructions. The 
antibody supplied in the IL-1β kit does not cross-react with pro–IL-1β. ELISA was also 
performed to assess the presence of cytokines within renal tissue homogenate. Tissue 
cytokine levels were expressed relative to the total protein content. Absorbance was read 
at 450 nm using a spectrophotometric ELISA plate reader (Anthos HTII; Anthos Labtec, 
Salzburg, Austria). 
 
6.3 Statistics 
All statistical analyses were performed using SPSS (IBM. Version 20) and graphs drawn 
using Graphpad Prism (GraphPad Software, Version 5.0d). Normality of continuous data 
was assessed using the Shapiro-Wilk test. Continuous variables are presented as means 
(standard deviation) where parametric, and median (interquartile range) where non-
parametric. Parametric data were compared using unpaired Student’s t-test, whereas 
non-parametric data were compared using the Mann Whitney U test for comparison of 
continuous data between 2 groups. For comparison of continuous variables between 
more than two groups, one-way analysis of variance (ANOVA) with post hoc Tukey’s test 
is used. A p-value <0.05 was taken as statistically significant.  
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6.4 In vivo study 
6.4.1 P2X7 receptor antagonist 
 
Figure 33 Chemical structure of P2X7 antagonist (A-438079) 
The P2X7 antagonist (A-438079) (Figure 33) was kindly donated by Abbvie (Abbott Park, 
IL, USA). Based on previously published data and personal communication with Abbvie, 
the pharmacokinetic profile of the P2X7 antagonist (A-438079) was determined. A 3 µM 
concentration of A-438079 has been shown to block 75% of IL-1β release from cultured 
peritoneal macrophages stimulated with LPS and BzATP (3 µg/ml LPS priming for 2 h 
followed by 30 min stimulation with 0.3 – 3.0µM BzATP) (Figure 34) (McGaraughty et al. 
2007).  
 
 
a. A-438079: P2X7 Selectivity 
 
b. A-438079 inhibition of IL-1β  release  
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Figure 34 P2X7 selectivity and effect on IL-1β release (P2X7-related modulation of 
pathological nociception in rats (McGaraughty et al. 2007). (a). A-438079 blocked BzATP 
(10µM)–mediated changes in intracellular Ca++ concentrations at rat P2X7 receptors but 
not at other P2 receptors. (b). A-438079 (0.3–3µM) attenuated the release of IL-1β from 
peritoneal macrophage cells following the application of 3µM BzATP. 
6.4.2 Selection of time points 
My aim was to study the in vivo activity of the drug and the clinical impact. The 72- hour 
characterization study informed timepoints for the antagonist study. 
The main pharmacological action of the P2X7 antagonist is to inhibit the NLRP3 
inflammasome activity and therefore reduce IL-1β and IL-18. In vivo activity was therefore 
defined as the ability of the P2X7 antagonist to reduce IL-1β and IL-18 release in the rat 
model of sepsis. As renal IL-1β is elevated at 6 h in this model, I therefore used this as 
the first predetermined timepoint. Serum IL-1β and IL-18 were elevated by 3 h and IL-1β 
remained elevated for 48 h. Therefore, one group of animals were given low dose 
DMSO/P2X7 antagonist at the same time as sepsis was induced (pre-treatment group) to 
evaluate if the drug could decrease serum IL-1β in vivo at 24 h. As urinary IL-18 was only 
elevated after a rise in serum creatinine, this was therefore not used as an endpoint as 
the aim was to prevent the onset of AKI in sepsis.  
The primary aim of this study was to evaluate the effect of P2X7 antagonism on 
preventing renal dysfunction (as defined by an elevated serum creatinine) in sepsis (i.e. 
the clinical impact). Serum creatinine was elevated at 3 h in septic animals compared to 
sham animals. However, this primarily reflects hypovolaemia as creatinine (and urea) 
promptly fell after fluid resuscitation was started. Serum creatinine was subsequently 
significantly elevated at 24 h in septic animals compared to sham animals. Thus, 24 h 
was therefore used as the second predetermined time point.  
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6.4.3 Dose calculation 
Unpublished data from Abbvie Pharmaceuticals demonstrates that the half-life of IV A-
438079 is 0.69 h (41 min) (Figure 35, Table 15). An intravenous dose of 10 µg/kg can 
achieve a peak serum concentration of 4000 ng/ml. I intended to give a dose of P2X7 
antagonist sufficient to inhibit IL-1β release. I was therefore aiming for a peak 
concentration of at least 3 µM which would blocked 75% of IL-1β release from 
macrophages in vitro) (Figure 34).  
A concentration of 3 µM A-438079 is equivalent to 1029 ng/ml (MW = 342.6). Therefore I 
chose an intravenous bolus of 10 µg/kg (giving a peak concentration of 4000 ng/ml) as 
the lower dose. As this drug was used to inhibit activity of tissue macrophages, a ‘high 
dose’ (20 µg/kg) was also chosen to achieve adequate tissue levels.  
 
 
Figure 35 Pharmakokinetics of A-438079 (Data supplied by Steve McGaraughty, Abbvie 
USA. Personal communication). The half-life of IV A-438079 is 0.69 h (41 min). An 
intravenous dose of 10 µg/kg can achieve a peak serum concentration of 4000 ng/ml. 
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Vbp (L/kg) Clp (L/hr-kg) T1/2 (hr) 
1.7 1.6 0.69 
Table 15 Pharmakokinetics of A-438079 (10µmol/kg IV dose) 
 
The antagonist was given as a single bolus to achieve a peak (therapeutic) concentration, 
followed by 4x the dose (i.e.: 40 µg/kg for the low-dose experiments) for the first half-life, 
followed by 2x the dose for the second half life, followed by 10 µg/kg/hr thereafter. For 
the 24 h experiments, a bolus dose of IV fluids was given at 6hrs as per protocol. In order 
to avoid dilution of the drug, the IV bolus contained 10µg/kg A-438079 (or twice as much 
for high-dose experiments) (Figure 36). 
 
 
Figure 36 Study protocol. As renal IL-1β is elevated at 6 h in this model, this time point 
was chosen as the first timepoint. Serum creatinine was significantly elevated at 24 h in 
septic animals. Thus, 24 h was therefore used as the second time point. The carrier ± 
antagonist was started at 2 h post sepsis induction- at either high dose (n=10- 12 per 
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group) or low dose (n=6 per group). In a separate experiment, the carrier and antagonist 
was started at the induction of sepsis at a low dose. 
6.4.4 Preparation of drug 
On dissolving the drug in water for a final concentration of 20µM, the pH at room 
temperature fell to 2.2, and at 38oC was 1.6. Higher concentrations of the drug produced 
even more acidic solutions. A stock solution of 80 µM had a pH of 1.4 at room 
temperature and 0.9 at 38oC. On addition of sodium hydroxide to neutralize the drug 
solution, the drug crystalized once the pH was >3. Preliminary experiments (data not 
shown) were carried out in which animals (n=7) received the low concentration of the 
drug. This however caused a significant metabolic acidosis and a raised anion gap 
compared to untreated septic animals.   
I then selected dimethylsulfoxide (DMSO) as a drug solvent. This is a commonly used 
drug solvent however itself has biological activity (see below). I therefore compared 
DMSO-treated septic animals to DMSO / P2X7 treated septic animals. The strength of 
DMSO used varied from 3-15% depending on the concentration of P2X7 required ( 
, Table 17).  
 
Time of 
infusion 
P2X7 
concentration 
(µM) 
P2X7  
(mg) 
H2O  
(ml) 
DMSO  
(ml) 
Total vol.  
(ml) 
DMSO 
(%) 
Initial bolus 10 2.25 0.9 0.1 1 10.0 
Continuous 
infusion 
10 2.25 3.2 0.1 3.3 3.0 
Second t1/2 20 4.5 3.15 0.15 3.3 4.5 
First t1/2 40 9 2.8 0.5 3.3 15 
Table 16 Example calculation for 330g rat in low dose experiment 
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Time of 
infusion 
P2X7 
concentration 
(µM) 
P2X7  
(mg) 
H2O  
(ml) 
DMSO  
(ml) 
Total vol.  
(ml) 
DMSO 
(%) 
Initial bolus 20 4.5 3.15 0.15 3.3 4.5 
Continuous 
infusion 
20 4.5 3.15 0.15 3.3 4.5 
Second t1/2 40 9 2.8 0.5 3.3 15 
First t1/2 80 18 2.8 0.5 3.3 15 
Table 17 Example calculation for 330g rat in high dose experiment 
6.4.5 DMSO 
Due to its amphipathic properties, DMSO is an effective solvent for water-insoluble 
compounds and is a hydrogen-bound disrupter. As such it is a commonly used solvent for 
many drugs in pharmacological studies. However, DMSO decreases IL-1β mRNA 
transcription and therefore reduces inflammation (Ahn et al. 2014). DMSO also inhibited 
NLRP3 inflammasome activity and attenuated IL-1β maturation, caspase-1 activity and 
ASC pyroptosome formation, but had no effect on NLRC4 and AIM2 inflammasomes. 
Pre-treatment with 10% DMSO resulted in a significant survival benefit in mice (Ahn et al. 
2014). However, there are also isolated reports of the pro-inflammatory action of DMSO 
in human PBMCs (Xing and Remick 2005) and low-dose toxicity in a retinal neuronal cell 
line (Galvao et al. 2014). The action of DMSO needs to be evaluated further before any 
firm conclusions are determined. Differences may be related to the dose of DMSO, 
cell/species type, and duration of stimulation.   
DMSO also exerts anti-inflammatory effects as a hydroxyl radical scavenger. In cardiac 
myocytes, DMSO can increase heme-oxygenase-1 (HO-1) mediated via activation of p38 
MAPK and Nrf2 translocation (Man et al. 2014). Furthermore, mitochondrial reactive 
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oxygen species can induce IL-1β and NLRP3 activity, and this was inhibited by DMSO 
(Ahn et al. 2014).  
Alternatives to DMSO as a solvent include ethanol and MF59. MF59 is an oil-in-water 
emulsion made of squalene, emulsified with two surfactants, polysorbate 80 and sorbitan 
trioleate (commercially known as Tween 80). Although MF59 does not act on the NLRP3 
inflammasome, it activates MyD88 for a Toll-like receptor-independent signaling pathway 
(Seubert et al. 2011). Ethanol also has immunomodulatory effects on the NLRP3 
inflammasome. The effects may depend on the cell type. In macrophages, ethanol 
decreased NLRP3 activation (Nurmi et al. 2013). In contrast, ethanol up-regulates NLRP3 
expression and inflammasome activation in astrocyte supernatant (Alfonso-Loeches et al. 
2014, Lippai et al. 2013). This is mediated by mitochondrial ROS generation and can be 
reversed by a specific mitochondria ROS scavenger (Alfonso-Loeches et al. 2014). As 
the purpose of this experiment was to investigate the potential role of NLRP3 inhibition in 
a clinically relevant model of sepsis, I chose to use DMSO.  
6.4.6 Sample size calculation 
The number of antagonist-treated animals and placebo-treated controls was calculated 
based on previous lab experience. I regarded a 20% change in a tested variable as an 
important biological effect. The sample size (n) was estimated according to the formula 
n=2f(α, P)σ2/()2, where f(α, P)is a function of the power and significance level of the study, 
σ is the standard deviation of the measured variable, and µ1 and µ2 are the mean values 
in the two groups for comparison. The study was designed to have a power of 90% and a 
significance level of 5%. In these circumstances f(α, P) has a value of 10.5. Substituting 
the above values gives n= 2 x10.5 x34.7/(54.5-(08x54.5))2 , i.e. n=6.1. Therefore I 
included at least 6 replicate animals per group per timepoint (Table 18).  
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  Treatment 2 h post- sepsis Pre-treatment 
Time Untreated Low dose 
DMSO 
Low dose 
DMSO/ 
P2X7 
High dose 
DMSO 
High dose 
DMSO/ 
P2X7 
Low dose 
DMSO/  
P2X7  
6hr 7 - - 6 6 - 
24h 12 6 6 10 10 6 
Table 18 Antagonist treatment groups and numbers of animals per group 
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Results 
6.4.7 Natural history of renal inflammasome expression 
6.4.7.1 P2X7 expression 
Naïve and sham-operated animals demonstrated minimal P2X7 presence on 
immunohistochemistry. P2X7 was present at a low level in distal tubular epithelial cells, 
and was predominantly localized to the basolateral membrane.  
There was variable expression of P2X7 in septic rats at 6h, and no significant difference 
in the expression of renal P2X7 at 6 hours between sham-operated and septic rats as 
quantified by ImagePro software. Expression of P2X7 in septic animals at 24h was 
present in both proximal tubules and distal tubules and was localized to the cytoplasm. In 
peri-mortem animals (excluded from statistical analyses) there was evidence of 
intraluminal debris, which stained intensely for P2X7 (Figure 37). At 24h, renal P2X7 
expression in septic compared to sham-operated animals (0.015±0.002 vs. 0.007 ± 
0.003; p=0.003) was significantly increased (Table 19), (Figure 38).  
  
 6hr 24hr 
 Sham Septic p Sham Septic p 
P2X7 score 0.009 ± 
0.006 
0.018 ± 
0.011 
0.310 0.007 ± 
0.003 
0.015 ± 
0.002 
0.003* 
Table 19 Renal histology P2X7 quantification (Arbitrary units) 
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Figure 37: Histological assessment of renal P2X7. (20x magnification) 
A: Naive kidney with minimal P2X7;  
B: Kidney from a 24 h sham animal with minimal P2X7, mainly within the capillary loops of 
the glomeruli and at the basolateral regions of tubules (black arrow);  
C: Kidney from a 24 h septic animal with a similar pattern as the 24 h shams but greater 
intensity and wider distribution;  
D: Kidney from a severe septic animal at 24 h with intense staining for P2X7 of 
intraluminal debris (red arrowhead)  
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Figure 38 Immunohistochemistry scores for P2X7 expression in naïve, sham and septic 
animals (n=6-8 per group). There is significantly increased renal tubular P2X7 expression 
at 24h in septic animals compared to sham animals. Bar graphs and error bars represent 
mean and standard deviation respectively of > 6 replicates (* p<0.05 sham serum vs. 
septic animals).  
 
Cultured NRK52E cells did not express pro-IL-1β or P2X7 protein under basal conditions. 
Cells treated with LPS showed significant increases in P2X7 and pro-IL-1β protein in LPS-
primed cells. There was no increase in pro-IL-1β or P2X7 protein when NRK52E cells 
were co-incubated with BzATP (Figure 39). 
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Figure 39 The presence of P2X7 and pro-IL-1β protein in LPS-primed NRK 52E rat 
tubular epithelial cells is demonstrated by Western blotting. P2X7 and pro-IL-1β protein 
were not detected under basal conditions. Experiment conducted once.  
 
6.4.7.2 Caspase-1 expression 
 
     
           
Figure 40 Immunofluoresence for caspase-1 of live kidney slice incubated in sham serum 
(left panel) and septic serum (right panel). Experiment conducted twice, each in triplicates  
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The live slice of the naïve rat kidney incubated in sham serum did not reveal any 
caspase-1 on immunofluroscence. When incubated in septic serum for 90 min, 
immunofluorescence revealed caspase-1 in proximal tubular cells (           
Figure 40).  
6.4.7.3 IL-1β  expression 
 
Figure 41 IL-1β Western blot of kidney homogenate from sham and septic animals at 6 h, 
12 h, and 24 h. Positive control (+) is a spleen from a septic animal. Loading control is 
alpha-tubulin (55kDa). Pro-Il1β (31kDa) is present in septic kidney homogenates only. 
The quantity of IL-1β expressed in septic kidneys increases from 6h to 24h. Active 
(cleaved) IL-1 β was not detected in kidney homogenate. n=2 per group. Experiment 
conducted once.  
 
There was no pro-IL-1β or active (cleaved) IL-1β expression in kidneys of sham-operated 
animals. Pro-IL-1 β was expressed in the kidneys of septic animals with an increment in 
the relative expression over time (from 6 to 24 h) (Figure 41). Active IL-1β was not 
detected. The results of the Western blot are consistent with the ELISA (Section 4.5.5). 
 
Cultured NRK52E cells did not release IL-1β into the supernatant as detected by ELISA 
on stimulation with LPS or LPS and BzATP (despite expression of pro-IL-1β in the 
homogenate of cells exposed to LPS (Figure 39). There was a significant amount of 
MCP-1 detected in the supernatant of cultured NRK52E cells stimulated with LPS (Figure 
42).  
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Figure 42 MCP-1 production by renal tubular epithelial cells. NRK52E cells produce 
MCP-1 on exposure to LPS. Experiments were conducted twice, in triplicates. Bar graphs 
and error bars represent mean and standard deviation respectively of 6 replicates 
(p<0.001) 
 
Effect of DMSO and P2X7 antagonist on IL-1β  production 
 
Figure 43 Effect of DMSO and P2X7 antagonist on monocyte IL-1β release. LPS priming 
followed by ATP stimulation resulted in significant IL-1β release from PBMCs. 2% IL-1β 
release was inhibited by the addition of 2% DMSO prior to ATP exposure. Addition of 10 
µM P2X7 antagonist had no added effect on the reduction of IL-1β release. 5 µM BBG 
had a significant inhibitory effect on monocyte IL-1β release. Experiments were 
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conducted twice, with each condition in duplicate. Data plotted represents mean and 
standard deviation.  
LPS and ATP together resulted in significant IL-1β production. Addition of 2% DMSO 
significantly inhibited the release of IL-1β. Addition of 10 µM P2X7 antagonist had no 
added effect on the reduction of IL-1β release. 5 µM BBG had a significant inhibitory 
effect on monocyte IL-1β release.  
6.4.8 Effect of P2X7 antagonist in sepsis 
One animal (untreated) in the 24 h study died prematurely. When treatment was 
commenced 2 h after the onset of sepsis, there were no clear benefits of treatment with 
low-dose DMSO or low-dose DMSO/P2X7 (data not shown in figures but tabulated in the 
appendix). However, if treatment with low-dose DMSO/P2X7 was commenced at the 
initiation of sepsis, there was an improvement in haemodynamics (tachycardia and stroke 
volume) at 6 and 24 h. At 24 h, MAP and global DO2 were higher, and serum creatinine 
was lower in pre-treated animals compared to untreated animals. There was also a trend 
for a lower serum IL-1β value (p=0.07) at 24 h in low dose pre-treated animals.  
Compared to untreated animals, high-dose DMSO treated animals showed no significant 
improvement in clinical parameters (Figure 44). At 6 h, animals treated with high dose 
DMSO had lower values of creatinine and lactate, compared to untreated animals. 
However, all animals had biochemical parameters within the normal clinical range and so 
the differences in creatinine and lactate are of doubtful clinical significance (Figure 45). 
The 24 h serum MCP-1 was higher in high dose DMSO treated animals (Figure 46). The 
mechanism and clinical significance behind these are unclear, as previous reports 
mention DMSO inhibition of MCP-1 transcription in response to LPS or IL-1β (Xing and 
Remick 2007, Xing and Remick 2007).  
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The combination of high dose P2X7 antagonist and DMSO had several beneficial effects. 
At 6 h, animals treated with high dose DMSO/P2X7 had a lower temperature and higher 
SaO2 compared to untreated animals (Figure 44). The 6 h renal IL-1β and IL-10 were 
significantly lower in DMSO/P2X7 treated animals, although this did not translate to a 
lower serum creatinine at 24 h (Figure 45). There was a trend to a lower serum IL-1β, 
creatinine, and urine NGAL at 24 h in DMSO/P2X7 treated animals, though none reached 
statistical significance.  
At 24 h, there was a significant improvement in cardiac function (stroke volume and heart 
rate) associated with DMSO/P2X7 treatment. The 24 h serum lactate was lower and 
albumin higher with DMSO/P2X7 treatment compared to untreated and DMSO-treated 
animals. Only serum lactate, albumin, and anion gap were significantly improved in high 
dose DMSO/P2X7 treated animals compared to high dose DMSO-treated animals at 24 h.  
6.4.8.1 Systemic variables  
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Figure 44 P2X7 antagonist experiment- Systemic variables following induction of 
experimental sepsis in Wistar rats (that received no drug, DMSO carrier, or P2X7 
antagonist in DMSO). At 6 h, the combination of P2X7 antagonist in DMSO blunted the 
increase in core body temperature, and tachycardia compared to untreated septic 
animals. At 24 h, the combination of P2X7 antagonist in DMSO was associated with a 
higher stroke volume than untreated septic animals. Box and whisker plots represent 
mean and standard deviation respectively. Experiments included 6 animals per group for 
6 h time point and 10 -12 animals per group for 24 h time point. (* p<0.05).  
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6.4.8.2 Biochemistry  
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Figure 45 P2X7 antagonist experiment- Biochemistry following induction of experimental 
sepsis in Wistar rats (that received no drug, DMSO carrier, or P2X7 antagonist in DMSO). 
Serum lactate and creatinine were statistically higher in the P2X7 antagonist/DMSO 
treated group compared to the DMSO treated group- though the clinical significance of 
the marginally elevated creatinine and lactate is unclear. Animals in the P2X7 
antagonist/DMSO treated group had a lower arterial lactate and higher serum albumin 
than the DMSO treated group and the untreated group. Only the pre-treated (P2X7 
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antagonist/DMSO) animals had a lower serum creatinine, despite a half of the dose. Box 
and whisker plots represent mean and standard deviation respectively. Experiments 
included 6 animals per group for 6 h time point and 10 -12 animals per group for 24 h 
time point. (* p<0.05). 
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6.4.8.3 Systemic cytokines  
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Figure 46 P2X7 antagonist experiment- Systemic cytokines following induction of 
experimental sepsis in Wistar rats (that received no drug, DMSO carrier, or P2X7 
antagonist in DMSO). Serum cytokines were not different between groups at 6 h. At 24 h, 
only the pretreatment group had a lower serum IL-1β compared to the untreated group. 
Box and whisker plots represent mean and standard deviation respectively. Experiments 
included 6 animals per group for 6 h time point and 10 -12 animals per group for 24 h 
time point. (* p<0.05) 
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Figure 47 P2X7 antagonist experiment- Renal cytokines following induction of 
experimental sepsis in Wistar rats (that received no drug, DMSO carrier, or P2X7 
antagonist in DMSO). At 6 h, the animals in the P2X7 antagonist/DMSO treated group 
had a lower renal IL-10 and IL-1b compared to untreated animals. At 24 h, this difference 
did not persist. Renal INF-g was significantly higher in the P2X7 antagonist/DMSO treated 
animals and the pretreated low dose P2X7 antagonist/DMSO compared to the untreated 
animals. Box and whisker plots represent mean and standard deviation respectively. 
Experiments included 6 animals per group for 6 h time point and 10 -12 animals per 
group for 24 h time point. (* p<0.05) 
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6.4.8.4 Urine Biomarkers 
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Figure 48 P2X7 antagonist experiment- Urine biomarkers following induction of 
experimental sepsis in Wistar rats (that received no drug, DMSO carrier, or P2X7 
antagonist in DMSO). Apart for a higher urine MCP-1 at 6 h in the P2X7 
antagonist/DMSO treated animals compared to the DMSO treated animals, there were no 
difference in urine biomarkers between groups at 6 h or 24 h. Box and whisker plots 
represent mean and standard deviation respectively. Experiments included 6 animals per 
group for 6 h time point and 10 -12 animals per group for 24 h time point. (* p<0.05) 
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6.5 Discussion 
6.5.1 Natural history of the inflammasome within intrinsic renal 
cells 
Using different techniques, I have demonstrated expression of various components of the 
NLRP3 inflammasome in this septic model. My findings are consistent with published 
data showing that LPS-primed Madin–Darby canine kidney (MDCK) renal tubular 
epithelial cells express Toll-like receptor 4, NLRP3, caspase-1, interleukin-1β and 
interleukin-18 mRNA (Jalilian et al. 2012). 
I found using both renal immunohistochemistry and cell culture techniques that renal 
tubular epithelial cells express P2X7 in response to sepsis and LPS, respectively. 
Immunohistochemistry revealed positive P2X7 staining of intraluminal debris. It is likely 
that the debris represents mucoprotein rather than shed tubular cells, as a TUNEL stain 
would be positive if the latter were the case. Increased staining is likely to represent non-
specific binding of protenaceous material to the P2X7 antibody. Nevertheless, Western 
blot of LPS-stimulated NRK52E renal tubular cells demonstrated expression of P2X7, 
confirming the positive staining of proximal tubules I visualized on immunohistochemistry 
(experiment repeated twice). Furthermore, tubular cells express caspase-1 on incubation 
of a live kidney slice in septic serum. The use of the live kidney slice experiment allows 
examination of the effect of circulating mediators on renal inflammation, independent of 
renal perfusion/blood flow. The latter experiment was performed on three slices incubated 
in pooled septic serum from 6 animals. 
In my 72 h model of sepsis and recovery, serum IL-1β was significantly elevated by 3 h. 
This was maintained for 24 h, followed by a gradual fall to normal levels by 48 h. Renal 
levels of IL-1β started to rise by 3 h but peaked at 24 h. Neither renal nor serum IL- β 
levels could differentiate between animals predicted to survive or die. There were no 
clear differences between IL-18 levels in sham and septic animals, with large inter-
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individual variations in levels. A non-significant increase in serum IL-18 was seen at 3 h. 
One would expect a significant correlation between serum IL-1β and IL-18 levels as their 
release is tightly coupled. The peak in IL-1β and IL-18 did coincide, lending evidence to 
the role of early inflammasome activation in sepsis. Urine IL-18 fell in septic animals 
compared to sham animals at 3 h. Urine IL-18 levels started to rise from 12 h in septic 
animals predicted to live, and peaked at 48 h. The peak in urine IL-18 coincided with 
clinical recovery. Urine IL-1β was not detectable in the urine of septic animals at either 6 
or 24 h. 
6.5.2 Effect of P2X7 antagonist in sepsis 
I hypothesized that P2X7 receptor antagonism ameliorates renal dysfunction in sepsis (as 
defined as a rise in serum creatinine). I did not find any difference in serum creatinine 
levels between P2X7 receptor antagonist-treated animals and untreated animals when 
treatment was initiated after the onset of sepsis. However, it is not possible to come to 
any firm conclusion, as I could not demonstrate a significant rise in serum creatinine in 
the untreated animals. In the 72 h characterization study (Chapter 4), there was a 
statistically significant rise in serum creatinine, though only 30% above baseline. The lack 
of rise in creatinine in the experiments repeated for the antagonist study is a reflection of 
the limitations of serum creatinine as a biomarker in AKI and also a limitation of this 
animal model of sepsis, where serum creatinine rise is not clinically significant. I therefore 
measured urine NGAL, a more sensitive biomarker of AKI than serum creatinine. 
Although urine NGAL was lower in animals treated with high dose DMSO/P2X7 compared 
to untreated animals (23 (15 – 40) vs. 40 (24-47) µg/ml respectively), this did not reach 
statistical significance so a Type II error may exist. 
DMSO/P2X7 reduced renal inflammation as indicated by lower renal IL-1β levels at 6 h. 
Treatment was initiated early enough (at 2 h), before renal IL-1β levels had peaked. The 
reduction in renal IL-1β was not sustained at 24 h, which may relate to the dosing 
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regimen used. In contrast to renal IL-1β, serum IL-1β peaked by 3 h in untreated animals. 
Therefore treatment initiated at 2 h did not significantly reduce either serum IL-1β or IL-18 
(see Appendix) at 24 h.  
Despite a trend towards a lower serum creatinine and urine NGAL at 24 h in DMSO/P2X7 
–treated animals, there was an increase in urine IL-18 that approached statistical 
significance (p=0.06) in DMSO/P2X7-treated animals compared to untreated animals. 
This was associated with a significant increase in renal INF-γ. Elevated urine IL-18 and 
NGAL are both markers of AKI. Yet, a fall in NGAL was associated with a rise in urine IL-
18 with P2X7 antagonist treatment. This was also associated with an increase in renal 
INF- γ expression. INF- γ is a potent modulator of P2X7 expression and activity in 
epithelial cells (Welter-Stahl et al. 2009). I hypothesize that inhibition of P2X7 receptor 
may have increased INF- γ expression by negative feedback, mediated via IL-18 
production (a potent inducer of INF-γ). The increase in IL-18 may have been via P2X7-
independent but TLR4-dependent pathways (Gupta et al. 2006).  
As would be predicted, there would be systemic effects of inhibition of the inflammasome 
in sepsis over and above renal-specific effects. The reduction in heart rate, and improved 
stroke volume, lactate and albumin at 24 h associated with high dose DMSO/P2X7 
treatment may be possibly explained by a reduction in systemic or cardiac inflammatory 
mediator levels. This needs to be evaluated further. Alternatively, DMSO increases 
heme-oxygenase-1 (HO-1) levels, mediated via p38 MAPK activation and Nrf2 
translocation in cardiac myocytes (Man et al. 2014). HO-1 is a potent anti-oxidant and 
improves cardiac myocyte survival.  
It seems unlikely that IL1-β and IL-18 are released by only one mechanism in 
polymicrobial sepsis, as redundancy is integral to the innate immune system. The inability 
of DMSO/P2X7 to reduce serum IL-1β levels may be explained by P2X7-independent 
mechanisms of IL-1 β release. Monocytes are capable of IL-1β release independent of 
P2X7 receptor activation (e.g. via TLR 7/8 ligands), though P2X7 activation accelerates 
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mature IL-1β release from monocytes (Ward et al. 2010). Splenic dendritic cells are able 
to release mature IL-1β in the absence of P2X7 activation, but require the NLRP3 
inflammasome. Intraperitoneal administration of LPS induced IL-1β production in serum, 
which was abrogated in Nlrp3-null mice but was unaffected in P2X7-deficient mice (He et 
al. 2013). IL-18 is also released by P2X7-independent pathways (Gupta et al. 2006). IL-
1β and IL-18 may be released independently of NLRP3 activity. NLRP3-deficient mice 
had detectable (but significantly reduced) levels of these cytokines (Mariathasan et al. 
2006). Accordingly, pre-treatment at time 0 with low dose DMSO/P2X7 lowered (but did 
not abrogate) serum IL-1β at 24 h. 
The number of improved parameters seen with combination treatment compared to 
DMSO and A-438079 alone suggests a synergistic effect. This is evident in that many of 
the parameters demonstrate a trend to improvement with DMSO alone that reaches 
statistical significance with combination treatment (haemodynamics at 6 and 24 h, 6 h 
temperature, 24 h reduction in renal IL-1β, and renal IL-10).  
DMSO/P2X7 receptor antagonist use was associated with a significant reduction in 
arterial lactate and improvement in serum albumin compared to DMSO-treated animals at 
24 h. Basal expression of P2X7 promotes cell growth in P2X7-transfected HEK293 
(Adinolfi et al. 2005). However, an ATP challenge resulted in mitochondrial fragmentation 
mediated by increases in ER Ca2+ concentration and subsequent cell death (Adinolfi et al. 
2009). Therefore, prevention of excessive P2X7 activation may have promoted 
mitochondrial health associated with improved oxidative phosphorylation and lower 
lactate. The improvement in serum albumin is likely to relate to reduced capillary leak 
from decreased systemic inflammation rather than increased albumin synthesis by the 
liver. Reduced capillary leak is likely due to less microvascular inflammation, although I 
did not quantify this.  
 199 
6.6 Limitations and further work 
The main limitation was the lack of significant rise in serum creatinine in untreated septic 
animals, as discussed above. The effects of P2X7 receptor blockade in this experimental 
model of sepsis is difficult to ascertain, as there is likely to be synergy with DMSO. 
However, in a clinically relevant model of sepsis, the potential role of NLRP3 inhibition 
(via the synergistic effect of DMSO and P2X7 receptor antagonism) warrants further 
investigation. I recognize that DMSO may have had beneficial effects in addition to 
NLRP3 inhibition (anti-oxidant), however I was unable to find another suitable diluent that 
also had no inflammation-modulating effects. Furthermore, in the pretreatment group, I 
did not perform an experiment with DMSO treatment alone. I cannot therefore conclude 
which changes seen in the treatment are attributable to P2X7 receptor blockade and 
which are due to DMSO. 
I performed ELISA and Western blots on whole kidney homogenate for cytokine 
measurement. Neither of these methods allows localization to specific cell types. P2X7 
immunohistochemistry, caspase-1 expression in the live kidney slice, and results from 
cell culture of NRK52E cells are consistent with PTEC expression of IL-1β, although I 
have not demonstrated this conclusively. NRK52E cells also produced MCP-1. 
Immunohistochemistry would enable localization of these cytokines. The effect of P2X7 
antagonism on renal tubular epithelial cells also needs to be investigated.  
The methods I used to measure cytokines have inherent limitations. ELISA and Multiplex 
are subject to error from endogenous binding protein and antibodies against cytokines 
(total and unbound cytokines), the pro-forms of the cytokines, partially degraded 
cytokines. Monocyte cell purity and phenotype were not ascertained and should be 
performed in future experiments.   
I found a progressive increase in renal IL-1β in septic animals from 6 to 24 h on whole 
tissue homogenate detected by Western blot and ELISA. It is not possible to differentiate 
between the IL-1β precursor and active IL-1β on ELISA. Western blot of whole kidney 
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homogenate revealed pro-IL-1β. Furthermore, I did not detect IL-1β in cell culture 
supernatant of LPS-stimulated NRK52E renal tubular cells despite the presence of pro-IL-
1β and P2X7 in cell lysates. The experiment was repeated twice but yielded similar 
results. There are a number of possibilities for this observation. Unlike IL-1β processing, 
the upregulation of pro-IL-1β is dependent on signaling via NF-κ B and not the 
inflammasome per se (Martinon et al. 2009). I cannot therefore conclude that there has 
been inflammasome activity, although there is evidence of the inflammasome 
components. Alternatively, cells that are immortalized (cell lines) may have altered 
inflammatory pathways, as cell death pathways and inflammation pathways overlap. 
Active (cleaved) IL-1β was also not detected in tissue homogenates of kidneys from 
septic animals. IL-1 β activation and release are closely coupled, and any active IL-1β 
may have been released into the circulation or urine. I could not detect any urinary IL-1β 
on ELISA. An alternative explanation would be that there is endogenous soluble IL-1R 
within the renal tissue, though this needs to be evaluated in the model.  
Although I have provided some insights into renal expression of the inflammasome and 
the P2X7 in sepsis, the expression of the P2X7 in other organs and on immune cells 
needs to be evaluated. Polymerase chain reaction (PCR) was not performed in any of the 
experiments, which may have differences at the transcriptional level.  
 
6.7 Conclusion 
The NLRP3 inflammasome has an important role in pro-inflammatory cytokine production 
and cell death. NLRP3 inflammasome inhibition has been shown to attenuate immune-
mediated injury in several in vivo models. Both DMSO and P2X7 antagonism inhibited 
NLRP3-mediated pro-inflammatory cytokine IL-1β production by peripheral blood 
monocytes in vitro. Combination drug therapies may be more efficacious than single drug 
therapies. Preliminary studies using knockout mice and endotoxin treatment have 
demonstrated a potential benefit of NLRP3 inflammasome inhibition in sepsis. However, 
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the role of the NLRP3 inflammasome has not been evaluated in a clinically relevant 
model of sepsis. I therefore studied the effect of NLRP3 inhibition in experimental sepsis 
using a fluid-resuscitated rodent model of faecal peritonitis, looking at both pre- and post-
treatment.  
I found that tubular P2X7 and caspase-1 expression and activation occured both in vivo 
and ex vivo. Combined treatment with DMSO and a P2X7 antagonist after the onset of 
sepsis reduced renal IL-1β expression early (6 h), with a trend towards a lower urine 
NGAL at 24 h. In addition, this DMSO/P2X7 antagonist combination reduced fever at 6 h, 
and improved haemodynamics (HR and SV) at 24 h. The P2X7 receptor antagonist had 
additional benefits of improving serum levels of albumin and lactate. Given these 
encouraging results in an in vivo model that is applicable to human disease, I believe 
further studies targeting the NLRP3 inflammasome in sepsis are warranted 
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Final overview 
 
Summary of findings, limitations, and future work 
 
The clinical problem 
Sepsis is a major global problem, with a high mortality and morbidity. Organ dysfunction 
is a hallmark of sepsis and AKI is a part of this spectrum. Despite the significant clinical 
and financial burden, we are only just beginning to understand the complexities that 
underlie this heterogeneous condition. Several changes observed in the process may be 
adaptive. However, if prolonged or excessive, these changes may become maladaptive 
and detrimental. The interplay between changes in global and intrarenal haemodynamics, 
local bioenergetics and metabolism, and immunological processes need to be dissected 
out in context to the acute inflammatory, established, and resolution phases of sepsis.  
There are several limitations that hinder the investigation of AKI in clinical practice, 
including the lack of access to histological specimens, the often uncertain timing of the 
onset of illness, the heterogeneity of AKI (drugs, hypovolaemia), and pre-existing CKD. It 
is therefore useful to have a clinically relevant model to investigate the pathophysiology 
and potential tools for diagnosis, monitoring, and management of sepsis-induced AKI. 
I have demonstrated that septic AKI can happen with very mild morphological renal 
changes, and that haemodynamic factors cannot fully explain the development of AKI. As 
such, I investigated more specific mechanisms including mitochondrial and 
immunological pathways. 
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Laboratory model of sepsis-induced AKI and recovery 
I used a fluid resuscitated model of faecal peritonitis with intermittent non-invasive 
haemodynamic monitoring to investigate the pathophysiology of septic AKI and recovery. 
Serum creatinine was only elevated relatively late (24 h) after the onset of sepsis, with 
changes in serum IL-1β occurring as early as 3 h. Renal histology demonstrated minimal 
histological injury and renal recovery was associated with an increase in renal 
macrophages. An acute increment in serum creatinine and/or fall in urine output are 
currently used criteria for the diagnosis of AKI. These however lack sensitivity and 
specificity. A better biomarker for the early diagnosis of AKI is required. Several have 
been investigated yet none have been validated and confirmed suitable for routine clinical 
use. Using an animal model of sepsis, I demonstrated the temporal changes of a panel of 
biomarkers in context to systemic inflammation and renal histology. The exact timing of 
insult along with the access to histological samples is a clear advantage of the animal 
model for this purpose. I demonstrated that urine NGAL was the most sensitive biomarker 
for renal inflammation, rising the earliest of those tested. A fall in urine KIM-1 and 
calbindin at 24 h may predict renal recovery. Future work should focus on obtaining serial 
samples of urine from patients and normalization to urinary creatinine concentration. The 
utility of novel biomarkers including TIMP-2 and IGFBP-7 needs to be investigated.  
Renal haemodynamics and bioenergetics  
Much emphasis is placed on the correction of global haemodynamic factors in sepsis. 
Yet, regional blood flow and microvascular perfusion may be altered in sepsis, and may 
not reflect global haemodynamics. The dogma that septic AKI is primarily a disorder of 
renal hypoperfusion has been challenged by studies demonstrating preserved or even 
elevated renal blood flow in sepsis and a relatively unchanged renal histology. 
Furthermore, ‘normal’ organ blood flow may not prevent the onset of organ dysfunction, 
as there may be a defect with cellular energetics. I demonstrated a fall in renal cortical 
oxygenation despite similar renal oxygen delivery and utilization at 24 h. The presence of 
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UCP-2 in the kidney was consistent with findings on multiphoton imaging of the live 
kidney slice. In these studies, incubation with septic serum containing circulating 
inflammatory factors resulted in a fall in tubular NADH, and mitochondrial membrane 
potential that are consistent with mitochondrial uncoupling. Furthermore, the amount of 
tubular ROS production was increased. These changes were prevented by pre-treatment 
with the ROS scavenger TEMPO. Mitochondrial uncoupling itself may be an adaptive 
mechanism to limit ROS production.  
Future work should determine if the same changes hold in physiological levels of oxygen. 
I have demonstrated an upregulation in UCP-2 protein within the kidney. The role of 
uncoupling in this organ needs to be better characterized with knowledge of the time 
course and the effect on ATP/ADP turnover. The effect of uncoupling can be determined 
either by inhibiting uncoupling (e.g. with genipin or siRNA) or by augmenting it (e.g. with 
dinitrophenol). Inhibition of uncoupling may result in greater ROS formation, the 
byproducts of which could be measured. 
The role of the NLRP3 inflammasome in sepsis-induced acute kidney injury 
Intrinsic renal cells demonstrate components of the inflammasome in various pro-
inflammatory diseases. Pharmacological inhibition and/or genetic deletion has 
demonstrated a protective effect in many preclinical models of AKI.  
Using a variety of techniques, I demonstrated expression of various components of the 
NLRP3 inflammasome in this long-term septic model, including upregulation of proximal 
tubular epithelial P2X7 at 6 h. The functional significance of de novo renal-specific 
inflammasome expression in sepsis is unclear. I could not demonstrate any difference in 
serum creatinine between P2X7 receptor antagonist-treated animals and untreated 
animals when treatment was initiated after the onset of sepsis. However, it is not possible 
to come to any firm conclusion as I did not demonstrate a significant rise in serum 
creatinine in the untreated animals. Nonetheless, there were beneficial effects of NLRP3 
inhibition on recovery of haemodynamics, lactate, and serum albumin. 
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Future work should focus on the effects of sepsis on renal tubular epithelial cells and the 
effect of NLRP3 inhibition. The experiments need to be conducted in a reliable model of 
septic AKI. The effects of inhibition of the NLRP3 inflammasome on survival also need to 
be ascertained using a more severe model.  
.  
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10 Appendix 
10.1 AKI definitions 
RIFLE Criteria 
RIFLE Creatinine clearance/ GFR Criteria Urine output criteria 
Risk Serum creatinine x1.5 or GFR decrease >25% < 0.5ml/kg/h x 6 h 
Injury Serum creatinine x 2 or GFR decrease >50% < 0.5 ml/kg/h x12 h 
Failure Serum creatinine x3, GFR decrease > 75% or 
serum creatinine ≥ 352 µmol/l with an acute 
rise >44 µmol/l  
< 0.3 ml/kg/h x 24 h, or 
anuria x 12 h 
Loss Persistent acute renal failure = complete loss 
of kidney function > 4 weeks 
 
End stage End-stage kidney disease > 3 months  
 
AKIN Criteria 
AKIN Creatinine clearance/ GFR Criteria Urine output criteria  
AKIN I Increase in serum creatinine ≥ 26.4 µmol/l 
or increase to ≥150-200% (1.5- to 2-fold) 
from baseline 
< 0.5 ml/kg/h for >6 h 
AKIN II Increase in serum creatinine to >200-300% 
(>2- to 3-fold) from baseline 
< 0.5 ml/kg/h for >12 h 
AKIN III Increase in serum creatinine to >300% (>3-
fold) from baseline (or serum creatinine 
≥354 µmol/l with an acute increase of ≥0.5 
mg/dl (44 µmol/l) 
< 0.3 ml/kg/h for 24 h or 
anuria for 12 h 
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10.2  72hr sepsis and recovery data 
(a: Naïve vs. sham; b sham vs good prognosis sepsis; c sham vs. poor prognosis 
sepsis; d good vs poor prognosis sepsis) 
 
10.2.1 Baseline data  
 
 
 
 
 
Group Weight 
(g) 
Temperature 
(oC) 
HR 
(/min) 
SV  
(mL) 
CO  
(ml/min) 
3hr Sham 326 ± 18 37.5 ± 0.2 427 ± 44 0.32 ± 0.02 141 ± 18 
3hr Sepsis Good Prognosis 316 ± 9 37.4 ± 0.3 428 ± 40 0.32 ± 0.03 138 ± 18 
3hr Sepsis Poor Prognosis 335 ± 29 37.8 ± 0.2 432 ± 32 0.32 ± 0.07 137 ± 16 
6hr Sham 314 ± 18 37.4 ± 0.2 384 ± 48 0.34 ± 0.05 b 136 ± 21 b 
6hr Sepsis Good Prognosis 332 ± 33 37.7 ± 0.5 410 ± 36 0.38 ± 0.04 129 ± 13 
6hr Sepsis Poor Prognosis 328 ± 27 37.9 ± 0.5 405 ± 26 0.36 ± 0.07 156 ± 23  
12hr Sham 355 ± 37 37.6 ± 0.2 426 ± 26 0.32 ± 0.07 146 ± 31 
12hr Sepsis Good Prognosis 324 ± 9 37.4 ± 0.3 416 ± 36 0.35 ± 0.03 146 ± 12 
12hr Sepsis Poor Prognosis 326 ± 19 37.3 ± 0.3 418 ± 32 0.32 ± 0.03 135 ± 17 
24hr Sham 350 ± 74 37.4 ± 0.5 439 ± 19 0.33 ± 0.04 137 ± 14 
24hr Sepsis Good Prognosis 328 ± 25 37.5 ± 0.4 416 ± 35 0.35 ± 0.03 147 ± 18 
24hr Sepsis Poor Prognosis 345 ± 66 37.5 ± 0.2 418 ± 34 0.32 ± 0.03 d 146 ± 12 
48hr Sham 342 ± 28 37.4 ± 0.4 394 ± 27 0.35 ± 0.05 135 ± 17 
48hr Sepsis Good Prognosis 324 ± 15 37.3 ± 0.2 413 ± 22 0.35 ± 0.06 137 ± 20 
72 Sham 337 ± 26 37.6 ± 0.5 400 ± 43 0.39 ± 0.07 143 ± 24 
72 Sepsis Good Prognosis 321 ± 9 37.6 ± 0.5 420 ± 33 0.36 ± 0.05 154 ± 21 
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10.2.2 Preoperative Cardiovascular data 
 
 
 
 
 
 
 
 
 
 
  
Group Change in HR 
(%) 
Change in SV 
(%) 
Change in CO 
(%) 
3hr Sham -1.6 ± 8.4 -7.0 ± 14.6 -9.2 ± 10.6 
3hr Sepsis Good Prognosis 4.6 ± 10.6 14.8 ± 19.5  11.4 ± 17.0 
3hr Sepsis Poor Prognosis 5.7 ± 8.4 -39 ± 15.5 -36.0 ± 14.2 
6hr Sham -0.4 ± 7.7 -8.0 ± 5.0 -8.6 ± 7.3 
6hr Sepsis Good Prognosis 18.8 ± 11.4 -34.2 ± 8.6 -21.9 ± 11.8 
6hr Sepsis Poor Prognosis 22.2 ± 9.0 -49.9 ± 12.3 -38.6 ± 16.0 
12hr Sham -0.5 ± 8.8 -4.8 ± 16.4 -5.8 ± 14.9 
12hr Sepsis Good Prognosis 9.0 ± 7.5 -35.5 ± 19.8 -29.3 ± 23.9 
12hr Sepsis Poor Prognosis 13.7 ± 4.6 -40.0 ± 13.2 -32.0 ± 14.7 
24hr Sham -2.7 ± 6.9  -9.3 ± 11.4 -12.0 ± 10.2 
24hr Sepsis Good Prognosis 9.1 ± 13.0 -29.3 ± 14.4 -22.8 ± 18.6 
24hr Sepsis Poor Prognosis 14.3 ± 15.3 -32.3 ± 17.4 -25.3 ± 19.9 
48hr Sham -4.1 ± 6.8 -13.5 ± 14.6 -16.8 ± 16.6 
48hr Sepsis Good Prognosis -2.4 ± 9.5 17.3 ± 15.5 -18.9 ± 19.7 
72 Sham -13 ± 8.2 -4.6 ± 14.5 -16.8 ± 16.3 
72 Sepsis Good Prognosis 0.6 ± 11.0 -2.7 ± 18.5 -3.6 ± 11.8 
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Preoperative data 
Group Temperature  
(oC) 
MAP  
(mmHg) 
SVR  
(dyne.s.cm5) 
DO2  
(ml.min-1) 
Naive 37.5 ± 0.4 116 ± 10 828 ± 103 224 ± 24 
3hr Sham 37.5 ± 0.4 139 ± 22  1132 ± 232 209 ± 19 
3hr Sepsis Good Prognosis 37.5 ± 0.3 131 ±7 1115 ± 158 221 ± 21 
3hr Sepsis Poor Prognosis 38.3 ± 0.9 130 ± 14 1532 ± 156 177 ± 23 
6hr Sham 37.4 ± 0.3 117 ± 8 1011 ± 180  191 ± 25 
6hr Sepsis Good Prognosis 38.0 ± 0.6 136 ± 13 1174 ± 269 229 ± 51 
6hr Sepsis Poor Prognosis 38.5 ± 0.4 137 ± 10 1626 ± 296 174 ± 30 
12hr Sham 37.7 ± 0.5 123 ± 8 1022 ± 199 217 ± 32 
12hr Sepsis Good Prognosis 38.8 ± 0.5 133 ± 13 1421 ± 365 194 ± 44 
12hr Sepsis Poor Prognosis 38.3 ± 0.4 134 ± 11 1496 ± 367 180 ± 35 
24hr Sham 37.5 ± 0.4 117 ± 8 941 ± 173 211 ± 42 
24hr Sepsis Good Prognosis 38.9 ± 0.5 127 ± 11 1219 ± 272 195 ± 44 
24hr Sepsis Poor Prognosis 38.4 ± 0.8 117 ± 20 1307 ± 621 173 ± 44 
48hr Sham 38.5 ± 0.8 118 ± 8 1091 ± 230 203 ± 43 
48hr Sepsis Good Prognosis 37.9 ± 0.7 112 ± 14 1054 ± 334 183 ± 40 
72 Sham 37.8 ± 0.3 127 ± 4 1028 ± 224 222 ± 53 
72 Sepsis Good Prognosis 37.5 ± 0.3 117 ± 13 824 ±136 228 ± 45 
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10.2.3 Arterial Blood Gas 
Group pH pCO2  (kPa) 
pO2  
(kPa) 
SaO2  
(%) 
Lactate  
(mmol/L) 
Base Deficit Hct 
(%) 
Hb  
(g/dl) 
Naive 7.44 ± 0.03 
4.8 ± 
0.4 
11.3 ± 
0.8 
90 ± 1 1.4 ± 0.4 0.54 ± 1.19 41 ± 2 13.3 ± 0.8 
3 h Sham 7.49 ± 0.02 
4.6 ± 
0.4 
12.1 ± 
1.1 
93 ± 2 0.8 ± 0.1 2.82 ± 1.41 42 ± 2 13.6 ± 0.8 
3 h Sepsis 
Good 
Prognosis 
7.51 ± 0.03 
4.1 ± 
0.6 
11.4 ± 
1.3 
92 ± 2 1.9 ± 0.5 0.94 ± 1.64 46 ± 4 15.2 ± 1.3 
3 h Sepsis  
Poor 
Prognosis 
7.50 ± 0.02 
4.1 ± 
0.3 
12.0 ± 
0.7 
93 ± 1 1.7 ± 0.4 0.77 ± 1.07 51 ± 3 16.7 ± 0.9  
6h Sham 7.43 ± 0.02 
5.2 ± 
0.5 
11.1 ± 
1.1 
90 ± 3 1.1 ± 0.2 1.17 ± 1.80 41 ± 3 13.4 ± 1.0 
6 h Sepsis 
Good 
Prognosis 
7.47 ± 0.03 
4.5 ± 
0.4 
10.7 ± 
0.8 
90 ± 2 1.0 ± 0.1 0.98 ± 1.34 48 ± 4 15.6 ± 1.4 
6 h Sepsis  
Poor 
Prognosis 
7.47 ± 0.04 
4.1 ± 
0.6 
11.2 ± 
0.8 
92 ± 2 1.4 ± 0.4 -1.31 ± 2.02 51 ± 3 16.5 ± 1.1 
12 h Sham 7.45 ± 0.02 
5.3 ± 
0.4 
12.2 ± 
1.2 
91 ± 2 0.7 + 0.2 3.63 ± 1.33 44 ± 5 14.5 ± 1.6  
12 h Sepsis 
Good 
Prognosis 
7.46 ± 0.03 
4.4 ± 
0.5 
12.4 ± 
1.3 
92 ± 3 1.2 ± 0.2 -0.82 ± 1.23 49 ± 3 15.9 ± 0.8 
12 h Sepsis 
Poor 
Prognosis 
7.42 ± 0.04 
4.8 ± 
0.3 
11.7 ± 
0.9 
90  ±3 1.6 ± 0.3 -1.19 ± 2.03 49 ± 3 16.1 ± 0.9 
24 h Sham 7.44 ± 0.06 
5.0 ± 
0.2 
11.3 ± 
1.4 
90 ± 3 0.8 ± 0.6 2.68 ± 1.97 40 ± 4 13.2 ± 0.8 
24 h Sepsis 
Good 
Prognosis 
7.46 ± 0.03 
4.4 ± 
0.5 
11.4 ± 
1.8 
90 ± 3 2.3 ± 0.5 -0.46 ± 2.11 44 ± 3 14.3 ± 1.0 
24 h Sepsis 
Poor 
Prognosis 
7.54 ± 0.06 
4.4 ± 
0.8 
10.8 ± 
2.3 
91 ± 4 3.0 ± 1.2 -1.28 ± 3.88 44 ± 4 14.4 ± 1.3 
48 h Sham 7.45 ± 0.03 
4.8 ± 
0.3 
12.1 ± 
1.4 
92 ± 2 1.0 ± 0.2 1.31 ± 2.27 42 ± 8 14.8 ± 1.0 
48 h Sepsis 
Good 
Prognosis 
7.48 ± 0.06 
4.6 ± 
0.8 
13.4 ± 
3.2 
94 ± 1 2.1 ± 0.9 1.09 ± 3.39 40 ± 6 13.1 ± 2.0 
72 h Sham 7.46 ± 0.02 
4.7 ± 
0.3 
11.6 ± 
0.5 
92 ± 1 1.0 ± 0.1 1.84 ± 1.21 43 ± 1 14.0 ± 0.5 
72h Sepsis 
Good 
Prognosis 
7.46 ± 0.07 
4.9 ± 
0.7 
10.7 ± 
4.4 
92 ± 4 1.8 ± 0.9 1.40 ± 2.67 40 ± 3 13.2 ± 1.2 
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10.2.4 Urea and Electrolytes 
 
Group Na+ 
(mmol/L) 
 
 
K+  
(mM/L) 
Cl- 
(mM/L) 
HCO3-  
(mM/L) 
Urea 
(mM/L) 
Creatinine 
(µM/L) 
Anion 
Gap 
(mM/L) 
Glucose  
(mM/L) 
Naive 138 ± 4 4.1 ± 0.4 103 ± 3 25.0 ± 0.9 6 ± 1 23 ± 2 13 ± 1 13.8 ± 3.2 
3 h Sham 142 ± 1 4.0 ± 0.3 102 ± 1 27.2 ± 1.1 6 ± 1 21 ± 2 17 ± 3 11.4 ± 2.1 
3 h Sepsis 
Good 
Prognosis 
141 ± 3 4.5 ± 0.6 102 ± 2 26.0 ± 1.0 8 ± 2 27 ± 5 18 ± 3 15.0 ± 4.8 
3 h Sepsis  
Poor 
Prognosis 
138 ± 2 4.8 ± 0.2 101 ± 1 25.9 ± 0.8 10 ± 2 31 ± 6 16 ± 1 11.6 ± 1.4 
6h Sham 137 ± 2 3.9 ± 0.2 104 ± 3 25.4 ± 1.4 5  ± 1 25 ± 3 12 ± 2 11.2 ± 1.2 
6 h Sepsis 
Good 
Prognosis 
137 ± 4 4.2 ± 0.5 102 ± 5 25.7 ± 1.2 8 ± 4 24 ± 8 13 ± 4 7.9 ± 1.5 
6 h Sepsis  
Poor 
Prognosis 
135 ± 2 4.4 ± 0.7 103 ± 4 24.1 ± 1.5 10 ± 4 30 ± 10 13 ± 5 7.8 ± 2.0 
12 h Sham 136 ± 2 3.7 ± 0.5 105 ± 2
 c 27.5 ± 1.0 5 ± 1 22 ± 5 8 ± 3 11.6 ± 0.8 
12 h Sepsis 
Good 
Prognosis 
140 ± 3 4.1 ± 0.2 105 ± 4 24.3 ± 0.9 5 ± 0 23 ± 3 15 ± 6 7.9 ± 0.5 
12 h Sepsis 
Poor 
Prognosis 
135 ± 2 4.0 ± 0.2 108 ± 3 23.5 ± 1.8 5 ± 1 22 ± 3 7 ± 2 7.1 ± 2.2 
24 h Sham 138 ± 2 3.8 ± 0.7 103 ± 3 24.4 ± 1.7 6 ± 1 25 ± 3 12 ± 1 12.5 ± 1.0 
24 h Sepsis 
Good 
Prognosis 
139 ± 3 3.6 ± 0.3 104 ± 4 24.4 ± 1.6 5 ± 1 28 ± 4 14 ± 1 9.1 ± 3.1 
24 h Sepsis 
Poor 
Prognosis 
139 ± 5 3.6 ± 0.4 105 ± 3 23.8 ± 3.0 7 ± 3 33 ± 14 12 ± 4 7.4 ± 2.6 
48 h Sham 138 ± 3 3.7 ± 0.3
  105 ± 3 25.8 ± 1.9 5 ± 1 26 ± 3 11 ± 3 11.7 ± 2.2 
48 h Sepsis 
Good 
Prognosis 
141 ± 3 4.1 ± 0.6 108 ± 7 25.7 ± 2.9 7 ± 2 29 ± 5 12 ± 4 9.5 ± 1.7 
72 h Sham 139 ± 3 4.0 ± 0.5 103 ± 2 26.2 ± 1.1 6 ± 1 27 ± 3
  14 ± 2 11.4 ± 1.6 
72h Sepsis 
Good 
Prognosis 
138 ± 3 3.9 ± 0.5 103 ± 3 25.8 ± 2.6 7 ± 1 27 ± 5 13 ± 2 11.6 ± 1.6 
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10.2.5 Liver Function tests 
 
 
 
 
 
 
 
 
 
 
  
Group Albumin (g/L) ALP (IU/L) ALT (IU/L) AST (IU/L) 
Naive 34 ± 7 158 ± 21 45 ± 7 101 ± 19 
3hr Sham 32 ± 3 123 ± 34 39 ± 11 109 ± 36 
3hr Sepsis Good Prognosis 30 ± 3 129 ± 6 36 ± 9 126 ± 26 
3hr Sepsis Poor Prognosis 28 ± 2 97 ± 19 37 ± 7 144 ± 22 
6hr Sham 28 ± 2 113 ± 32 38 ± 9 125 ± 50 
6hr Sepsis Good Prognosis 27 ± 2 129 ± 47 44 ± 12 215 ± 107 
6hr Sepsis Poor Prognosis 26 ± 3 138 ± 22 54 ± 20 231 ± 120 
12hr Sham 30 ± 2
  99 ± 27 38 ± 10 98 ± 16 
12hr Sepsis Good Prognosis 31 ± 3 159 ± 52 46 ± 7 146 ± 22 
12hr Sepsis Poor Prognosis 24 ± 3 133 ± 16 38 ± 7 134 ± 25 
24hr Sham 29 ± 2 116 ± 30 36 ± 8
  92 ± 27 
24hr Sepsis Good Prognosis 25 ± 3 163 ± 44 32 ± 10 126 ± 45 
24hr Sepsis Poor Prognosis 23 ± 3 185 ± 71 34 ± 90 181 ± 107 
48hr Sham 31 ± 3 113 ± 27 43 ± 17 105 ± 24 
48hr Sepsis Good Prognosis 26 ± 4 250 ± 61 25 ± 6 111 ± 28 
72 Sham 29 ± 1 111 ± 20 41 ± 3 93 ± 22 
72 Sepsis Good Prognosis 27 ± 4 150 ± 38 28 ± 13 89 ± 21 
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Serum Cytokines 
 
  
Group IL-1β   
(pg/ml) 
IL-6  
(pg/ml) 
IL-10  
(pg/ml) 
MCP-1  
(ng/ml) 
INF-g 
(pg/ml) 
IL-18  
(pg/ml) 
Naive 
1  
(1 - 1) 
1  
(1 - 1) 
11  
(1 - 36) 
54  
(45 – 180) 
1 
 (1 - 1) 
131  
(15 - 237) 
3 h Sham 
1  
(1 - 1) 
1  
(1 - 1) 
185  
(1 - 416)  
61  
(40 – 84) 
1  
(1 - 1) 
192  
(107 - 477) 
3 h Sepsis 
Good Prognosis 
1134 
(1008 - 1296) 
2728  
(1 - 4521) 
930  
(634 - 1402) 
121  
(146 – 880) 
1  
(1 - 1) 
440  
(151 - 498) 
3 h Sepsis Poor 
Prognosis 
1373  
(805 - 1710) 
6264  
(1 - 10842) 
1208  
(500 - 1507) 
649  
(394 – 973) 
1  
(1 - 1) 
310  
(210 - 355) 
6 h Sham 
1  
(1 - 1)  
1  
(1 - 6)  
65  
(1 - 82)  
98  
(72 – 118) 
16  
(15 - 16)  
293  
(267 - 315) 
6 h Sepsis 
Good Prognosis 
1198  
(892 - 1604) 
16746  
(8941 - 24266) 
2984  
(1956 - 4071) 
538  
(487 – 635) 
47  
(35 - 161) 
243  
(51 - 420) 
6 h Sepsis Poor 
Prognosis 
1737  
(1293 - 2067) 
34971  
(13981 - 47523) 
5065  
(3274 - 6030) 
781  
(595 – 1018) 
23 
 (21 - 237) 
164  
(124 - 299) 
12 h Sham 
1  
(1 - 1) 
1  
(1 - 1) 
23  
(1 - 47) 
100  
(67 – 195) 
1  
(1 - 1) 
222  
(181 - 263) 
12 h Sepsis 
Good Prognosis 
1007  
(798 - 1067) 
984  
(746 - 1552) 
2198  
(1983 - 2645) 
515  
(450 – 646) 
1  
(1 - 1) 
132  
(103 - 248) 
12 h Sepsis 
Poor Prognosis 
1601  
(1177 - 1774) 
15068  
(4330 - 27014) 
2655  
(1475 - 4113) 
728  
(511 – 752) 
1  
(1 - 1) 
194  
(53 - 375) 
24 h Sham 
1  
(1 - 1) 
1 
 (1 - 1)  
325  
(106 - 744) 
66  
(46 – 93) 
1  
(1 - 1) 
96  
(36 - 235) 
24 hr Sepsis 
Good Prognosis 
481  
(207 – 1294) 
210  
(1 – 1087) 
3710  
(1889 – 3874) 
432  
(326 – 576) 
1  
(1 - 1) 
188  
(116 – 794) 
24 h Sepsis 
Poor Prognosis 
1188  
(767 – 2640) 
12112  
(1 – 44573) 
4381  
(1702 – 7816) 
480  
(466 – 826) 
1  
(1 - 1) 
219  
(66 – 690) 
48 h Sham 
1  
(1 - 83) 
1  
(1 - 1) 
154  
(1 -616) 
100 (10 – 
107)  
185  
(164 – 207) 
48 h Sepsis 
Good Prognosis 
1361  
(163 - 1463) 
89  
(1 - 255) 
2411  
(1978 - 4702) 
275  
(149 – 303) 
1  
(1 - 1) 
339  
(223 – 454) 
72 h Sham 
1  
(1 - 1) 
1  
(1 - 1) 
275  
(214 - 280) 
75  
(48 – 106) 
1  
(1 - 1) 
171  
(99 – 242) 
72 h Sepsis 
Good Prognosis 
148  
(67 - 373) 
1  
(1 - 1) 
966  
(334 - 1889) 
140  
(74 – 228) 
1  
(1 - 1) 
209  
(200 – 402) 
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10.2.6 Renal Cytokines  
 
 
Group IL-10  
(pg/mg protein) 
IL-1β  
(pg/mg protein) 
IL-4 
(pg/mg protein) 
INF-γ   
(pg/mg protein) 
MCP-1 
(pg/mg protein) 
Naive 
286  
(224 - 446) 
104  
(100 - 124) 
866  
(642 -1144) 
10808  
(6175 - 11858) 
253  
(195 - 3008) 
3 h Sham 414 (363 - 585) 33 (18 - 74) 503 (480 - 563) 6250 (5867 - 7706) 508 (417 - 523) 
3 h Sepsis 
Good Prognosis 
389  
(388 -568) 
108  
(75 - 117) 
487  
(289 - 576 
4536 
 (4223 - 6425) 
621 
 (481 - 692) 
3 h Sepsis Poor 
Prognosis 
326  
(230 - 444) 
86  
(65 - 143) 
303 
 (225 - 424) 
7271  
(3838 - 8446) 
681  
(523 - 871) 
6 h Sham 
316 (212 - 344) 88 (76 - 144) 967 (696 - 1480) 
10982  
(7303 - 12379)  322 (180 - 538) 
6 h Sepsis 
Good Prognosis 241 (240 - 320) 213 (147 - 233) 647 (488 - 734) 
12977  
(11109 - 12873) 504 (167 - 704) 
6 h Sepsis Poor 
Prognosis 256 (222 - 318) 177 (110 - 277) 936 (636 - 1560) 
9007  
(6133 - 13567) 687 (493 - 859) 
12 h Sham 
392 (281 - 445) 114 (91 - 144) 769 (717 - 856) 
9384  
(7862 - 11515) 426 (302 - 580) 
12 h Sepsis 
Good Prognosis 313 (209 - 327) 190 (168 - 226) 781 (447 - 893) 3799 (3602 - 4607) 569 (525 - 647) 
12 h Sepsis 
Poor Prognosis 343 (228 - 437) 201 (152 - 270) 964 (886 - 1242) 8753 (8508 - 9610) 414 (263 - 717) 
24 h Sham 
326 (228 - 665) 171 (165 - 178) 1080 (930 - 1088) 
9279  
(9275 - 11886) 520 (110 - 705) 
24 hr Sepsis 
Good Prognosis 
355  
(208 – 628) 
157  
(140 – 309) 
1114  
(842 – 1485) 
9090  
(4608 – 10945) 
729  
(573 – 1273) 
24 h Sepsis 
Poor Prognosis 276 (270 – 359) 218 (167 – 280) 833 (595 – 1017) 3767 (2920 – 5227) 542 (218 – 948) 
48 h Sham 204 (180 - 515) 126 (71 - 403) 907 (568 - 1093) 7434 (5469 - 9170) 402 (69 - 555) 
48 h Sepsis 
Good Prognosis 436 (378 - 459) 216 (147 - 278) 1125 (917 - 1275) 
7962  
(3429 - 13908) 592 (422 - 702) 
72 h Sham 
456  
(439 - 518) 
140  
(114 - 152) 
844  
(744 - 913) 
11953  
(10542 - 16858) 
432  
(226 - 504) 
72 h Sepsis 
Good Prognosis 268 (166 - 477) 68 (66 - 100) 749 (703 - 973) 
9394  
(7521 - 11757) 437 (280 - 454) 
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10.2.7 Serum Biomarkers 
 
 
 
 
 
 
Group Serum NGAL (pg/ml) Serum Cyst C (ng/ml) 
Naive 38 (26 - 56)  2163 (1830 - 2389) 
3 h Sham 442 (354 - 668) 2725 (2177 - 2946) 
3 h Sepsis Good Prognosis 1807 (1449 - 2183) 2770 (2439 - 3201) 
3 h Sepsis Poor Prognosis 3405 (1417 - 4640) 2883 (2839 - 3000) 
6 h Sham 849 (691 - 905) 1948 (1617 - 2328) 
6 h Sepsis Good Prognosis 9044 (6430 - 10959) 1876 (1816 - 2395) 
6 h Sepsis Poor Prognosis 7860 (5808 - 7997) 2462 (2270 - 2588) 
12 h Sham 121 (106 - 236) 1977 (1940 – 2055) 
12 h Sepsis Good Prognosis 6622 (6184 - 7723) 2364 (2328 - 2365) 
12 h Sepsis Poor Prognosis 13936 (8533 - 14449) 2217 (1895 - 2958) 
24 h Sham 408 (269 - 692) 2091 (1773 - 2361) 
24 h Sepsis Good Prognosis 13272 (13187 - 16766) 2525 (2226 – 2882) 
24 h Sepsis Poor Prognosis 13450 (10278 - 17792) 2836 (2776 – 3158) 
48 h Sham 843 (396 - 1887) 1749 (1713 - 2444) 
48 h Sepsis Good Prognosis 5257 (50 - 14531) 2342 (1987 - 2492) 
72 h Sham 1408 (433 - 6009) 2845 (1895 - 3108) 
72 h Sepsis Good Prognosis 8830 (2920 - 14445) 2503 (2338 - 3089) 
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10.2.8 Urine biomarkers- 1 
 
 
 
Group Urine NGAL 
(ng/ml) 
Urine CystC 
(pg/ml) 
Urine IL18  
(pg/ml) 
Urine MCP-1  
(pg/ml) 
Naive 279 (218 – 421) 
234 
 (164 - 256) 
7288  
(5641 - 8771) 
6300  
(4925 - 6827) 
3 h Sham 
1133  
(895 - 1549) 
283  
(227 - 286) 
7261 
 (5800 - 8268) 
7121  
(5912 - 7496) 
3 h Sepsis Good 
Prognosis 
2379  
(1807 - 3456) 
137  
(69 - 279) 
3174 
 (241 - 4164) 
4413 
 (2764 - 4506) 
3 h Sepsis Poor 
Prognosis 
6024  
(3709 - 6266) 
323 
 (223 - 378) 
3206  
(2896 - 5344) 
4098 
 (3074 - 7308) 
6 h Sham 
2315  
(886 - 3026) 
220 
 (123 - 271) 
2259 
 (1651 - 6796) 
2592 
 (1594 - 7377) 
6 h Sepsis Good 
Prognosis 
6360 
 (6023 - 7643) 
273  
(228 - 350) 
1256  
(665 - 2064) 
1403  
(646 - 2314) 
6 h Sepsis Poor 
Prognosis 
7267  
(7016 - 7645) 
238  
(80 - 382) 
5930  
(1896 - 7847) 
2326  
(2225 - 6709) 
12 h Sham 
454  
(376 - 2057) 
53 
 (23 - 176) 
2038  
(1270 - 6266) 
1472 
 (937 - 3435) 
12 h Sepsis Good 
Prognosis 
8396  
(8152 - 9364) 
245  
(200 - 245) 
5880  
(3233 - 7261) 
6790 
 (6258 - 8202) 
12 h Sepsis Poor 
Prognosis 
9358 (8343 - 9740) 
245  
(213 - 287) 
2654  
(1421 - 3807) 
4245  
(2986 - 4432) 
24 h Sham 2611 (1197 - 2978) 71 (48 - 102) 990 (323 - 3286) 1619 (657 - 3644) 
24 h Sepsis Good 
Prognosis 
32625 
 (28307 - 40179) 
436  
(217 - 577) 
3656  
(769 - 4832) 
5247  
(1391 - 6041) 
24 h Sepsis Poor 
Prognosis 
30435 
 (29885 - 123555) 
343 
 (242 - 740) 
1100  
(725 - 2576) 
2280 
 (1740 - 4119) 
48 h Sham 
3878  
(3192 - 4426) 
90  
(77 - 106) 
1764  
(924 - 5012) 
1978  
(984 - 4712) 
48 h Sepsis Good 
Prognosis 
30733  
(11969 - 42586) 
365  
(254 - 608) 
7014  
(3782 - 11900) 
6363 
 (3620 - 8275) 
72 h Sham 
2133  
(1201 - 2396) 
155  
(93 - 170) 
2914  
(2647 - 4185) 
3432 
 (3005 - 4416) 
72 h Sepsis Good 
Prognosis 
4082  
(3811 - 11478) 
209 
 (207 - 374) 
1587  
(1446 - 4935) 
2213  
(1794 - 4225) 
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10.2.9 Urine biomarkers- 2 
 
  
Group Urine Calbindin 
(ng/ml) 
Urine Clusterin  
(ng/ml) 
Urine KIM-1  
(ng/ml) 
Urine Osteopontin  
(ng/ml) 
Naive 51 (0 -66) 21 (19 - 36) 250 (200 - 320) 2210 (910 - 2510) 
3 h Sham 97 (57 - 99) 95 (76 - 151) 260 (210 - 370) 390 (210 - 720) 
3 h Sepsis Good 
Prognosis 
159 (91 - 235) 174 (110 - 202) 320 (180 -990) 460 (190 - 930) 
3 h Sepsis Poor 
Prognosis 
112 (50 - 134) 182 (180 - 283) 640 (400 - 670) 500 (320 - 560) 
6 h Sham 67 (45 - 89) 133 (49 - 198) 120 (90 - 520) 920 (480 - 1620) 
6 h Sepsis Good 
Prognosis 
79 (72 - 158) 138 (42 - 328) 2510 (290 - 3960) 610 (280 - 720) 
6 h Sepsis Poor 
Prognosis 
186 (165 - 217) 344 (50 - 880) 1480 (770 - 5500) 810 (620 - 920) 
12 h Sham 29 (0 -50) 21 (5 - 24) 0 (0 - 30) 420 (150 - 580) 
12 h Sepsis Good 
Prognosis 
74 (72 - 83) 20 (17 - 46) 610 (430 -740) 430 (390 - 630) 
12 h Sepsis Poor 
Prognosis 
80 (62 - 89) 145 (80 - 251) 2490 (1560 -3080) 770 (720 - 960) 
24 h Sham 64 (29 - 124) 18 (15 - 48) 120 (70 - 190) 850 (480 -860) 
24 h Sepsis Good 
Prognosis 
59 (45 - 82) 153 (89 - 208) 450 (160 - 570) 470 (70 - 1000) 
24 h Sepsis Poor 
Prognosis 
51 (36 - 191) 183 (48 - 339) 212 (110 - 520) 100 (60 - 290) 
48 h Sham 82 (57 - 130) 55 (34 - 168) 240 (110 - 370) 630 (220 - 1010) 
48 h Sepsis Good 
Prognosis 
63 (58 - 167) 175 (88 - 381) 770 (420 - 960) 820 (190 - 1370) 
72 h Sham 73 (51 - 95) 29 (20 -45) 400 (290 - 420) 230 (210 - 560) 
72 h Sepsis Good 
Prognosis 
67 (52 - 82) 119 (78 - 128) 500 (320 - 650) 460 (140 - 890) 
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10.2.10 Urine Electrolytes 
 
  
Group Urine Na+ (mmol/l) Urine Cr (mmol/l) Fe Na+ 
Naive 44 (30 - 109) 4.8 (3.1 - 11.2) 2.35 (0.85 - 2.92) 
3 h Sham 81 (45 - 84) 2.2 (2.0 - 2.7) 0.43 (0.30 - 0.46) 
3 h Sepsis Good Prognosis 32 (18 - 48) 1.9 (1.4 - 5.9) 0.21 (0.09 - 0.46) 
3 h Sepsis Poor Prognosis 23 (21 - 30) 6.0 (5.3 - 10.4) 0.07 (0.06 - 0.08) 
6 h Sham 40 (36 - 45) 1.6 (1.5 - 1.8) 0.44 (0.39 - 0.49) 
6 h Sepsis Good Prognosis 36 (14 - 89) 1.7 (0.9 - 2.5) 0.60 (0.25 - 0.84) 
6 h Sepsis Poor Prognosis 30 (29 - 63) 2.6 (2.3 - 11.8) 0.18 (0.11 - 0.22) 
12 h Sham 60 (54 - 66) 1.2 (1.0 - 1.3) 0.67 (0.65 - 0.85) 
12 h Sepsis Good 
Prognosis 
45 (37 - 57) 1.3 (1.2 - 1.4) 0.54 (0.51 - 0.65) 
12 h Sepsis Poor 
Prognosis 
38 (33 - 66) 1.6 (1.3 - 2.5) 0.39 (0.22 - 0.82) 
24 h Sham 38 (33 – 66) 1.6 (1.3 - 2.5) 0.39 (0.22 - 0.82) 
24 h Sepsis Good 
Prognosis 
59 (39 - 116) 2.2 (1.6 - 2.4) 0.76 (0.33 - 1.27) 
24 h Sepsis Poor 
Prognosis 
23 (14 - 45) 3.7 (2.0 - 7.5) 0.21 (0.13 - 0.25) 
48 h Sham 63 (45 - 82) 2.7 (2.1 - 3.7) 0.47 (-.39 - 0.54) 
48 h Sepsis Good 
Prognosis 
74 (18 - 107) 4.7 (1.6 - 5.9) 0.23 (0.09 - -0.47) 
72 h Sham 90 (71 - 126) 3.2 (2.7 - 3.5) 0.53 (0.46 - 0.58) 
72 h Sepsis Good 
Prognosis 
75 (57 - 108) 3.3 (2.6 - 4.4) 0.40 (0.29 - 0.44) 
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10.2.11 Renal Macrophages 
  
Group Serum- Renal MCP-1 Renal Glomerular 
macrophages 
Renal interstitial 
macrophages 
Naive NA 0 (0 - 0.4) 3.0 (2.4 - 4.3) 
3 h Sham 0.0086 (0.0044 - 0.0131) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 
3 h Sepsis Good 
Prognosis 0.0033 (0.0008 - 0.0039) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 
3 h Sepsis Poor 
Prognosis 0.0011 (0.0008 - 0.0023) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 
6 h Sham 0.0031 (0.0015 - 0.0070) 0.8 (0.4 - 5.4) 6.6 (2.6 - 12.5) 
6 h Sepsis Good 
Prognosis 0.0011 (0.0007 - 0.0014) 2.1 (0.0 - 3.7) 24.5 (0.0 - 35.0) 
6 h Sepsis Poor 
Prognosis 0.0007 (0.0007 - 0.0009) 1.5 (0.4 - 4.0) 15.0 (1.0 - 50.0) 
12 h Sham 0.0046 (0.0031 -0.0052) 0.2 (0.0 -0.3) 1.3 (0.0 - 6.0) 
12 h Sepsis Good 
Prognosis 0.0012 (0.0011 - 0.0013) 0.0 (0.0 - 0.7) 0.0 (0.0 - 10.5) 
12 h Sepsis Poor 
Prognosis 0.0009 (0.0005 - 0.0015) 3.7 (2.4 - 5.7) 27.5 (16.0 - 46.0) 
24 h Sham 0.0119 (0.0071 - 0.0149) 0.4 (0.2 - 0.6) 4.4 (2.8 - 12.0) 
24 h Sepsis Good 
Prognosis 0.0019 (00013 - 0.0022) 1.6 (0.0 - 2.6) 19.0 (13.0 - 40.0) 
24 h Sepsis Poor 
Prognosis 0.0011 (0.0009 - 0.0015) 1.3 (1.1 - 1.7) 41.0 (21.2 - 45.0) 
48 h Sham 0.0040 (0.0035 - 0.0044) 0.3 (0.1 - 3.2) 5.9 (4.0 - 21.1) 
48 h Sepsis Good 
Prognosis 0.0025 (0.0021 - 0.0030) 6.0 (0.0 -11.0) 47.0 (0.0 -202.0) 
72 h Sham 0.0067 (0.0021 - 0.0089) 0.8 (0.4 - 0.9) 10.6 (7.6 - 13.1) 
72 h Sepsis Good 
Prognosis 0.0041 (0.0015 - 0.0082) 6.0 (2.4 - 9.9) 43.5 (24.5 - 83.0) 
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10.2.12 Effect of fluid resuscitation 
* p<0.05 compared to resuscitated septic animal 
 
 Fluid resuscitated No fluid resuscitation 
Change in cardiac output (%) -26 (-38 - -7) -35 (-56 - -29) 
Change in stroke volume (%) -38 (-49 - -25) -49 (-62 - -37) 
Change in heart rate (%) 19 (10 – 41) 25 (16 – 27) 
Global O2 delivery (ml.min-1) 183 (153 – 194) 185 (124 – 195) 
Mean arterial pressure (mmHg) 138 (127 – 145) 136 (123 – 143) 
Temperature (oC) 38.4 (38.1 – 38.8) 39.3 (38.6 – 39.6) 
 
 Fluid resuscitated No fluid resuscitation 
Lactate (mmol.l-1) 1.2 (1.0 – 1.5) 1.6 (1.5 – 1.7) * 
Base Excess (mmol.l-1) 0.6 (0.0 – 2.1) -2.3 (-3.0 - -0.6) 
Urea (mmol.l-1) 6.4 (5.3 – 7.0) 8.1 (6.8 – 9.8) * 
Creatinine (µmol-1) 23.0 (21.0 -27.5) 32.0 (26.0 – 34.0) * 
Haematocrit (%) 48 (42 – 51) 50 (45 – 55) 
O2 Saturation (%) 90 (89 – 91) 90 (89 – 91) 
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10.3 Renal Haemodynamics 
• p<0.05 for sham vs. sepsis (at corresponding time points);  
• § p<0.05 for Naïve vs. sepsis. ( ) indicated approaching significance (p 
0.05-.0.06) 
10.3.1 Baseline Variables 
 6hr 24hr 
 Sham 
n = 6 
Septic 
n = 6 
Sham 
n = 7 
Septic 
n = 8 
Weight (g) 330 ± 25 332 ± 25 351 ± 32 332 ± 26 
Stroke volume (mL) 0.36 ± 0.03 0.35 ± 0.04 0.34 ± 0.03 0.35 ± 0.03 
Heart rate (min-1) 425 ± 23 410 ± 30 428 ± 27 424 ± 31 
Cardiac output (ml/min) 152 ± 11 142 ± 18 146 ±14 149 ± 8 
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10.3.2 Systemic variables  
 Naive Sham 6 h Sepsis 6 h Sham 24 h Sepsis 24 h 
Weight (g) 
348  
(326 - 359) 
325  
(305 - 358) 
332  
(320 - 345) 
365  
(323 -370) 
323  
(313 - 330) 
Temperature (oC) 
37.5  
(37.1 - 37.8) 
37.2  
(36.8 - 37.4) * 
38.4  
(38.1 - 38.6) § 
37.4  
(36.9 - 37.8) * 
38.3  
(38.0 - 38.4) § 
Mean Arterial 
Pressure (mmHg) 
113 
 (108 - 123) 
118  
(110 - 120) 
120  
(115 - 128) 
120  
(110 - 130) 
115  
(110 - 130) 
Syst vasc resist 
(dyne.s.cm5) 
860 
 (173 - 914) 
884 
 (747 - 1026) 
994  
(929 - 1092) § 
903  
(876 - 1088) 
979  
(966 - 1137) 
Change in heart 
rate (%) - 
4 
 (3 - 6) (*) 
16 
 (10 – 19) § 
-7 
 (-8 - -5) * 
6  
(-3 - 9) 
Change in cardiac  
output (%) - 
-12 
 (-15 - -12) 
-23 
 (-39 - 1) (§) 
-13 
 (-22 - -5)  
-24 
 (-43 - 10) § 
Change in stroke  
volume (%) - 
-16 
 (-17 - 0) 
-34  
(-56 - -12) § 
-2 
 (-10 - 2) * 
-29  
(-39 - -15) § 
SaO2 (%) 90 (89 - 91) 89 (87 - 90) 92 (91 - 94) 92 (88 - 93) 88 (86 - 91) 
Global DO2  
(ml.min-1) 
227  
(209 - 239) 
217  
(216 - 224) 
216  
(203 - 227) 
220  
(210 - 239) 
217  
(205 - 224) 
Glucose (mmol.l-1) 13 (11 - 16) 12 (11 - 12) 12 (10 - 12) 14 (11 - 15) * 10 (9 -11) § 
Lactate (mmol.l-1) 1.3 (1.0 - 1.6) 1.5 (1.2 - 1.8) 1.5 (1.2 - 1.6) 1.3 (1.3 - 1.7) *  1.7 (1.6 - 2.5) 
Anion Gap  
(mmol.l-1) 
13  
(12 - 14) 
14 
 (13 - 16) 
15  
(12 - 16) 
12  
(12 - 14) 
12  
(11 - 13) 
 
Syst vasc resist = systemic vascular resistance 
  
 265 
10.3.3 Renal haemodynamic variables 
 
 Naive Sham 6 h Sepsis 6 h Sham 24 h Sepsis 24 h 
RBF (ml.min-1) 
16.3  
(15.1 - 19.5) 
20.7  
(18.0 - 22.0) 
16.4  
(15.8 - 20.0) 
20.2  
(18.0 - 23.0) * 
16.6  
(16.2 - 18.6) 
Renal DO2 (ml.min-1) 27 (24 - 33) 34 (28 - 38) 30 (28 - 36) 37 (33 -39) * 28 (27 - 34) 
Renal/Global DO2 (%) 12 (10 - 14) 16 (12 - 17) 14 (12 - 18) 16 (14 - 19) 16 (12 - 16) 
Renal VO2 (ml.min-1) 11 (10 - 14) 9 (8 - 13) 8 (7 - 11) § 15 (11 - 19) 12 (11 - 13) 
ERO2 (%) 45 (36 - 53) 30 (24 - 40) 29 (23 - 31) § 44 (34 - 47) 43 (34 - 44) 
Renal vein lactate  
(mmol.l-1) 
1.3  
(1.1 - 1.5) 
1.8  
(1.4 - 2.2) 
1.7  
(1.2 - 2.2)  
2.3  
(1.8 - 3.1) * 
3.9  
(2.2 - 4.6) § 
Lactate Consumption 
(umol.min-1) 
-0.15 
(-0.20 - 0.05) 
-0.20 
(-0.008 - 0.003) 
-0.20 
(-0.004 - 0.00) 
-0.05 
(-0.14 - -0.04) 
-0.13 
(-0.17 - -0.07) 
Renal vein Glucose 
(mmol.l-1) 19 (15 - 20) 18 (16 - 19) 16 (13 - 18) 21 (15 - 24) * 13 (4 - 16) 
Glucose 
Consumption 
(mmol.l-1) 
-0.04 
(-0.05 - -0.03) 
-0.06 
(-0.08 - -0.03) 
-0.04 
(-0.06 - -0.02) 
-0.08 
(-0.1 - -0.04) * 
-0.02  
(-0.04 - 0.04) § 
Renal Cortex pO2  
(mmHg) 
12.8 
 (12.3 - 14.5) 
12.5 
 (11.5 - 13.0) 
11.9 
 (10.5 - 13.8) 
13.0 
 (11.0 - 18.0) * 
10.8 
 (7.5 - 11.5) § 
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10.4 Antagonist data 
a: p < 0,05 for DMSO vs DMSO/P2X7 for 6 or 24hr. b: DMSO vs untreated. C: DMSO/P2X7 vs. 
untreated. D: Pre-treatment vs. untreated 
10.4.1 Baseline data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Group Weight (g) Temperature (oC) 
   
6 h sepsis untreated 340 (308 – 373) 37.4 (37.1 – 38.0) 
6 h high dose DMSO 311 (295 - 370) 37.6 (37.5 - 37.8) 
6 h high dose P2X7 360 (350 – 380) 37.6 (37.5 - 38.2) 
   
24 h sepsis untreated 338 (330 – 340 ) 37.4 (37.2 – 37.8) 
24 h low dose DMSO 330 (327 - 3340) 37.9 (37.5 - 38.3) 
24 h high dose DMSO 333 (315 - 350) 37.4 (37.3 - 38.0) 
24 h low dose DMSO/P2X7 336 (317 - 340) 37.5 (37.5 - 37.9) 
24 h high dose DMSO/P2X7 346 (317 - 360) 37.6 (37.2 - 37.8) 
24 h P2X7 pretreatment 380 (360 - 388) 37.7 (37.3 - 38.0) 
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10.4.2 Baseline CVS 
 
  
Group HR (/min) SV (mL) CO (ml/min) 
    
6 h sepsis untreated 408 (385 – 435) 0.36 (0.33 – 0.40) 153 (136 – 161) 
6 h high dose DMSO 421 (408 - 436) 0.33 (0.28 - 0.38) 134 (130 - 156) 
6 h high dose P2X7 394 (373 - 431) 0.31 (0.28 - 0.39) 133 (113 - 147) 
    
24 h sepsis untreated 404 (384 – 429) 0.31 (0.30 – 0.33) 132 (120 – 137) 
24 h low dose DMSO 384 (370 - 409) 0.34 (0.31 - 0.34) 125 (115 -146) 
24 h high dose DMSO 401 (390 - 453) 0.34 (0.33 - 0.42) 151 (143 - 162) 
24 h low dose DMSO/P2X7 412 (410 - 432) 0.35 (0.31 - 0.36) 146 (199 - 155) 
24 h high dose DMSO/P2X7 425 (408 - 437) 0.33 (0.31 - 0.36) 140 (130 - 153) 
24 h P2X7 pretreatment 429 (412 - 453) 0.34 (0.30 - 0.36) 149 (132 - 151) 
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10.4.3 Preoperative CVS data 
  
Group Change in HR (%) Change in SV (%) Change in CO (%) 
    
6 h sepsis untreated 16 (14 – 29) -49 (-56 - -37) -41 (-47 - -27) 
6 h high dose DMSO 15 (10 - 18) -32 (-42 - -28) -27 (-31 - 19) 
6 h high dose P2X7 16 (14 - 18) c -38 (-50 - -35) -29 (-42 - 23) 
    
24 h sepsis untreated 19 (2 – 22) -31 (-37 - -24) -23 (-34 - -12) 
24 h low dose DMSO 13 (9 - 14) -29 (-36 - -25) -23 (-27 - -15) 
24 h high dose DMSO 5 (-2 - 16) -22 (-39 - 15) -22 (-36 - -13) 
24 h low dose DMSO/P2X7 6 (4 - 11) -17 (-21 - -6) -10 (-21 - 5) 
24 h high dose DMSO/P2X7 -1 (-6 - 7) c -25 (-30 - 16) (c) -23 (-27 - -16) 
24 h P2X7 pretreatment 7 (0 - 9) d -29 (-30 - 0) -22 (-26 - -1) 
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10.4.4 Preoperative data 
  
Group Temperature (oC) MAP (mmHg) SVR (dyne.s.cm5) DO2 (ml.min-1) 
     
6 h sepsis untreated 39.7 (39.1 – 39.7) 138 (128 – 153) 1681 (1240 – 1774) 174 (146 – 214) 
6 h high dose 
DMSO 
38.4 (38.3 - 39.0) 135 (130 - 137) 1312 (1048 - 1704) 199 (176 - 233) 
6 h high dose P2X7 38.7 (38.6 - 38.7) 136 (135 - 145) 1358 (1311 - 1572) 217 (199 -231) 
     
24 h sepsis 
untreated 
38.2 (37.6 -38.6) 125 (110 – 125) 1078 (1009 – 1217) 184 (170 – 190) 
24 h low dose 
DMSO 
38.2 (37.9 - 38.7) 127 (120 - 128) 1111 (883 - 1193) 190 (160 - 198) 
24 h high dose 
DMSO 
38.3 (37.8 - 38.5) 127 (112 - 134) 1126 (871 - 1244) 198 (183 - 224) 
24 h low dose 
DMSO/P2X7 
38.5 (38.1 - 38.5) 132 (126 - 137) 1033 (969 - 1156) 226 (217 - 241) 
24 h high dose 
DMSO/P2X7 
38.2 (37.6 - 38.7) 123 (117 - 130) 1105 (817 - 1265) 185 (174 - 234) 
24 h P2X7 
pretreatment 
38.1 (37.1 - 38.5) 130 (125 - 140) d 1120 (1089 -1128) 219 (203 - 240) d 
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10.4.5 Arterial Blood Gas 
Group pH pCO2  
(kPa) 
pO2  
(kPa) 
SaO2  
(%) 
Lactate 
(mmol/L) 
Base  
Deficit 
Hct  
(%) 
Hb  
(g/dl) 
6 h sepsis  
untreated 
7.47  
(7.44–7.52) 
4.1 
(3.9–4.6) 
11.3  
(10.5–11.7) 
91  
(90–93) 
1.2  
(0.9 – 1.2) 
-0.5 
 (-0.7–0.9) 
51  
(47 – 53) 
16.7 
 (15.2-17.4) 
6 h  
high dose  
DMSO 
7.44 
(7.43-7.50) 
4.5 
(4.0-4.8) 
12.0 
 (11.1-12.8) b 
93  
(92-94) b 
1.0 
 (0.9-1.0) b 
-0.2 
 (-1.6- -0.1) 
50 
 (48 -51) 
16.5 
 (15.7-16.7) 
6 h  
high dose  
P2X7 
7.45  
(7.40-7.46) 
4.4  
(4.0-4.7) 
11.9 
 (11.6-12.3) c 
94  
(92-95) c 
1.2  
(1.1-1.3) a 
-1.6 
 (-2.6- -0.3) 
55 
 (53-55) a,c 
18.0 
(17.3-18.1)a,c 
         
24 h sepsis  
untreated 
7.44  
(7.44–7.49) 
4.1  
(4.1–4.7) 
12.1 
 (11.3–12.6) 
92 
 (89–93) 
2.2  
(2 – 2.4) 
-0.3 
 (-2.2- -0.5) 
45 
 (45 – 46) 
14.7  
(13.6–14.9) 
24 h  
low dose  
DMSO 
7.48  
(7.47-7.48) 
4.5  
(4.0- .7) 
12.1 
 (11.4-12.7) 
93 
 (91-93) 
2.1  
(1.2-2.8) 
1.2 
 (-0.8 - 2.5) 
44  
(43 - 45) 
14.5 
 (14.1-14.8) 
24 h 
high dose  
DMSO 
7.48  
(7.46-7.48) 
4.4  
(4.3-4.8) 
12.0 
 (11.7-12.2) 
93  
(91-94) b 
2.2  
(2.1-2.2) 
1.5 
 (0.0- 2.0) b 
43 
 (42 - 45) 
14.1  
(13.7-14.7) 
24 h  
low dose  
DMSO/P2X7 
7.50  
(7.46-7.56) 
4.2  
(4.1-4.9) 
12.6 
 (12.3-13.1) 
93 
 (92-95) 
2.4  
(1.16-2.6) 
-0.1 
 (-0.1- 1) 
46 
 (43 - 49) 
14.9 
 (14.1-15.9) 
24 h  
high dose  
DMSO/P2X7 
7.45  
(7.42-7.46) 
4.42  
(4.2-4.9) 
12.1 
 (10.3-12.9) 
93 
 (90-94) 
1.4  
(0.9-1.8) a,c 
0.2 
 (-2.0- 1.7) 
45 
 (41 - 45) 
14.6 
 (13.5-14.9) 
24 h P2X7  
pretreat 
7.48 
 (7.46-7,48) 
4.8  
(4.6-4.9) 
11.8 
 (9.9-13.1) 
93 
 (88-94) d 
1.7 
 (1.4-2.3) (d) 
1.9 
 (0.3- 2.1) d 
46 
 (43 - 47) 
15.2 
 (15.0-15.3) 
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10.4.6 Urea and Electrolytes 
Group Na+  
(mmol/L) 
K+  
(mmol/L) 
Cl-  
(mmol/L) 
HCO3- 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Anion 
Gap  
(mmol/L) 
Glucose 
(mmol/L) 
         
6 h sepsis 
untreated 
138  
(134 – 140) 
4.6  
(4.2 – 4.8) 
100  
(94 – 102) 
24.7  
(23.7 – 26.2) 
7.8  
(6.1–17.9) 
25 
 (17 – 36) 
19  
(18 – 20) 
7.0  
(6.2 – 7.6) 
6 h  
high dose 
DMSO 
136  
(136 - 139) 
4.3  
(4.2 - 4.6) 
100  
(99 - 107) 
24.6  
(24.1 - 24.7) 
7.4 
 (7.1 -8.2) 
19  
(15 - 23) b 
17  
(4 - 18) 
6.5  
(6.0 - 7.1)b 
6 h  
high dose 
P2X7 
137  
(136 - 141) 
4.3  
(4.3 - 4.3) 
109 
 (99 - 113) 
24.1  
(22.3 - 24.8) 
9.7  
(7.0 - 
12.9) 
26  
(24 - 31)a 
9  
(6 - 18) 
7.7  
(7.3 - 8.1)a 
         
24 h sepsis 
untreated 
143  
(136 – 144) 
3.7  
(3.6 – 3.8) 
106  
(104–108) 
24.8  
(23.2 – 25.5) 
5.3  
(5.1 – 5.6) 
25  
(22 – 27) 
15  
(13 – 17) 
8.5  
(7.9 – 9.2) 
24 h  
low dose 
DMSO 
140  
(137 - 142) 
3.7  
(3.6 - 4.0) 
106  
(103 - 106) 
25.9  
(24.3 - 26.6) 
4.5  
(4.1 - 5.8) 
28  
(26 - 32) 
12  
(12 - 13) 
9.4  
(8.7 - 9.7) 
24 h  
high dose 
DMSO 
143  
(141 - 144) b 
3.7  
(3.6 - 4.1) 
105  
(104 - 107) 
26.2  
(24.9-26.6)b 
4.7  
(4.4 5.4)b 
23  
(20 - 26) b 
16  
(13 - 17) 
8.6  
(8.1 - 9.6) 
24 h  
low dose 
DMSO/P2X7 
140  
(135 - 142) 
3.9  
(3.8 - 3.9) 
107  
(104 - 108) 
25.4  
(25.1 - 25.5) 
4.4  
(3.9 - 4.5) 
26  
(25 - 27) 
11  
(9 - 12) 
9.4  
(8.7 - 10.4) 
24 h  
high dose 
DMSO/P2X7 
142  
(139 - 143) c 
3.6  
(3.3 - 3.9) 
107  
(105 - 109) c 
25.2  
(23.3 -26.1) 
4.4  
(4.1 - 4.9) c 
23  
(18 - 26) c 
13  
(11 - 14) a 
8.7  
(8.0 - 10.5) c 
24 h P2X7 
pretreat 
143  
(142-143)d 
3.5  
(3.4 - 4.0) 
106  
(105 - 106) 
26.4  
(24.4-26.6)d 
4.3  
(3.6-4.6)d 
22  
(19 - 22) d 
14  
(14 - 16) 
8.9  
(8.5 - 9.2) 
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10.4.7 Liver Function tests 
 
  
Group Albumin (g/l) ALP (IU/L) ALT (IU/L) AST (IU/L) 
     
6 h sepsis untreated 28 (27 – 30) 127 (100 – 152) 50 (45 – 544) 206 (167 – 248) 
6 h high dose DMSO 25 (23 - 27) 131 (109 - 143) 45 (42 - 55) 180 (162 - 207) 
6 h high dose P2X7 26 (25 - 28) 132 (112 - 145) 48 (47 - 55) 199 (180 -259) 
     
24 h sepsis untreated 23 (21 – 24) 138 (114 – 173) 31 (29 – 44) 143 (123 – 212) 
24 h low dose DMSO 29 (25 - 32) 144 (116 - 185) 36 (33 - 47) 140 (122 - 145) 
24 h high dose DMSO 24 (22 - 25) 179 (142 - 205) 31 (27 - 33) 140 (113 - 154) 
24 h low dose DMSO/P2X7 26 (26 - 27) 158 (138 - 168) 28 (27 - 37) 127 (116 - 146) 
24 h high dose DMSO/P2X7 27 (25 - 28) a, c 142 (128 - 191) 33 (31 - 35) 118 (95 - 129) c 
24 h P2X7 pretreatment 25 (23 - 28) 131 (121 - 163) 29 (27 - 31) 114 (114 - 125) 
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10.4.8 Serum Cytokines 
 
 
 
 
 
Group IL-1β   
(pg/ml) 
IL-6  
(pg/ml) 
IL-10  
(pg/ml) 
MCP-1  
(ng/ml) 
IL-18  
(pg/ml) 
      
6 h sepsis 
untreated 
1737  
(1473 – 1944) 
13980  
(8697–31736) 
4017  
(2164 – 6340) 
538  
(481 – 1018) 
299  
(164–386) 
6 h high dose 
DMSO 
1924  
(1853 - 2218) 
25036  
(20255-25947) 
2576  
(2378 - 3616) 
668  
(572 - 763) - 
6 h high dose 
P2X7 
1989 
 (1214 - 2382) 
20643  
(18217-29203) 
3152 
 (2297 - 4870) 
568  
(392 - 698) - 
      
24 h sepsis 
untreated 
1462  
(907 – 2245) 
1  
(1 – 2477) 
2997  
(1717 – 3792) 
470  
(403 – 502) 
188  
(66 – 317) 
24 h low dose 
DMSO 
584  
(487 - 1395) 
1 
(1 - 1) 
4071  
(1975 - 5309) 
336  
(164 - 406) - 
24 h high dose 
DMSO 
1808  
(973 - 2657) 
450  
(43 - 1148) 
2034  
(393 - 4681) 
704  
(519 - 734) 
210  
(164 - 745) 
24 h low dose 
DMSO/P2X7 
609  
(556 - 957) 
1  
(1 - 1) 
2202 
 (2013 - 3035) 
429  
(370 - 479) - 
24 h high dose 
DMSO/P2X7 
768  
(178 - 1456) 
1 
 (1 - 3274) 
2387  
(2122 - 4587) 
514  
(164 - 769) 
93  
(93 - 201) c 
24 h P2X7 
pretreatment 
661  
(281 - 1395) (d) 
972  
(1 - 1993) 
3384  
(2378 - 6340) 
384  
(318 - 500) - 
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10.4.9 Renal Cytokines  
 
 
 
 
  
Group IL-10 
(pg/mg  
protein) 
IL-1β  
(pg/mg  
protein) 
INF-γ  
 (pg/mg  
protein) 
IL-4 
(pg/mg  
protein) 
MCP-1 
(pg/mg  
protein) 
Serum/Renal 
MCP-1  
gradient 
       
6 h sepsis 
untreated 
248  
(186 – 318) 
128  
(101 – 
162) 
6707  
(6133 – 6818) 
625  
(488 – 936) 
590 
 (318 – 704) 
0.0007  
(0.0007–0.0009) 
6 h high dose 
DMSO 
126  
(112 - 147) 
126  
(112 - 147) 
8652  
(7917 - 8834) 
1028  
(824 - 1805) 
624 
 (512 - 688) 
0.0009  
(0.0009 - 0.001) 
6 h high dose 
P2X7 
70 
 (60 - 100)c 
70  
(60-100)c 
7110  
(5615 - 9104) 
1801 
 (675 - 2342) 
390 
 (264-457) a,c 
0.00065  
(0.0005-0.001) 
       
24 h sepsis 
untreated 
276  
(270 – 322) 
170  
(144–279) 
3767  
(3205 – 4821) 
946  
(639 – 1200) 
641 
(425 – 1080) 
0.0013  
(0.0007–0.0015) 
24 h low dose 
DMSO 
212  
(130 - 265) 
162  
(136-220) 
7779  
(7165 - 9927) 
537  
(480 - 1132) 
702 
 (422 - 817) 
0.00185  
(0.0015-0.003) 
24 h high dose 
DMSO 
219  
(211 - 252) 
210  
(128-256) 
4126  
(3243 - 6713) 
751 
 (593 - 871) 
902 
 (627 - 1155) 
0.0013  
(0.0011-0.0021) 
24 h low dose 
DMSO/P2X7 
308  
(258 - 348) 
165  
(111-224) 
8986  
(6408 - 9307) 
779  
(664 - 792) 
610  
(175 - 647) 
0.00145  
(0.0002-0.0017) 
24 h high dose 
DMSO/P2X7 
224  
(169 - 331) 
280  
(195-380) 
7584  
(4387 - 9544) 
593  
(480 -1218) 
741 ( 
394 - 830) 
0.0015  
(0.0012-0.0024) 
24 h P2X7 
pretreatment 
188  
(184 - 256) 
222  
(212 - 238) 
8607  
(7982-12227)d 
1048  
(895 - 1225) 
836  
(560 - 968) 
0.00225  
(0.0018-0.0041) 
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10.4.10 Urine biomarkers  
Group Urine  
NGAL 
(µg/ml) 
Urine  
KIM-1 
(ng/ml) 
Urine  
IL-18  
(ng/ml) 
Urine  
MCP-1  
(ng/ml) 
Osteopontin 
(ng/ml) 
Clusterin  
(ng/ml) 
Calbindin  
(ng/ml) 
        
6 h sepsis 
untreated 
27  
(24 – 38) 
2.4  
(1.2 – 4.4) 
3643  
(1266 – 5674) 
3284  
(1343 – 5619) 
0.78  
(0.28 – 1.02) 
43  
(33 – 232) 
180  
(157–244) 
6 h high dose 
DMSO 
20	  	  
(17	  -­‐	  33)	  
1.82  
(1.03 - 2.14) 
2021  
(1605 - 2421) 
3152  
(2350 -3538) 
0.88  
(0.36 - 1.81) 
253  
(245 - 319) 
119  
(119 - 141) 
6 h high dose 
P2X7 
23	  	  
(23	  -­‐	  27)	  
2.80  
(1.97 - 6.1) 
2844 
 (2462 - 3534) 
4360  
(3888-4926) a,c 
1.02  
(0.73 - 1.44) 
205  
(152 - 536) 
264  
(118 - 452) 
        
24 h sepsis 
untreated 
39	  	  
(24	  –	  46)	  
0.44  
(0.11 – 0.45) 
769  
(725 – 2576) 
1740  
(1391 – 4119) 
0.09  
(0.08 – 0.29) 
175  
(130 – 338) 
46  
(36 – 52) 
24 h low dose 
DMSO 
29	  	  
(21	  -­‐	  32)	  
- - - - - - 
24 h high dose 
DMSO 
30	  	  
(25	  -­‐	  44)	  
0.36  
(0.15 - 0.64) 
2085  
(1497 - 3899) 
2710  
(1336 - 5009) 
0.37  
(0.33 - 0.58) 
307  
(227 - 667) 
89  
(75 - 112) 
24 h low dose 
DMSO/P2X7 
29	  	  
(24	  -­‐	  30)	  
- - - - - - 
24 h high-dose 
DMSO/P2X7 
23	  
(15	  -­‐	  40)	  
0.31  
(0.21 - 0.61) 
3505  
(2880-5979) c 
3044  
(2608 - 5701) 
1.02  
(0.37-1.53)c 
290  
(89 - 699) 
100 
(68 - 120) 
24 h P2X7 
pretreatment 
39	  	  
(35	  -­‐	  52)	  
0.27  
(0.16 - 0.31) 
4104  
(1245 - 5781) 
3965  
(1595 - 5201) 
0.66  
(0.66 -0.96) 
240  
(205 - 264) 
142  
(63 - 144) 
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